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Abstract
Obesity has recently become a major global health problem. Epidemiologic studies 
indicate that obesity is an important risk factor for type 2 diabetes (T2DM), 
atherosclerosis and low testosterone in men. Importantly, testosterone replacement 
treatment (TRT) can improve the condition of these diseases. According to human 
and animal studies testosterone can act as an anti-inflammatory and anti- atherogenic 
factor leading to inhibition of the risk factors and consequence of T2DM and 
atherosclerosis. Consequences of these diseases include dysregulation in atherogenic 
factors such as apolipoproteins or pro-inflammatory mediators such as cytokines and 
chemokines and their receptors. The effect of testosterone on these factors remains 
unclear.
The objective of the present study was to demonstrate whether testosterone has anti­
inflammatory and anti-atherogenic action and by which mechanisms. This was 
achieved by using in vivo human and mice studies as well as in vitro models. The in 
vivo human study was conducted on short and long term studies, to determine the 
effect of TRT on anti and pro-inflammatory cytokines, HDL fractions and 
apolipoproteins in diabetic hypogonadal patients. Samples of liver tissue from 
testicular feminization mice (Tfin) were studied to investigate the effect of 
testosterone therapy on mRNA expression of adiponectin, PP ARp/5, PAI-1, 
apolipoproteins and pro-inflammatory chemokines with their receptors. Additionally, 
models of cell culture were studied including human macrophage THP-1 cells and 
mouse 3T3L1 cells to study the effect of testosterone with or without blocked 
androgen receptor (AR) on CX3CR1 and CCR2 and pro-inflammatory cytokines in 
macrophage cells and on adiponectin, PP ARp/8, PAI-1, leptin and chemokines in 
adipocyte cells, respectively.
In the clinical studies, a reduction in adiponectin levels after 3months was seen in the 
short-term study and an increase in HDL2 and HDL2/HDL3 ratio in the long-term 
study. No significant effect of testosterone was observed on body composition and 
atherogenic factors in either the short or long-term studies. In the animal study, 
testosterone increased hepatic expression of mRNA adiponectin, PP ARp/8 and PAI- 
1 mRNA expression in Tfin. In the cell culture studies, testosterone treatment 
increased CCR2 mRNA expression and decreased secretion of IL-8 and TNF level in 
the supernatant of THP-1 macrophages. Testosterone decreased secretion of CCL2 
and CX3CL1 from 3T3L1 adipocytes while increasing PAI-1 mRNA expression in 
these cells. The action of testosterone was based on the type of cells and time, route 
and dose size of treatment.
In conclusion, although testosterone therapy showed a positive effect on some risk 
factors of obesity and its associated conditions, negative effects were also seen. 
However the exact mechanism of action of testosterone that influences risk factors of 
obesity and its associated conditions in men with low testosterone remain unclear, 
therefore further studies are needed to fully elucidate the above finding.
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1.1 Introduction
Obesity leads to a wide range of serious diseases such as metabolic syndrome, type two 
diabetes (T2DM), and atherosclerosis as well as in men, testosterone deficiency, which 
has resultant complications e.g. increased risk of cardiovascular disease (CVD). Obesity 
is a substantial public health problem that increases morbidity, mortality and has 
substantial long term economic and social costs. This raises public-health concerns 
(Saad et ah, 2012; van Stijn et ah, 2014).
1.2 Obesity
The prevalence of obesity has increased substantially over past decades in most 
industrialised countries. It is a disease that is present among all age groups in both 
genders and is rapidly reaching pandemic proportions (Ogden et ah, 2014). Prospective 
causes of this epidemic are attributed to a combination of factors in an individual, which 
lead to an imbalance between food intake and energy expenditure. The main factors are 
endocrine disorders, environmental and genetic contributors with inappropriate life style 
such as changes in dietary patterns and a lack of regular physical activity (Pradhan, 
2007).
1.2.1 Measurement of obesity
A clinical definition of obesity is known as a body mass index (BMI) or Quetelet Index 
of > 30 % Kg/m2 (Poirier et ah, 2006). Therefore, BMI is considered the main indictor of 
obesity (Table 1.1). Waist to hip ratio (WHR) is a second measure used for estimating the 
degree of obesity. Some studies established that the waist circumference, not WHR, is a 
better indicator of abdominal fat and a predictor of risk of cardiovascular disease and 
hypertension in diabetic patients (Balkau et ah, 2007; Alberti et ah, 2009). In a number 
of studies, WHR or waist circumference was considered more significant than BMI in 
measuring the body fat distribution (Table 1.2) (Seidell et ah, 1997, Yusuf 2005, Van 
Gaal et ah, 2006).
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Underweight < 18.5 Low (but risk of other clinical problems 
increased)
Normal Range 18.5-24.9 Average
Overweight
(pre-obese) 25.0-29.9 Mildly increased
Obese >30.0
Class 1 30.0-34.9 Moderate
Class 11 35.0-39.9 Severe
Class 111 >40.0 Very severe
Table 1.1: Classification of overweight and obesity in adults according to BMI and 
co-morbidities. (Adapted from Cheah and Kam, 2005).
Not overweight <94.0 <80.0
Pre-obese 94.0-101.9 80.0-87.9
Obese >102.0 >88.0
Table 1.2: Classification of abdominal obesity by waist circumference (cm)
(Adapted from Cheah and Kam, 2005).
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It also indicates abdominal (central, visceral, android) obesity, which is associated with 
an increased risk of morbidity, compared to gluteofemoral (peripheral, 
gynoid) obesity (Wang et al., 2005; Yusuf et al., 2005). The body fat percentage has 
been considered an additional approach to obesity measurement, which is calculated by 
taking height, age, gender, weight and waist measurement into account. This calculation 
gives the exact body fat and the measure can be used to determine the amount of body fat 
that should be lost to reduce risk of obesity associated conditions. A number of other 
measurement tools have been used to assess body fat composition, including the 
measurement of subcutaneous skin fold by means of a caliper or ultrasound, bioelectrical 
impedance analysis (BIA), densitometry, or imaging procedures; nevertheless, most of 
these measurements are not readily used in clinical practices, and do not add considerable 
information involving risks compared to BMI and waist circumference measurements 
(Jagannathachary and Kamaraj, 2010; Pischon et al, 2007).
Functional differences between peripheral and visceral adipose tissue (VAT) have been 
reported (Gesta et al., 2007). Visceral adipose tissue has higher metabolic activity than 
peripheral adipose tissue (Abate and Nicola, 2013). Furthermore, the subcutaneous fat 
accumulation in the abdomen is more contributory to diabetes, coronary vascular 
diseases (Hajer 2008; Bastard, 2006) and hypogonadism (Abate et al., 2002) than 
peripheral adiposity. This may explain why these diseases, in particular heart disease, are 
more widespread among men than women, because men have more upper fat body than 
women, who have more lower body fat in general. Also these conditions are more 
common among women with central obesity compared to women with peripheral obesity 
(Blouin et al., 2008).
1.2.2 Structure of adipose tissue
Mammalian adipose tissue is histologically identified as a loose association of lipid- 
filled cells, called adipocytes, which are held together by a framework of collagen 
fibres. Adipose tissue also contains fibroblastic connective tissue, leukocytes, 
macrophages, and preadipocytes, in various stages of development. It can be classified 
into two types: white adipose tissue (WAT) and brown adipose tissue (BAT). The 
presence, amount, and distribution of both types depend on the species, but the WAT is 
the main type of adipose tissue and is located under the skin (Witkowska-Zimny and
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Walenko, 2011). It usually surrounds the internal organs and prevents them from 
jarring. WAT is also found in the lymph nodes and the skeletal muscle. The WAT plays 
a significant role in insulation against heat loss and mechanical and/or structural support 
and most prominently, is a storage site for energy in the form of long chain fats 
Vazquez-Vela et al, 2008). Approximately 60 to 85% of the weight of WAT is lipid, 
with 90-99% being triglycerides. Small amounts of free fatty acids, diglyceride, 
cholesterol, phospholipid and minute quantities of cholesterol ester and monoglyceride 
are also present (Satterfield and Wu, 2011). BAT derives its name from the rich blood 
vessels and densely packed mitochondria in it. It is located near or around some organs 
including: brain, spinal cord, heart, lungs, and kidneys during cold stress. In infants, 
BAT comprises 5% of the total body mass and it decreases in humans as they age; it 
almost disappears by adulthood (Symond et al, 2013; Enerback 2010).
1.2.3 Development of adipose tissue
The differentiation of these cells starts at the adipoblast to pre-adipocyte stage and then 
to an immature adipose cell until it becomes a mature adipose cell, typically referred to 
as an adipocyte (Tang et al, 2008). Concerning the level of adipocytes, different cell 
populations at different stages of development are known to be present in adipose tissue 
during foetal life and early infancy. Some of these cells contain small amounts of lipid 
and represent the adipose cell mass at an early age. Then the level of the body fat 
increases after birth by increasing the fat cell size (Lonn et al, 2010). These processes 
are influenced by several factors including catecholamines, p-adrenoreceptor-mediated 
agents, thyroid hormones, insulin, growth hormone, glucocorticoids and sex steroids, 
which have been studied in vitro by using pre-adipocyte clonal cell lines, principally of 
mouse and rat origin (Zancanaro et al, 1995, Yang 2005). Both adipocyte number and 
size are responsible for increasing the size of adipose tissue mass (Tang et al, 2008). 
Hyperplastic growth is a means of enhancing the number of adipocytes by mitotic 
activity in the precursor cells. In contrast, hypertrophic growth is a means of increasing 
the size of adipocytes as a result of augmenting lipid accumulation within the cells 
(Schling and Loffler, 2002).
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1.2.4 Functions of adipose tissue
The fat storage capability of adipose tissue is associated with its traditional function as 
an energy storage tissue, but its role as an active immune-modulator and endocrine 
organ is a relatively new concept (Trayhun, 2005; Rosen et al, 2014). This concept has 
been an area of intense investigation and has been examined by highly varied 
experimental approaches to study the main secreted molecules from adipose tissue. 
Adipose tissue produces various substances with autocrine, paracrine and 
neuroendocrine actions (Figure 1.1). These substances have a role in glucose 
metabolism, insulin sensitivity, lipid oxidation, immune and vascular function and 
hormonal status (Lago et al, 2007; La Merrill et al, 2013).
1.2.5 Adipocyte endocrinology
At the beginning of the 1990s, a big advance in the recognition of the endocrine and 
secretory role of adipose tissue occurred (Rasouli and Kern, 2008). Adipocytokines or 
Adipokines is a general term that refers to a bioactive produced by the adipose tissue. 
Hotamisligil et a l (1993) reported that tumour necrosis factor alpha (TNFa) expression 
increases in obesity and has a significant responsibility in insulin resistance mechanisms 
(Hajer et al, 2008) and adipose tissue metabolism such as the stimulation of lipolysis 
and apoptosis (Dunger et al, 1996; Rabinovitch et al, 1999). However, a radical 
change in viewpoint occurred following the discovery of leptin in 1994 by Friedman 
and colleagues (Zhang et al, 1994). This vital hormone is made predominantly by white 
fat, assigning to the tissue an endocrine function. It plays a role in the regulation of 
food intake and energy expenditure by stimulating the hypothalamus, the centre of 
appetite and energy balance (Lago et al, 2007). Therefore, the discovery of leptin 
helped scientists understand the secretory role of WAT and its role in the regulation of 
metabolic and physiological homeostasis. It is now well established that adiponectin, 
leptin, adipsin, resistin, visfatin, complement factor 3, interleukin-6 (IL-6), IL-lp, IL-8 
IL-10, TNF-a, angiotensinogen and plasminogen activation inhibitor-1 (PAI-1) are also 
all produced and released by adipose tissue (Trayhum and Wood, 2005; Bullo' et al, 
2013).
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Figure 1.1: The multiple functions of white adipose tissue. The function of this tissue 
includes: synthesis, secretion and storage of lipids and production of cytokines, 
chemokines and other adipokines such as adiponectin, leptin, PPARp/5 and PAI. CCL: 
CC-chemokine ligand (CCL); CXCL: CXC-chemokine ligand (CXCL); IL: interleukin, 
PAI-1: plasminogen activator inhibitor 1, PPARp/5: peroxisome proliferator-activated 
receptor, TNF-a tumour necrosis factor, IFNy: Interferon gamma (Adapted and 
modified from Lago et al, 2007).
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Furthermore, adipose tissue is a source of chemokines including CCL2 (MCP-1) and 
fractalkine (CX3CL1) (Suganami and Ogawa 2010; Shah et al, 2011). In addition, 
overwhelming evidence has established that the residence of macrophage cells in WAT 
assists strongly in the secretory function of adipose tissue (Weisberg et al, 2003) 
(Figure 1.2).
It has been suggested that the main source of pro-inflammatory adipokines is 
macrophages, although other cells in adipose tissue such as adipocytes, preadipocytes 
and vascular cells contribute to their secretion (Fain, 2006, Sell and Eckel, 2009). Two 
types of macrophage (Ml and M2) are located in adipose tissue. Ml macrophages are 
predominantly found in adipose tissue of fatter people and they produce TNF-a and IL- 
6; thereby increasing inflammation, whereas M2 macrophages secrete IL-10 which is an 
anti-inflammatory cytokine. Both types of macrophage, together with fat cells have the 
ability to accumulate lipids and release cytokines (Fuentes et al, 2010).
Adipose tissue is an active endocrine organ, and its relationship to inflammation and the 
immune system has become the focus of much research aimed at understanding this 
relationship, its causes and consequences, in the hope that will offer new targets for 
drug development for controlling obesity and reducing its role in the occurrence of 
cardiovascular disease (CVD), T2 DM and testosterone deficiency.
1.3 Inflammation and key molecules
The key markers of inflammation include: immune cells, biological molecules such as 
cytokines, chemokines and innate effector mechanisms (Romagnani, 2002). Chronic 
systemic inflammation is associated with a reduced human life span (Finch and 
Crimmins, 2004). Although there is limited information on markers of systemic 
inflammation and their mechanism of action, there is an association between chronic 
inflammation and several diseases found in the developed world, including obesity (De 
Heredi et al, 2012), diabetes (Wang et al, 2013), atherosclerosis (Libby et al, 2009) as 
well as low testosterone, which leads to increased risk of other disease (reviewed from 
Saad et al, 2012). Therefore, a key to preventing and treating these conditions is 
reducing inflammation.
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Figure 1.2: Adipose tissue cellular components and molecules synthesized in lean 
and obese adipose tissue. Changes in adipocyte and fat size lead to physical changes in 
the surrounding area and modifications of the paracrine function of the adipocyte. 
Increased migration of monocytes to adipose tissue in response to CX3CLland CCL2 
via their receptors CX3CRland CCR2 leads to activation of macrophages from M2 to 
Mlphenotyp. This leads to reduction in anti-inflammatory factors including: 
adiponectin, IL-10 and PPARp/5 and increased secretion of free fatty acid (FFA) and 
pro-inflammatory factors including: IL-ip, IL-6, and leptin, PAI-1, CCL2, CX3CL1 and 
IL-8. The result of all these changes is damage to endothelial cells (EC) and 
development of insulin resistance (IR). (f) increase, (j) decrese. (Drawn using 
information from Ouchi et al, 2011, Shah et al, 2011; Yao et al, 2014).
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1.3.1 Factors linking obesity with inflammation
There is a causal link between obesity and the activation of the innate immune system 
(Bastard et al., 2006) leading to a low-grade inflammatory state, which has been 
observed in obese individuals and this could play a central role in obesity, T2DM- 
related IR and cardiovascular complications (De Heredi et al, 2012).
However, the occurrence of low-grade inflammation in obesity is not clearly 
understood, although hypotheses to explain this have been proposed. It could be a result 
of insufficient blood supply in growing adipose tissue, which leads to decreased 
oxygenation (Pasarica et al., 2009). Further evidence implicating adipocytes in innate 
immunity, is that fat cells have the ability to synthesize and release pro-inflammatory 
cytokines and chemokines (see section 1.2.5) (Monteiro and Azevedo 2010, Skurk et 
al, 2005, Wood et al., 2009).
These factors can activate inflammatory signalling pathways, resulting in the induction 
of further biological markers of inflammation. Although the expression, production and 
secretion of inflammation-related adipokines are augmented in adipose tissue with 
obesity, the major exception to this example of increased inflammation is adiponectin, 
the expression and concentration of which falls in obese individuals, given the anti­
inflammatory action of the hormone. Adiponectin controls the level to which adipose 
tissue is in a state of ‘inflammation’ in the obese (Von Eynatten et al., 2006; Hoffstedt 
et al., 2004; Kumada et al., 2003).
In addition, in rodent genetic models of obesity, the expression of genes coding for 
these factors in WAT result from the infiltration of macrophages of obese mice (Bastard 
et al., 2006). This is a further biological clue demonstrating that immune cells are 
implicated in obesity. There is substantial evidence supporting the significance of body 
weight loss in reducing gene expression of pro-inflammatory factors and the infiltration 
of macrophages in WAT (Clement et al., 2004). Furthermore, there have been several 
suggestions that explain and clarify the process that led to such macrophage cells 
residing specifically in WAT. One of the explanations was that macrophage cell 
accumulation in the adipose tissue was a low-grade inflammation state in obesity 
(Wellen 2005; Ford 2003).
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Other research suggests that macrophages may derive from preadipocytes (Cousin et al, 
2003) while some studies have indicated that macrophages originate from bone marrow 
precursors (Weisberg et al, 2003). In addition, leptin may have a stimulatory role in 
macrophage infiltration from the blood circulation to the WAT (Curat, 2004). 
Moreover; adipocytes can produce and release chemokines including CCL2 and 
CX3CL1 which are chemoattractant recruiting factors for circulating monocytes. Both 
chemokines are now well acknowledged for over-production in obesity (Martinovic et 
al, 2005; Shah et al, 2011). Moreover, some factors can link obesity to the immune 
system via toll-like receptors (TLR). These receptors are a family of pattem-recognition 
receptors that play a significant role in the innate immune system. They can be 
stimulated by saturated fat to enhance the expression of pro-inflammatory IL-6 and 
TNF-a (Huang et al, 2006). There is a signalling cascade that promotes the NF-kB 
pathway of both TLR2 and TLR4 in fat and macrophage cells, which then activates the 
transcription of many pro-inflammatory genes that encode pro-inflammatory molecules 
including cytokines, chemokines and other effectors of the innate immune response 
(Brown et al, 2011).
1.3.2 Adipokines and their effects
Adipocytokines are biologically active factors which work locally and systemically to 
influence glucose and fatty acid metabolism, insulin sensitivity, adipocyte 
differentiation, inflammation and the immune response. These biomarkers are classified 
according to their action as pro or anti-inflammatory factors.
1.3.3 Pro-inflammatory Adipokines
1.3.3.1 Interleukin-lp
IL-lp is a pro-inflammatory cytokine produced by a variety of cells including 
macrophages, monocytes and adipocytes. The IL-1 family contains three polypeptides 
ILl-a, IL-lp and an interleukin-1 receptor antagonist (IL-Ira) (Kim et al, 2008). They 
play a potent role in the regulation of immune cells and inflammation. A positive 
correlation between IL-lp and BMI has been reported in humans. In both human and 
rodent obesity, adipose tissue expression of IL-lp is highly up-regulated in visceral
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compared with subcutaneous fat (Moschen et al, 2011; Shaul et al, 2010). Nov et al 
(2013) suggesting that IL-ip is a regulator of adipose inflammation by promoting 
leukocyte and macrophage recruitment and enhancing macrophage lipid accumulation. 
IL-lp is also positively associated with IR; the mechanism by which IL-lp causes IR 
and subsequently affects the development of diabetes is under investigation. It has been 
suggested that it could impair insulin secretion and its signalling by stimulating insulin 
receptor substrate-1 (IRS1) serine phosphorylation (Zeyda and Sultnig, 2007). In 
addition, it may induce pancreatic beta cell apoptosis in diabetic patients resulting in 
Type 1 diabetes (Zeyda and Sultnig, 2007). The available data certainly emphasise that 
the adipocytokines, IL-lp with IL-6, have been closely linked to endothelial cell 
dysfunction (Caballero, 2003). Both IL-ip and TNF-a play a role in the induction of 
CX3CL1 by primary endothelial cells where CX3CL1 can contribute to the 
pathogenesis of atherosclerosis (Jones et al, 2010). Furthermore, IL-ip similarly to IL- 
6 and TNF-a, can also induce the liver to produce C-reactive protein (CRP) a marker of 
inflammation (Malkin et al, 2004a).
1.3.3.2 Interleukin 6
IL-6 is produced by a number of cell types including macrophages, T helper 
lymphocytes and adipocytes (Papanicolaou and Vgontzas, 2000). A positive correlation 
between IL-6 and obesity has been reported (Rocha et al, 2011). In particular, 
circulating IL-6 levels increase with an increase in BMI. Abdominal subcutaneous and 
visceral depots are both considered as the main source of this cytokine as well as white 
blood cells. Other studies confirmed that IL-6 mRNA expression is higher in VAT than 
in subcutaneous adipose tissue (SAT) (Mohamed et al, 1998, Rocha et al, 2011).
IL-6 plays an important role in the development of inflammatory conditions such as
T2DM and CVD. According to animal model and human studies, IL-6 is involved
directly in progressing T2DM by causing IR in some distant tissues such as skeletal
muscle, liver and vascular endothelial cells (Hu et al, 2004, Wallenius et al, 2002;
Klover et al, 2003). The possible mechanism of action of IL-6 is by impairing the
action of insulin (Bastard et al, 2006). IL-6 binds to its receptor (IL6R) which pathway
leads to phosphorylation signals via the Janus-kinase/signal transducers and activators
of transcription (JAK/STAT). JAK/STAT pathway is employed in the signalling of
many cytokines. The phosphorylated sites on the receptor and JAKS serve as docking
sites for the SH2 (Src Homology 2) containing STATS. Phosphorylated STATS
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dimerizes and translocates into the nucleus to regulate target gene transcription. 
However, the stimulation of the JAK/STAT receptor system via IL-6 could dysregulate 
insulin action by inhibiting serine/threonine phosphorylation of Insulin Receptor 
Substrate (IRS), which is an important ligand in the insulin response of human cells, or 
by increasing suppressors of cytokine signalling (SOCS) (Bastard et al, 2006; de Luca 
and Olefsky, 2008).
IL-6, in addition to its role in the reduction of insulin action, also has a role in causing 
CVD that is linked to inflammation by inducing hepatic CRP secretion (Rocha and 
Folco, 2011, Lee et al., 2012). It is established that the IL-6 content of adipose tissue is 
strongly correlated with circulating levels of both IL-6 and CRP, particularly, IL-6 is 
produced mainly via VAT, which might demonstrate the causal relationship between 
central depots and CVD (Hu et al., 2004). IL-6 secreted from the adipose tissue directly 
passes to the liver via the blood, where it augments hepatic triglyceride and very low 
density lipoprotein (VLDL) production, reduces lipoprotein lipase (LPL) activity and 
enhances lipolysis. This leads to dyslipidemia development which is considered as a 
cardiovascular risk complication in humans. Thus, IL-6 seems to play a role in the 
development of coronary disease and diabetes linking both diseases with obesity and 
inflammation (Bastard et al., 2006). Besides these diseases, IL-6 also has a role in 
reduction of testosterone levels by inhibiting hypothalamic production of GnRH and 
subsequent release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) 
from the pituitary. This causes a state of hypogonadotrophic hypogonadism (Kelly and 
Jones, 2013).
1.3.3.3 Tumour necrosis factor
TNF-a is a multifunctional cytokine secreted from a number of different cell types, 
principally macrophages and lymphocytes. It can also be released from muscle cells and 
adipose tissues (Sewter et al., 1999). It was initially identified as a suppressor of 
tumours; it is now involved as a significant factor in the progression of IR and heart 
disease (Pischon, 2007). TNFa was the first cytokine to be implicated in the 
pathogenesis of obesity and IR (Hotamisligil et al., 1993). TNF-a mRNA expression is 
similar in both VAT and SAT, where VAT is strongly associated with IR and 
hyperinsulinaemia (Dusserre et al, 2000).
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Other factors, such as leptin, have been proposed to induce TNF-a by other cell types 
including macrophages. TNF-a mRNA is over-expressed in adipose tissue in rodent 
models of obesity, however, the actual role of TNF-a in obese humans remains to be 
elucidated (Sakurai et al., 2013). Weight loss in fatter people is associated with a 
significant reduction in TNF-a mRNA expression in adipose tissue and improved 
insulin sensitivity (Manco et al., 2007). Therefore, it is thought that TNF-a expression 
in obese adipose tissue could originally derive from macrophage infiltration, under the 
control of leptin, rather than from the adipocytes themselves (Bastard et al., 2006). In 
addition, there is also a debate related to the physiological role of TNF-a in the 
development of IR and CVD. One possible link between IR and diabetes is that TNF-a 
can cause the phosphorylation of the insulin receptor substrate-I (IRS-I) protein on 
serine residues. This leads to impeding the interaction of insulin with its receptor beta 
subunit and its signalling pathway. Another mechanism suggested is that TNF-a may 
down-regulate glucose transporter type 4 (GLUT 4) an insulin-responsive glucose 
transport protein (Hotamisligil et al., 1996; Shi et al, 2004). TNF-a also reduced 
peroxisome proliferator-activated receptor (PPAR) expression a transcription factor that 
is abundant in adipose tissue, which may also play a role in the sensitivity of cells to 
insulin (Zehda and Stulnig, 2007). As for the role of TNF-a in the incidence of micro- 
vascular or macro-vascular complications in diabetes, TNF-a can also directly cause 
endothelial dysfunction by inducing endothelial cells, hepatocytes and adipose tissue to 
express plasminogen activator inhibitor (PAI-1) that leads to a pro-coagulant state 
(Laaksonen et al., 2005). TNF-a also sustains the development of CVD by promoting 
hepatic CRP synthesis that is the main predictor of CVD, (Figaro et al., 2006, Hu et al., 
2004, Malikan et al., 2004a). In addition, TNF-a controls IL-6 synthesis and both are 
pro-inflammatory factors associated with obesity, inflammation with diabetes and CVD 
(Hoffstedt et al, 2004). Additionally, TNF-a can, like IL-6, be associated with low 
testosterone and a state of hypogonadotrophic hypogonadism (Kelly and Jones, 2013).
1.3.3.4 C-reactive protein
CRP is the one of the acute phase proteins secreted by the liver. It is increased 
considerably during systemic inflammation/infection and is found to be a sensitive 
marker of low grade systemic inflammation. Several studies have observed that the 
level of CRP increses with increasing BMI (Ford, 2003), serum lipid and fasting blood
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glucose (Wexler et al, 2005, Thorand et al, 2003, Santos et al., 2005). In addition, 
following the Women’s Healthy Lifestyle study, losing body weight contributed to a 
reduction in CRP levels, indicating the important role of inflammation in body fat 
(Isidoris et al, 2000).
The nature of the association of CRP with IR and T2DM is not fully understood. 
Previous studies have confirmed that CRP concentration in plasma increased two fold in 
diabetic patients compared with non-diabetic subjects with acute coronary syndrome 
before and after coronary stenting (Aggarwal et al., 2003; Huoya et al., 2009). 
Furthermore, Barzilay et al., (2001) found at least a two-fold higher risk of T2DM 
within 3-4 years in obese individuals with higher CRP levels. Moreover, it is expected 
that a decrease in insulin sensitivity could lead to increased CRP expression by 
counteracting the action of insulin on hepatic acute-phase protein synthesis. The 
circulating level of CRP is a useful marker of CVD and stroke in men and women 
(Lowe et al., 2014, Kapoor et al., 2007). Evidence suggests that the production of CRP 
is induced by IL-1, IL-6, and TNF-a leading to the correlation of CRP with heart 
disease and inflammation (Klover et al., 2003, Laaksonen et al, 2005). Thus, CRP is 
considered as a marker of both inflammation and cardiovascular events; including 
myocardial infarction, stroke, peripheral arterial disease and sudden cardiac death 
(Spagnol et al, 2007).
1.3.3.5 Chemokines
Chemokines constitute a family of over 40 different cell signalling molecules. The 
structure of these chemokines is small disulphide-linked polypeptides of typically 60 - 
70 amino acids (Linton and Fazio, 2003). They have been classified into different 
subfamilies on the basis of these conserved structural features. Most chemokines 
contain four conserved cysteines which form two essential disulphide bonds, Cysl- 
Cys3 and Cys2-Cys4. The backbone of the chemokine molecule consists of beta strands, 
while the N and C terminus of the protein appear to have a less ordered structure (Table 
1.3). Chemokines are also associated with chronic inflammation related to obesity such 
as IR, T2DM and CVD (Ota et al., 2013). Adipose tissue chemokines increase in 
obesity and have an important role in leukocyte recruitment into inflammatory adipose 
tissues. It has been proposed that ffactalkine (CX3CL1) and monocyte chemotactic 
protein-1 (MCP-1/ CCL2) are vital factors for adipose tissue macrophage recruitment
and IR in obesity (Ferrante et al., 2007; Dahlman et al., 2005).
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Family
C chemokines XCLl Lymphotactina/SCMa XCR1
XCL2 Lymphotactinp/SCMp XCR1
CCL1 1-309, TCA3, P500 CCR8
CCL2 MCP-1, MCAF, (mouse; JE) CCR2
CCL3 LD78a, LD78b, MIP-la CCR1, CCR5
CCL4 Act-2, HC21or 400, MIP-lb, CCR5
CCL5 RANTES CCR6
CCL7 MCP-3 CCR1,CCR2, CCR5
CCL8 M CP-2, HC14 CCR3
CC chemokines CCL11 eotaxin CCR3CCL13 CCL12 NA I (mouse) MCP CCR2, CCR3
CCL14 MCP-4, NCC-1, CKblO CCR1
CCL15 HCC-1, HCC-3, NCC-2, MCIF CCR1, CCR4
CCL16 NCC-4, LEC, HCC-4, LMC, CCR1
CCL17 TARC CCR4
CCL18 DC-CK1, PARC, MIP-4, CKb7 Unknown
CCL19 ELC, MIP-3b, exodus-3, CKbll CCR7
CCL20 MIP-3a, LARC, exodus-1, CKb4 CCR6
CCL21 SLC, 6Ckine, exodus-2, CKb9 CCR7
CCL22 MDC, STCP-1, DC/B-CK CCR4
CCL23 MIP-3, MPIF-1, CKb8 CCR1
CCL24 MIP-3, MPIF-1, CKb8 CCR3
CCL25 TECK, Ckbl5 CCR9
CCL26 eotaxin-3, IMAC, MIP-4a CCR3
CCL27 ALP, ILC, ESkine, CTAK CCR10
CCL28 MEC, CCK1 CCR10
CXC chemokines CXCL1 GROa, MGSA-a, NAP-3 CXCR1, CXCR2
CXCL2 GROb, MIP-2a, MGSA-b CXCR2
CXCL3 GROg, MIP-2b, CINC-2b CXCR2
CXCL4 PF4 CXCR3B
CXCL5 ENA-78 CXCR2
CXCL6 GCP-2 CXCR1, CXCR2
CXCL7 NAP-2, LA-PF4, MDGF, LDGF CXCR2
CXCL8 IL-8, NAP-1 CXCR1, CXCR2
CXCL9 mig CXCR3
CXCL10 IP-10 CXCR3
CXCL11 I-TAC CXCR3
CXCL12 SDF-la, SDF-lb, PBSF CXCR4
CXCL13 BLC, BCA-1 CXCR5
CXCL14 BRAK, MIP-2g, BMAC, KS1 Unknown
CXCL16 - CXCR6
CX3C chemokines CX3CL1 Fractalkine CX3CR1
Table 1.3: Classification of chemokines and their receptors. To date, over 40 human
chemokines and 20 receptors have been discovered in humans. These chemokines are 
classified into four families (C, CC, CXC, and CX3C) dependent on the position of the 
first two cysteine motifs while chemokine receptors are classified on the basis of their 
ligand (Adapted from Mantovani et al., 2006).
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On the basis of their molecular structure, both chemokines are derived from the two 
subgroups: CC chemokine ligands (CCL) and CX3C chemokine ligand (CX3CL1) (see 
tablet.3), which bind to CC chemokine receptor (CCR), (Bruserud et al, 2010) or 
CX3C chemokine receptor (CX3CR) (Shah et al, 2009), respectively.
There is evidence demonstrating that CCL2, with its receptor CCR2, plays a key role in 
the recruitment of monocytes and infiltration of macrophage cells from the blood into 
adipose tissue. This comes from the study of CCR2-knock-out mice, where IR, hepatic 
steatosis, and macrophage accumulation in adipose tissue induced by a high-fat diet 
were reduced (Kanda et al, 2006). Moreover, there are high levels of CCL2 in both 
white adipose tissue and plasma in obese mice (Sartipy et al, 2003, Weisberg et al, 
2003, Xu et al, 2003) and it is secreted by the mouse 3T3L1 adipocyte cell line (Kanda 
et al, 2006). Additionally, CCL2- or CCR2-deficient mice showed a relative reduction 
in adverse metabolic outputs (Inouye et al, 2007).
In contrast, other studies found that lack of CCL2 neither attenuates obesity-associated 
macrophage recruitment to adipose tissue nor improves metabolic function, which 
indicates that CCL2 is not critical for obesity-prompted macrophage migration and 
systemic IR (Inouye et al, 2007 and Kirk et al, 2008). A further study reported that 
although CCR2/CCL2 is important for adipose tissue macrophage accumulation, 
deletion of these molecules only decreases macrophage recruitment to adipose tissue by 
~40% indicating that there are further chemotactic signals that are key to this process 
(Oh etal., 2012).
One of these signals is CX3CL1, which is a chemokine that has a dual structure and 
function as both an adhesion molecule and chemoattractant. Soluble CX3CL1 released 
from the cell membrane, strongly chemoattracts leukocytes (T cells and monocyte cells), 
while the membrane-bound chemokine induces strong adhesion of cells expressing the 
G protein-coupled receptor CX3CR1, through which it exerts its effect (Maegdefessel 
et al, 2009; White et al, 2010). It is thought that CX3CL1, with its receptor, is 
involved in recruitment of inflammatory monocytes and macrophages to adipose tissue 
as well. Shah and co-workers (2011) reported that CX3CL1 is elevated in the serum of 
obese patients, suggesting that CX3CL1/CX3CR1 may also be implicated in adipose 
tissue inflammation (Umehara et al, 2004; Morris et al, 2012).
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Recent data has reported that CX3CL1 is expressed in adipocytes and that CX3CR1 
signalling in macrophages is down-regulated by peroxisome proliferator-activated 
receptor (PPAR-y) agonists (Digby et al, 2010). It has been established that CX3CL1 is 
significantly increased in obesity but it can also be induced by induction of 
inflammation in vivo (Shah et al., 2011). In this study it was found that both the stromal 
vascular fraction and specific adipocytes were responsible for production of CX3CL1, 
promoting monocyte adhesion to human adipocytes. In addition, visceral adipose tissue 
is known to have greater inflammatory leukocyte infiltration (Baranova et al, 2005) and 
has higher CX3CL1 levels than subcutaneous fat. Adipose tissue macrophages in obese 
individuals express high levels of CX3CR1 (Zeyda et al, 2010). Moreover, humans 
with two common non-synonymous coding SNPs (single-nucleotide polymorphism) in 
the CX3CR1 gene and the variants causing greater expression of CX3CR1, tended to be 
associated with greater waist circumference, were more IR, and had higher leptin levels, 
but lower adiponectin levels in serum. Furthermore, these alleles tended to be associated 
with the presence of metabolic syndrome and T2DM. The association of SNPs in 
CX3CR1 with atherosclerosis and obesity (Sirois-Gagnon et al, 2011) was also 
reported (Kasama et al, 2010).
This suggests that CCL2 and CX3CL1 play important roles in the pathogenesis of 
metabolic syndrome, T2DM and CVD, therefore, inhibition of the interaction of these 
chemokines with their receptors might provide the basis for development of new 
therapies for these conditions.
1.3.3.6 plasminogen activator inhibitor
PAI-1, which is encoded by the SERPINE1 gene, is synthesised by WAT and is a key 
inhibitor of tissue plasminogen activator (tPA) (Kathiresan et al, 2005). Additionally, 
PAI-1 is produced by liver and endothelial cells but is synthesised largely by visceral 
adipocytes (Skurk and Hauner, 2004; Bastelica et al, 2002). It is noticeably elevated in 
serum in obese people and patients with IR, T2DM and CVD (Chen et a l , 2006). An 
increased in plasma PAI-1 level in obesity is well recognized in animals and humans 
(Bastard and Pieroni, 1999, Morange et al, 2000; Skurk and Hauner, 2004). More 
recently PAI-1 levels have been considered as one of the biomarkers used to predict
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obesity-associated diseases; weight loss leads to normalized or decreased levels of PAI- 
1 (Gonzalez et al., 2012).
There is increased expression of PAI-1 mRNA in adipose tissue through adipose 
differentiation processes in vitro (Bastelica et al, 2002). PAI-1 as an acute-phase 
protein, increases in response to inflammation or injury in the circulation. Inflammatory 
mediators, such as TNF-a, IL-1, IL-6 and transforming growth factor p (TGFp), have 
been shown to stimulate PAI-1 production (Hermans and Hazelzet, 2005). There are 
also hormones that regulate the expression of PAI-1 mRNA including insulin, 
glucocorticoids and sex hormones (Skurk and Hauner, 2004). Local hypoxia and the 
associated cellular stress stimulate the expression of angiogenic factors including 
vascular endothelial growth factor (VEGF), hepatocyte growth factor and PAI-1. These 
induce the inhibition of adiponectin gene transcription leading to reduction in 
adiponectin mRNA stability and in adiponectin expression in obese mice (Hosogai et al, 
2007; Bell et al, 2008). The induction of leptin and PAI-1 gene transcription 
simultaneously in adipose tissue suggests that the dysregulation of adipokine secretion 
is part of the cellular mechanism in response to hypoxia and associated cellular stress 
conditions (Chen et al, 2006). Clinical studies have shown that PAI-1 correlates obesity 
with T2DMM, CVD and low testosterone through indirect effects on insulin signalling, 
by influencing adipocyte differentiation or by regulating recruitment of inflammatory 
cells within adipose tissue, which ultimately leads to IR, characterized by visceral fat 
accumulation (Pergola et al, 2000; Alessi et al, 2007). Moreover, over-production of 
PAI-1 in excess visceral fat inhibits the fibrinolytic system and consequently may lead 
to thrombotic vascular disorders (Ryo et al, 2004). This is due to a shift in the balance 
between fibrinolysis and thrombosis, towards thrombosis facilitating the formation of 
micro-thrombi and by the ability of PAI-1 to inhibit plasminogen-induced migration of 
vascular smooth muscle cells (VSMCs) resulting in plaques prone to rupture with thin 
fibrous caps, necrotic cores and rich in macrophages (Chu et al, 2001 ).
1.3.3.7 Leptin
Leptin is a 16-kDa protein and was discovered by Friedman and colleagues (Zhang et 
al, 1994). It is one of the most important adipose-derived hormones and is encoded by 
the leptin gene (Lep (ob)) located on chromosome 7 in humans. It is a hormone that is 
almost exclusively expressed and produced by WAT and more particularly by
differentiated mature adipocytes, which binds to its receptor in the hypothalamus and 
other tissues (Ahima et al, 2000). This is evidenced from several human and animal 
studies (Trayhum and Beattie, 2001).
Leptin is a key appetite-regulating hormone, with effects on energy expenditure. There 
is a significant association between leptin and both BMI and fat mass. Circulating levels 
of leptin (Considine et al., 1996) and adipose tissue leptin mRNA expression are 
increased proportional to body fat mass, in obesity (Vidal et al, 1996). However in 
obese people, receptors of leptin are insensitive to the effects of leptin leading to leptin 
resistance (Myers et al, 2010). The pathway of leptin control in obese people is 
defective to some extent, thus the body does not sufficiently receive the satiety effect, 
subsequent to eating. Furthermore, although leptin functions predominantly at the level 
of the central nervous system to control food intake and energy expenditure, there is a 
relationship between leptin and the low-grade inflammatory state in obesity, suggesting 
that leptin could display peripheral biological activities as a function of its cytokine-like 
structure (Ahima et al, 2000). The role of leptin in the inflammatory response by 
association with the presence of hyperleptinemia, without obesity (Loffreda et al, 1998, 
van Dielen et a l , 2001; Bastard et a l , 2006) and in controlling TNF-a production by 
macrophages, although, the exact mechanisms have not been identified (Bastard et a l ,
2006). Moreover, the leptin receptor has been recently detected in peripheral tissues, 
suggesting further roles for leptin and a much broader range of actions than initially 
supposed. One of these functions is regulation of glucose metabolism, where 
considerable evidence suggests that insulin and leptin act in the brain as adiposity 
negative feedback signals (Morton and Schwartz, 2011). Certainly, recent study 
revealed that leptin has an effect on modulation of insulin action in the liver, normalizes 
hyperglycemia and hyperinsulinemia and increases insulin sensitivity (Amitani et al, 
2013).
An additional role for leptin in vascular diseases has been reported, with elevated 
plasma leptin leading to adipocyte dysfunction, which is associated with the presence of 
risk factors for vascular disease such as increased BMI, CRP, low density lipoprotein 
(LDL) and triglycerides (TG) (Wolk et al, 2004, Brennan et al, 2007; Iribarren et al,
2007). Finally, leptin has an inhibitive role on the hypothalamic -pituitary -testicular 
axis causing a state of hypogonadotrophic hypogonadism and low testosterone levels 
(Jones, 2010). Therapeutic potential of leptin in obesity, T2DM, testosterone deficiency 
and CVD has been proposed (Amitani et al, 2013).
20
1.3.4 Anti-inflammatory adipokines
1.3.4.1 Adiponectin
Adiponectin is highly expressed in adipose tissues and has a varied nomenclature: 
ACRP30 (adipocyte complement-related protein of 30kDa), adipoQ in mouse and 
GBP28 (gelatin-binding protein 28) and/or APM1 (adipose most abundant gene 
transcript 1) (Kadowaki and Yamauchi 2005). Recent genetic studies have reported that 
the expression of adiponectin mRNA is dependent on the adipose tissue localization, 
with higher expression in SAT than in VAT (Bastard et al, 2006). Adiponectin has two 
receptors, adipoRl and adipoR2, adipoRl is expressed in skeletal muscle whereas 
adipoR2 is in the liver (Rocha and Folco, 2011; Yamauchi et al, 2003). In addition, as 
opposed to other adipose derived proteins, the level of adiponectin decreased with 
increased body fat and increased with weight loss. Therefore, low levels of adiponectin 
are correlated with T2DM, CVD and dyslipidemia (Lihn et al, 2004). Further 
investigation is required to understand how low levels of adiponectin lead to IR and its 
components. Studies in mice indicate injection of adiponectin stimulate non-esterified 
fatty acid oxidation and at the same time, reduce plasma levels of glucose (Fruebis et 
al, 2001). After treating these animals with adiponectin for the long term, there is a 
decrease in the triglyceride storage in liver and muscle, an improvement in insulin 
sensitivity by reducing hepatic glucose, a decline in triglyceride and free fatty acid 
levels and a rise in HDL concentration (Yamauchi et al, 2001; Hoffstedt et al, 2004). 
This was confirmed by clinical studies suggesting that circulating adiponectin was 
positively associated with enzymes that control lipid metabolism and also explained the 
negative correlation between adiponectin and CVD (Siasos et al, 2012). Furthermore, 
adiponectin is also considered as a potential anti-atherogenic factor, but it remains 
unclear which pathways mediate the inverse relationship between adiponectin and CVD 
and diabetes (Ouchi et al, 2001, Diez and Iglesias et al, 2003; Siasos et al., 2012). 
relationship may relate to the role of adiponectin in the inhibition of TNF-a induced 
activation of NF-kB suggesting a role as an anti-atherosclerotic factor. TNF-a and IL-6 
both decrease human adipocyte mRNA expression of adiponectin, which is an 
additional means by which these two adipokines induce IR (Ouchi et al, 2000, Bruun et 
al, 2003). Additionally, adiponectin can stimulate adenosine monophosphate-activated 
protein kinase (AMPK), which it is known to mediate the cellular malonyl CoA 
concentration by suppressing acetyl CoA and this demonstrates additional mechanisms
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of action for adiponectin in improved insulin sensitivity (Bastard et al, 2006). 
Adiponectin also plays a role in regulating liver glucose production by reducing mRNA 
expression of phosphoenol pyruvate carboxykinase and glucose-6-phosphatase, two key 
enzymes in neoglucogenesis (Kadowaki and Yamauchi, 2005). Furthermore, 
adiponectin might protect the vascular wall by controlling the atherogenesis process: 1) 
by alteration of endothelial cell adhesion molecules, 2) conversion of macrophages into 
foam cells and 3) modulating vascular smooth muscle cell proliferation. Moreover, an 
inverse relationship was seen between adiponectin and the level of testosterone in 
diabetic men (Kapoor et al, 2007; Bai et al., 2011). In addition, testosterone 
administration is associated with a decline in serum adiponectin in animals and by 
reduced protein secretion in cultured adipocytes (Nishizawa et al., 2002). However, the 
mechanism of the reduction in adiponectin levels during testosterone treatment is not 
understood.
1.3.4.2 Interleukin -10
Interleukin-10 is an anti-inflammatory cytokine, which is a major inhibitor of pro- 
inflammatory cytokine and chemokine production (Hong et al., 2009). It is secreted by 
lymphocytes, macrophages and monocytes. Juge-Aubry et al. (2008) have found that 
IL-10 is also produced by human WAT explants following lipopolysaccharide (LPS) 
and TNF-a treatment in vitro. In addition, Esposito et al. (2003) conducted the first 
study which showed a significant relationship between lower levels of IL-10 and 
metabolic syndrome in women, independent of age and body weight. However, the 
main actions of anti-inflammatory cytokines in human obesity are unclear. Studies have 
reported that anti-inflammatory cytokines are suitable for the treatment of T2DM as IL- 
10 was shown to promote pancreatic P-cell function in response to glucose in vitro 
(Pennline et al, 1994). In this regard, plasma levels of IL-10 are strongly associated 
with insulin sensitivity in healthy subjects and decrease in obese and diabetic patients 
(Scarpelli et al., 2006).
Animal studies have demonstrated the protective effect of IL-10 against some 
inflammatory conditions including atherosclerotic lesion formation and stability 
(Esposito et al, 2003). All these anti-inflammatory effects for IL-10 may relate to its 
role in the inhibition of TNF-a effect, lowering CRP (Manigrasso et al, 2005) and IL-6 
(Ouyang et al., 2011). Furthermore, a positive relationship has been noted between IL-
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10 and adiponectin, where adiponectin is able to increase the level of IL-10 in human 
macrophages (Kumada et al., 2003).
1.4 Testosterone deficiency
Low testosterone is associated with a number of health problems in men including 
obesity, metabolic syndrome, diabetes and CVD, but the exact mechanisms involved are 
unclear. There is an association between testosterone levels and mortality in men, but 
causality has not been proven (Ma and Tong, 2010). Testosterone replacement therapy 
leads to improvement the signs and symptoms of low testosterone in men (Jones and 
Saad, 2010). Testosterone is an androgen male hormone, synthesised in Leydig cells of 
the testis and to a lesser extent in the adrenal glands and female ovaries. The core of its 
structure is cholesterol, which is the initial substrate in steroidogenesis (Figure 1.4). The 
steroidogenesis of testosterone is usually under luteinizing hormone (LH) control, 
which is produced by pituitary gland. The secretion of LH hormone is regulated by 
GnRH (Veldhuis et al., 2009).
The binding of testosterone to specific proteins is required for transportation through the 
blood stream. 60-80% is bound to the sex hormone binding globulin (SHBG) and 20- 
40% is bound to albumin, whereas approximately 2% is transported as free testosterone 
(FT) (Kapoor et al., 2005; Schwarcz and Frishman, 2010) (Figure 1.3). The 
physiological action of the androgen depends on diverse factors such as the number of 
androgen molecules, distribution of the androgen and its metabolites inside the cells and 
interaction with its receptors. The key functions of testosterone are maintenance of male 
reproductive organs and spermatogenesis, the induction of primary and secondary 
sexual characteristics in males and in the regulation of lipid metabolism (Nieschlag et 
al., 2012). \Testosterone acts following conversion to dihydrotestosterone by 5a- 
reductase, which is the bioactive form, in order to bind to its receptors (AR). It is 
converted to estradiol by aromatase and then stimulates the estrogen receptor (ER) 
(Corbould, 2007) (Figure 1.4)., Testosterone action is regulated by both genomic and 
non-genomic mechanisms. For genomic mechanisms, the AR plays a role in the 
mediation of androgen action via activating transcription and altering gene expression. 
Testosterone can directly bind to inactive ARs in the cytoplasm, which forms a complex 
with its ligand (Pratt and Toft 1997, Deffanco 2000; Wilson et al., 2011).
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Figure 1.3: Fractions of circulating total testosterone in men. Non-SHBG-bound 
testosterone is called bioavailable testosterone and comprises both albumin-bound 
testosterone and free testosterone. Bioavailable testosterone is readily available to the 
tissues. T: testosterone. SHBG: Sex hormone binding Glubin (Adapted from Kapoor, 
2005).
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Figure 1.4: The Synthesis of testosterone pathway from cholesterol in human testis.
Blue: Enzyme (Redrawn using information from Nieschlag et al., 2012).
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Upon ligand binding, the nuclear receptors translocate from the cytosol to the nucleus, 
where they dimerize and bind to regulatory DNA sequences on target genes, activate 
transcription leading to protein synthesis (Simental et al, 1992, Isaacs, 2004; Wilson et 
al, 2011). In addition, testosterone can act in a genomic mode, when it is converted to 
DHT in the cytoplasm by 5a-reductase by the same process (Rommerts, 2004). 
However, it should be noted that DHT has a much higher affinity for the AR than its 
precursor testosterone and has a slower detachment rate from the receptor complex, 
amplifying the effects of testosterone more than two-fold, therefore it is considered a 
more potent androgen. The other form of androgen activation is transformation of 
testosterone to estradiol by the enzyme aromatase, which diversifies androgen action by 
facilitating effects mediated via ERs. Consequently, while DHT may be considered a 
potent androgen because of its ability to bind to the AR, testosterone has a wider 
spectrum of action which includes diversification by aromatisation and hence ER 
mediated effects (Rommerts, 2004). In addition to this genomic effect for testosterone 
and DTH, it has been reported that androgens, as well as progesterone and estrogen, can 
exert quick, non-genomic actions (Falkenstein et a l, 2000).
Non-genomic androgen activity implicates the rapid induction of conventional second 
messenger signal transduction cascades, compared to significant delay between ligand 
binding and the effect on the genomic androgen receptor pathway. Furthermore, second 
messenger induction by non-genomic steroid action is insensitive to inhibitors of 
transcription and translation. Testosterone may display these non-genomic effects by 
binding to a G-protein coupled receptor specific for the SHBG-testosterone complex, 
which, in turn, initiates a cAMP-mediated non-transcriptional pathway, rapidly 
affecting intracellular calcium concentrations (Heinlein et al, 2002). Calcium 
fluctuations are subsequently involved in the activation of intracellular signalling; 
ultimately influencing specific target proteins and cellular responses (Heinlein et al,
2002) (Figure 1.5). As testosterone acts in genomic and non-genomic modes, it can 
have multiple functions in several tissues (Diano et al, 1999; Schwarcz and Frishman, 
2010). Several types of androgen receptor blockers such as flutamide, nilutamide and 
bicalutamide are used for determining the mechanism by which these androgens act. 
Inhibition of the main enzymes involved in metabolism of androgen, such as aromatase 
or 5a-reductase, is a further approach for understanding the action of this androgen.
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Figure 1.5: Summary of genomic and non-genomic of androgen action. The
genomic signalling of androgen (A) converts testosterone to dihydrotestosterone by 5a 
reductase which binds to the AR. The binding of dihydrotestosterone to AR results in 
translocation to the nucleus. The androgen receptor dimer binds to a specific sequence 
of DNA known as a hormone response element. In the non-genomic of androgen action 
(B), testosterone mediates rapid effects through G-protein coupled receptors leading to 
effects including fast intracellular Ca2+ increases, activation of Ca2+-dependent enzymes 
and second messenger cascades including cAMP, which activates protein kinase. AR: 
androgen receptor; DHT: dihydrotestosterone, mAR: putative membrane AR, ARE: 
androgen response element, GDP: Guanosine diphosphate, GTP: Guanosine-5'- 
triphosphate, ATP: adenosine triphosphate; cAMP: cyclic adenosine monophosphate, 
PK: protein kinase. (Drawn using information from Lattouf et al, 2006; McGrat et al, 
2008).
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Advancing age and conditions such as diabetes and obesity are common causes of low 
testosterone (Gooren, 2003). According to the Endocrine Society’s Clinical Practice 
Guideline, low testosterone is defined as a total testosterone (TT) concentration of less 
than 300 ng/dl or less than 10.4 nmol/1 for total testosterone and less than 5 ng/dl or less 
than 0.17 nmol/1 for free testosterone (Hall et al, 2008).
Diagnosis of testosterone deficiency is dependent on both biochemical and clinical data. 
The period of the secretion of testosterone, which is usually in the early morning 
between 8:00 am and 11:00 am, should be taken into consideration when measuring TT 
in serum. Variations in laboratory methodology are another factor to be considered 
when reviewing these data (Crawford, 2007, Kapoor et al, 2007; Schwarcz and 
Frishman, 2010).
1.4.1 Low testosterone and the link to obesity
The incidence of testosterone deficiency has increased along with the increase in obesity 
in aging men (Surampudi et al, 2012). In recent studies, where body fat has been 
determined in relation to sex hormone concentrations in men, testosterone (or free 
testosterone) concentrations associate negatively with measures of central fat 
accumulation, rather than other peripheral adipose tissues (Alexandersen and 
Christiansen, 2004). Several epidemiological studies indicate an inverse relationship 
between serum testosterone and obesity. Low serum testosterone predicts the 
development of central obesity and accumulation of intra-abdominal fat. Also, low total 
and free testosterone and SHBG concentration are related to an increased risk of 
developing MetS, independent of age and obesity (Allan and McLachlan, 2010, 
MacDonald et al, 2010; Brand et al, 2011). Lowering serum testosterone levels in 
older men with prostate cancer, treated with androgen deprivation therapy (ADT), 
increases body fat mass (Faris and Smith, 2010). In the same way, high BMI and central 
adiposity are accompanied by and predict low serum total, and to a lesser extent free, 
testosterone and SHBG concentrations (Laaksonen et al, 2005; Wang et al, 2011). 
Low testosterone influences the increase in the degree of obesity, particularly in central 
positions, which indicates the inverse relationship between both total and free 
testosterone and SHBG and WHR (Van Aders et al, 2005, Chandel et al, 2008 and 
Mohasseb et al, 2013). This may explain the development of IR as a result of obesity 
among low testosterone patients (Pradhan, 2007). It also explains the significant
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relationship between the spread of T2DM and CVD among hypogonadal patients (Fu et 
al., 2008). Furthermore, in ADT of prostate cancer patients, both visceral and 
subcutaneous abdominal fat increased in a 12-month prospective observational study 
(Hamilton et al, 2011). Generally, androgens can regulate different phases of adipocyte 
functions such as lipid metabolism and differentiation by their effect on ARs, which 
regulate its functions by activating the downstream genes in human adipose tissues. 
This seems to be related to the function of testosterone as a suppressor of lipoprotein 
lipase in adipose tissue, whereby this enzyme plays a significant role in the regulation of 
triglyceride uptake and lipid mobilization; it ultimately leads to reduction in visceral fat 
mass (Cohen, 1999; Traish et al., 2009). This action is usually absent in the low 
testosterone individual and it consequently lead to augmentation of the level of 
abdominal fat body in a cycle of low testosterone levels and obesity (the hypogonadal- 
obesity cycle hypothesis) (Figure 1.6).
Other possible mechanisms of testosterone actions are related to its structure as a steroid 
hormone, which can be aromatized by aromatase in the adipose tissue to estradiol, 
causing a reduction in the level of testosterone. The aromatase level is often high in 
adipose tissue of obese individuals and is associated with testosterone conversation to 
17b estradiol (E2). E2 has inhibitive action on hypothalamic production of GnRH and 
subsequent release of LH and FSH from the pituitary. This, in sequence, decreases 
gonadal stimulation and inhibits testosterone release, thus causing a state of 
hypogonadotrophism and the increase in obesity (Kelly and Jones, 2013). As a result of 
the increase in obesity, there is an increase in production of IL-6, TNF-a and leptin from 
visceral adipocytes. These mediators have the ability to inhibit LH and FSH hormone 
secretion by binding to their receptors in the pituitary gland. Therefore, the role of both 
hormones in the stimulation of released testosterone from the testes is absent. This leads 
to exacerbation of the testosterone deficiency state in obese people (Ding et al, 2006, 
Jones, 2010). In addition, testosterone therapy led to a decrease in obesity in 
hypogonadal and eugonadal men (Dandona and Rosenberg, 2011). Moreover, 
testosterone replacement reduced IR and increased insulin sensitivity in obese people, 
which leads to decreasing symptoms of T2DM and CVD (Jones et al, 2011). However, 
clinical findings are not as clear, for example, there was no change in visceral fat mass 
in aged men with low testosterone levels following 6 months of transdermal TRT, yet 
subcutaneous fat mass was significantly reduced in both the thigh and the abdominal 
areas when analysed by magnetic resonance imaging (MRI) (Frederiksen et a l, 2012b).
28
Estradiol
Hypothalamic- 
pituitary axisTNF-aIL-6
Leptin
T Insulin 
resistance i  LH pulse amplitude
' Adipocyte number 
and size
Testis
Aromatase
Adipose
tissue i  TestosteroneTriglyceride
uptake
Figure 1.6: The Hypogonadal-Obesity-Adipocytokine hypothesis, (i) An increase in 
aromatase activity in adipocytes converts testosterone to estradiol. This decreases the 
suppressive testosterone action on lipoprotein lipase, (ii) Activation of lipoprotein lipase 
increases triglyceride up-take by adipose tissue, (iii) Increased adipocyte mass is 
associated with greater insulin resistance, (iv) Estradiol and adipocytokines TNF-a, IL-6 
and leptin (as a result of leptin resistance in human obesity) impairs the hypothalamic- 
pituitary-testicular axis response to declining androgen levels (blue arrows). The orange 
arrows represent the hypogonadal-obesity cycle. Green arrow, low testosterone 
stimulates the formation of adipocytes from pluripotent stem cells. LH: luteinizing 
hormone +, positive effect; -  negative effect. (Adapted from Jones, 2010).
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In addition, testosterone treatment in the short-term decreased WC in diabetic patients 
(Jones 2010), whereas a placebo-controlled clinical study in middle-aged obese men 
found a neutral effect of testosterone on lean tissue mass after eight months of treatment 
and effects on fat tissue mass depended on the region measured (visceral fat tissue mass 
decreased, whereas subcutaneous fat tissue mass remained unchanged) (reviewed from 
Saad et al., 2012).
1.5 Type two diabetes
Type two diabetes mellitus (T2DM) is a set of related diseases in which the body cannot 
regulate the amount of glucose in the blood. This is a result of IR, which is identified as 
the failure of target organs to respond normally to the action of insulin. IR causes the 
incomplete suppression of hepatic glucose output and impaired insulin-mediated 
glucose uptake in the periphery (skeletal muscle and adipose), leading to an increase in 
insulin requirements (Adilson et al., 2008). The outcomes of IR include impaired 
insulin action which is known as the first stage of T2DM, glucose intolerance, 
hyperglycemia, hyperinsulinemia and dyslipidemia, which are collectively referred to as 
metabolic syndrome (MetS) (Tony and Sudhesh, 2005; Van Gaal et al., 2010). 
Progressive development of IR is a prediabetic state which is today a common 
metabolic abnormality of people living in developed societies. According to the 
American Heart Association and the National Heart, Lung and Blood Institute (Tony 
and Sudhesh, 2005) clinical criteria for diagnosis of IR or MetS is dependent on the 
following features:
• Waist circumference >102cm in men and in women more than 88cm.
• Fasting triglyceride (TG) concentration >150mg/dl (1.7 mmol/1).
• HDL cholesterol <40 mg/dl
• Blood pressure >130/85mmHg
• Fasting glucose level >1 lOmg/dl (>6.1 mmol/1).
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1.5.1 The role of insulin in glucose and lipid metabolism
Insulin assists the transport of glucose from the blood by stimulating the translocation of 
GLUT4 to the plasma membrane (de Luca and Olefsky, 2008). It promotes storage of 
glucose in the form of glycogen in the liver by stimulating enzymes that are directly 
involved in glycogen synthesis such as phosphofructokinase and glycogen synthesase. 
When the liver is saturated with glycogen, any further glucose is converted to fatty acid 
synthesis (De Luca and Olefsky, 2008; Kaipe et al., 2011). These fatty acids are 
exported from the liver to other tissues by lipoproteins in the blood circulation. 
Lipoproteins act as transporters of fatty acids to other tissue such as adipocytes, which 
use them to synthesise triglycerides. Insulin also suppresses the degradation of fat in 
adipose tissues by inhibiting the lipoprotein lipase that hydrolyses triglycerides to 
release fatty acids (Frayn et al., 2006). By these mechanisms, insulin is associated with 
further accumulation of triglyceride in fat cells leading to an increase in fat 
accumulation in adipose tissue (Nussey and Whitehead, 2013).
1.5.2. The effect of absence of insulin action on glucose and lipid 
metabolism
The absence of insulin action is usually as a result of a defect in insulin secretion or IR 
(Bailey, 2007). In cases of IR, there is a reduction in tissue capacity to respond to 
insulin even though there is hyperinsulinemia. Because of this, the body acts as if it is 
fasting in an insulin absence state. Thus, all the aforementioned effects of insulin are 
reversed. Firstly, an increase in the glucose concentration in blood leading to 
hyperglycemia is seen. Secondly, glycogenolysis and hepatic gluconeogenesis are 
increased (Silvio et al., 2012). Finally, it provokes lipolysis in fat tissue as a 
consequence of the stimulation of hormone sensitive lipase and the inhibition of 
lipogenesis. This causes hydrolysis of the stored triglyceride, releasing large quantities 
of fatty acids into the blood (Figure 1.7). Consequently, the plasma FFAs then become 
the main energy substrate used by essentially all tissues of the body besides the brain. 
The excess of fatty acids in plasma also promotes liver conversion of some of the fatty 
acids into phospholipids and cholesterol, two of the major products of fat metabolism 
(Blaschke et al., 2006). These two substances, along with excess triglycerides formed at 
the same time in the liver, are then discharged into the blood as lipoproteins with their 
co-receptors such as, Apo Al and Apo B, Apo E.
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Figure 1.7: Association of lipolysis in adipose tissue with insulin resistance 
development. The exposure of the liver to elevated free fatty acid concentration results 
in increased ( T ) very low density lipoprotein (VLDL) and glucose production resulting 
in peripheral hyperinsulinaemia which enhances insulin resistance and hyperglycemia. 
(Adapted and redrawn from Tony and Sudhesh, 2005).
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Occasionally, plasma lipoproteins increase as much as three fold in the absence of 
insulin leading to a dyslipidemia state leading to CVD in T2DM patients (Tony and 
Sudhesh, 2005; Mooradia 2009).
1.5.3 Obesity and diabetes
The development of T2DM relates to several risk factors, but the most significant ones 
are defined by an increase in the prevalence of sedentary lifestyles and the incidence of 
obesity. Obesity is a powerful risk factor involved in the development of T2DM with 
more than two-thirds of patients with T2DM being obese (Hossain et al, 2007). The 
risk of developing diabetes increased five-fold with BMI of 25kg/m2 compared with 
those with BMI of 22 kg/m2. The risk becomes higher, reaching 28-fold with BMI of 30 
kg/m2 and 93-fold with a BMI > 35 kg/m2. IR is a common association with obesity, 
where obese people cannot use insulin efficiently and this leads to the progression to 
T2DM and its complications including, hyperglycaemia, dyslipidemia, hypertension and 
CVD (Tony and Sudhesh, 2005). There are different pathways and mechanisms that 
link obesity with IR, including the distribution of body fat, the role of free fatty acids 
(FFA), adipokines, pro and anti-inflammatory mediators and genetic factors.
1.5.4 The role of obesity in insulin resistance induction and diabetes
1.5.4.1 Adipose tissue distribution
The distribution of adipose tissue is an important factor in IR, for instance, visceral
depots contribute more than peripheral adipose tissues to IR. The reasons include:
visceral adipose tissue is metabolically and hormonally more active than other body fat
tissue (Ferrannini et al, 2008). The level of FFAs in central fat tissue is higher than in
other sites (Fain, 2006). These higher FFAs can flux directly from the central fat tissue
into the liver via the hepatic portal vein, compared with other adipose tissues, which
drain into the liver via the systemic blood circulation (Kapoor et al, 2005). In addition,
the number of macrophages is higher in central body fat than in peripheral fat depots
(Trayhum and Wood, 2005). IL-6, which enhances CRP liver synthesis and induces IR,
is also largely expressed in visceral abdominal adipose tissue, compared with
subcutaneous abdominal tissue (Fried et al, 1998; Kershaw and Flier, 2004). Moreover,
the expression of genes for angiogenesis and fatty acid-binding protein 4 (require for
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fatty acid transfer in adipocytes) are higher in visceral adipose tissue than in 
subcutaneous abdominal tissue (Wagenknecht et al, 2003). Conversely, TNF-a 
synthesis is similar in both fat sites, whereas leptin secretion is mostly in subcutaneous 
adipose tissue (Bastard et al., 2006).
1.5.4.2 Free fatty acid and Toll-like receptor 4
FFAs are more resistant to the metabolic effect of insulin and more sensitive to lipolytic 
hormones. An increased delivery of FFAs to the liver may reduce insulin binding to 
hepatocytes, and impair insulin action with increased hepatic glucose production 
(Caballero, 2003). These FFAs can also compete with glucose as an alternative source 
of energy. FFAs also reduce the response of cells in the liver and adipose tissue to 
insulin, via their effect on the receptors for insulin, which causes hyperinsulinemia 
(Boden et al, 2005; Guilherme et al, 2008). FFAs can stimulate TLR4 which belongs 
to the family of Toll-like receptors that function as pattern recognition receptors that 
guard against microbial infections as part of the innate immune system. The stimulation 
of TLRs leads to activation of NFkB, JNK and IkB kinase (IKK) signal pathway and 
then increased expression of TNF-a and plasma levels of CCL2, which enhance IR (Shi 
et al, 2006; Huang et al, 2006) (Figure 1.8).
1.5.4.3 Adipocyte-derived factors
Fat cells and macrophages in adipose tissue produce a range of mediators including 
TNF-a, IL-ip, IL-6 , resistin, PAI-1 ad CCL2, which play a role in the development of 
IR and T2DM in skeletal muscle, liver and endothelial cells (Caballero, 2003, Olefsky 
and Glass, 2010, Schenk et al, 2008; Donath et al, 2011). These adipocytokines can 
impair glucose tolerance through specific intracellular signalling pathways, involving 
NF-kB, IKK, Activating Protein-1 (AP-1) and JNK signalling pathway. All these 
pathways could interact with insulin signalling via serine/threonine inhibitory 
phosphorylation of IRS (Hajer et al, 2008, Pradhan, 2007; Blaschke et al, 2006) 
(Figure 1.8). On the other hand, a low concentration of anti-inflammatory cytokines 
such as adiponectin and IL-10 is associated with IR and hyperinsulinaemia (Makki, 
2013). Adiponectin and IL-10 both reduced the level of IL-6 and TNF-a, which induce 
IR and correlate negatively with insulin sensitivity in human (Bruun et al, 2003; Makki, 
2013).
34
Glucose
Glucose
uptake
Glucose utilization 
Glycogen synthesis 
Lipid synthesis 
Protein synthesis
Lipolysis
Gluconeogenesis
3-------------- 1
Glucose
Plasma
membrane
FFA
Cytokines 
receptor
f Lipolysis 
Gluconeogenesis
TNF-o*~ 
JNK ; IL4 * "
• Inflammatory 
gene expression
Figure 1.8: The pathway of insulin signalling and its impairment in inflammation.
(A) Insulin binds to receptor with both a and p subunits. This ligand binding activates 
IRS, triggering of PI3K leading to the activation of AKT. The PI3K/AKT pathway 
regulates the insulin action on metabolic effects including glucose uptake and utilization, 
lipid synthesis, glycogen synthesis, protein synthesis, and glycogen synthesis). (B) 
Activation of TLRs by FFA inhibits IRS directly through activation of the NFkB and 
AP-1 signallings pathways or indirectly via stimulating pro-inflammatory cytokines (IL- 
6 and TNF-a) production, which prevent action of SOCS. TNF-a supresses GLUT4 or 
IRS via stimulation of the serine kinases, Ikkb. IL-6 and leptin act as negative regulators 
via stimulation of the Jnkl. All these action links inflammation to obesity-induced IR. 
IRS: Insulin Receptor Substrate, GLUT4: glucose transport 4, PI3K: Phosphoinositide 
3-kinase, Akt: Protein Kinase B, FFA: free fatty acid, TLRs: Toll-like receptors, NFkB: 
nuclear factor kappa, AP-I: Activator Protein-I, IKKb: IkappaB kinase, JNK: Jun N- 
terminal kinases, SOCS: Suppressor of cytokine signalling, (Drawn using information 
from De Luca and Olefsky, 2008; Friihbeck et al., 2001).
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Furthermore, low adiponectin level, as well as leptin, may negatively affect biochemical 
reactions of glucogenesis and glucose uptake (Kajowaki and Yamauchi, 2005). Leptin 
as an insulin-sensitizing hormone and its deficiency, or resistance, as a potential link 
between obesity and diabetes, has been reviewed recently (Martin et al, 2008; 
Cummings 2013) (Figure 1.8). Additionally, CX3CL1 and CCL2 are significantly 
increased in obesity and are good predictors for the development of T2DM (Panee 
2012). Their role as important immune mediators in physiological and pathological 
processes might also translate into increased macrophage infiltration into adipose tissue, 
as observed in obesity (Tateya et al, 2010; Shah et al., 2011).
1.5.4.4 Peroxisome proliferation activated receptors (PPARs)
The peroxisome proliferator-activated receptors (PPARs) are a family of nuclear 
receptors which are ligand-modulated transcription factors that regulate gene expression 
of numerous proteins involved in lipid metabolism, glucose homeostasis and 
inflammatory pathway regulation (Shoelson et al., 2006). PPARa, PPARp/5 and PPARy 
are expressed in several tissues includes smooth muscle, vascular wall and adipose 
tissue (Issemann et al., 1993, Shulman et al., 2005; Filip-Ciubotaru et al., 2011). These 
receptors are essential for the actions of many insulin sensitizers (Bhatia and 
Viswanathan, 2006). For example, PPARa null mice demonstrated that PPARa 
activates genes implicated in lipid metabolism in the liver including fatty acid uptake 
and p-oxidation taking place in the mitochondria (Im et al., 2011). PPAR6 is expressed 
in metabolically active sites such as liver, muscle, and fat, and has a role in metabolic 
syndrome (Lee et al, 2006). PPARS ligands reduce triglyceride accumulation in BAT 
and liver and enhance fatty acid oxidation in genetically obese mice (Tanaka et al.,
2003).
In models of high-fat diet-induced obesity, PPARS ligands result in retarded weight 
gain indicating that clinical use of PPARS activators could be beneficial as anti-obesity 
agents (Cho et al., 2012). PPARS is an important regulator of energy expenditure and 
glucose and lipid metabolism (Billin et al, 2008), where it increases 
glycolysis/lipogenesis in the liver while activating fat burning in muscle (Lee et al, 
2006). PPARy shows a significant anti-inflammatory action at the level of macrophage- 
mediated pro-inflammatory responses. It inhibits recruitment of macrophages to sites of 
inflammation via the suppressor of transcription of CCL2 as well as its receptor CCR2
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(Szanto et al, 2008). PPARy activation has been shown to inhibit macrophage pro- 
inflammatory cytokines synthesis, TNF-a, IL-lp and IL-6 via an effect on NF-kB 
(Lefebvre et al, 2006; Szanto et al, 2008). However, it is clearly noted that PPARs 
contribute to the development of IR or impaired insulin secretion through their role in 
lipid metabolism, glucose homeostasis and inflammatory factor production, thus, 
PPARs are potential therapeutic targets for IR.
1.5.5 Low testosterone and the link to T2DM
IR and hyperglycemia are key features of T2DM, which is usually combined with 
abdominal obesity. Abdominal obesity is also associated with testosterone deficiency; 
therefore, obesity is linked to testosterone deficiency and T2DM. Overwhelming 
evidence demonstrates that a reduction in testosterone is associated with the progress of 
several clinical features linked to T2DM: total testosterone is conversely correlated with 
IR and insulin concentration in men (Simon et al, 1997 and Jones, 2010). Furthermore, 
numerous studies indicate that testosterone deficiency is a predictor for the prevalence 
of IR and T2DM in healthy men (Oh et al, 2002; Jones and Saad, 2009). Testosterone 
deficiency is more widespread among male diabetic patients (Grossmann et al, 2008) 
and hypogonadism cases are also coupled with T2DM (Kapoor et al, 2007).
It is known that central obesity is associated with low testosterone and vice versa. In a 
German study, low level testosterone was observed with an inverse correlation with 
BMI in 155 diabetic patients compared to 155 healthy controls (Zietz, 2000). An 
improvement in IR and a significant reduction in the level of fasting post-prandial and 
mean daily blood glucose were initially observed in men with T2DM who were treated 
with testosterone (Boyanov et al, 2003). Possible explanations for the inverse 
relationship between testosterone and IR are: firstly, a significant reduction in central 
obesity following testosterone treatment leads to reduced level of aromatase in adipose 
tissue, thus inhibiting conversion of testosterone to estradiol and prevention of a 
negative feedback of estradiol on testosterone secretion via the hypogonadal pituitary 
axis (Dandona and Dhindsa, 2011). Secondly, FFAs are associated with IR, therefore, 
testosterone replacement therapy by decreasing abdominal fat mass leads to reduced 
circulating levels of FAAs and subsequently IR. The effect of testosterone on reduction 
of central obesity could be by decreasing the uptake of triglycerides to adipocytes
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through inhibition of the lipoprotein lipase enzyme activity (Marin et al, 1992; Kapoor 
et al., 2005). Finally, further actions of testosterone in T2DM include: the action of 
testosterone as an anti-inflammatory factor that inhibits pro-inflammatory cytokine and 
chemokine expression especially associated with IR (Pittas et al., 2004; Norata et al., 
2006).
It has long been known that testosterone acts as an immune-modulatory factor and its 
reduction is accompanied by the development of subclinical inflammatory states 
(Malikan et al., 2004). It is known that an increase in inflammatory factors such as IL-6, 
TNF-a and IL-ip is accompanied by lowering of testosterone in obesity cases. 
Therefore, this may demonstrate the presence of an inverse relationship between the 
pro-inflammatory factors and testosterone level. Accumulating evidence suggests that 
testosterone can inhibit pro-inflammatory factors secretion and stimulate anti­
inflammatory mediator release (Vodo et al., 2013). Furthermore, reduction in the levels 
of IL-6, IL-ip and TNF-a secreted by monocytes was noted in androgen deficient men 
with T2DM after testosterone treatment (Corrales et a l, 2006). Short-term studies 
indicated that there was an inverse relationship between testosterone level and CRP, IL- 
6 and TNF-a, in diabetic and non-diabetic hypogonadal men (Kapoor et al., 2007). 
However, the reason for this inverse relationship is not fully known, (Beavers et al.,
2010) but the reduction of fat mass by testosterone treatment may be the reason for a 
lower inflammation and explain this inverse relationship. However, the cellular 
mechanism of testosterone action on inflammatory factors remains unclear.
1.6 Atherosclerosis
Atherosclerosis is the main cause of increased rates of cardiovascular death in the 
developed world. It is an inflammatory disease, characterized by lesions in the large and 
middle arteries containing lipids, immune infiltrates, particularly monocytes/ 
macrophages and T cells, connective tissue elements and debris (Hansson et al, 2006; 
Erzengin, 2014). This can lead to myocardial infarction in the heart and/or to ischemic 
stroke (Koelink et al., 2012). The cause of atherosclerosis is a complex combination of 
genetic factors and metabolic disorders such as obesity and T2DM. Endothelial 
dysfunction is central to the pathogenesis of atherosclerosis (Tardif, 2009). The result of 
endothelial injury is an increase in leukocyte adhesion molecules such as intercellular
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cell adhesion molecules-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) 
(Nakashima et al, 1998, Monaco and Paleolog, 2004; Lucas and Greaves, 2001). There 
is also an increase in pro-inflammatory and pro-atherogenic factors including cytokines, 
chemokines and their receptors. All these contribute to exacerbation of the damage to 
the endothelium, with increased monocyte recruitment into the sub-endothelial space, 
where they differentiate into macrophages. These recruited macrophages take up LDL 
via scavenger receptors to form foam cells, the hallmark of fatty streak lesions (Qiu et 
al., 2006 and Stenmark et al., 2013). The lesions develop into fibro-fatty plaques, which 
contain large numbers of macrophages, fibrous cap and migrated and proliferated 
smooth muscle cells (Figure 1.9). When plaques are damaged and rupture, pro- 
thrombotic material is exposed to the coagulation system, with ensuing inhibition of 
blood flow and induction of CVD (Libby et al, 2011; Frostegard, 2013).
1.6.1 The role of monocyte / macrophage cells in atherosclerosis
In humans, accumulation of foam cells derived from phagocytosis of lipids by 
monocytes and macrophages is seen in aortic fatty streaks (Auffray et al., 2009, Gordon, 
2003; Takahashi et al., 1996) and these are the main leukocyte subset that accumulates 
at lipid laden vascular sites in atherosclerosis (Ley et al., 2011). The production of 
leukocyte chemoattractant molecules activates receptors on rolling monocytes leading 
to integrin-dependent firm adhesion to the endothelium and subsequent diapedesis into 
the sub-endothelium (Golias et al., 2007). Migration of monocytes into the vessel intima 
leads to differentiation of these cells into macrophages in response to the local over­
expressed macrophage-colony-stimulating factor (M-CSF) (Libby et al., 2002, 2010, 
Glass and Witztum 2001; Koelink et al, 2012). Inside the arterial intima and under 
atherogenic conditions, macrophages accumulate in the aorta and show reduced 
emigration from lesions (Hansson et al., 2001; Ley et al, 2011). In ApoE and MCS-F 
(op/op) deficient mice, which are deficient in tissue macrophages, are dramatically 
protected from atherosclerosis, despite high levels of cholesterol (Smith et al., 1995; 
Linton and Fazio, 2003).
Macrophages secrete TNFa and IL-lp and chemokines including CX3CL1, CCL2 and 
IL-8 which are associated with local inflammation (Lusis, 2000, Lucas and Greaves, 
2001, Braunersreuther et al, 2007, Tabas et al., 2007; Koltsova and Ley, 2011).
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Figure 1.9: The progression of atherosclerotic plaque as a result of obesity and its 
complications. The conditions associated with obesity including high levels of 
proinflammatory factors, insulin resistance, hyperglycemia and dyslipidemia can causes 
endothelial dysfunction. This leads to production of adhesion molcules, VCAM1, ICAM 
and chemokines by endothelial cells (EC). Monocytes migrate into the arterial wall in 
response to binding of their chemokine receptors, CX3CR1 and CCR2 with ligands 
CX3CL1 and CCL2. Monocytes differentiate into macrophages in response to local 
macrophage colony-stimulating factors (M-CSF). The LDL in the artery wall is modified to 
oxidized LDL (oxLDL) and loaded onto macrophage scavenger receptors (ScRs) resulting 
in formation of foam cells. Ox-LDL and chemokines stimulate the production of IL-lp, IL- 
6, IFNy and TNF-a by macrophages and foam cells. More advanced stages of 
atheroseclerosis include smooth muscle cell proliferation, formation of fibrous caps, 
necrotic cores, calcification, rupture, haemorrhage and thrombosis. IEM: internal elastic 
membrane. (Drawn using information from Lucas and Greaves, 2001, Barlic and Murphy, 
2007, Liu and Jiang, 2011).
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Macrophages are considered as the main source of IL-8 in atherosclerotic plaques, 
which can modulate migration of monocytes and accumulation of macrophages in the 
endothelial space (reviewed from Apostolakis et al., 2007). Thus, IL-8 is suggested as a 
proatherogenic chemokine acting as a factor linking immune activity and lipid 
metabolism (Autieri et al., 2012). Scavenger receptors (ScRs) associated with uptake of 
modified LDLs by macrophages are under the control of cytokines in lesions (Menno et 
al, 2000). ScRs regulate the load of oxidised LDL in macrophages and lead to LDL 
cholesterol accumulation and subsequently the transformation of macrophages into 
foam cells in early- through to mid-stage atherogenesis (Greaves and Gordon, 2009, 
Hansson 2005; Williams and Tabas, 1998). Foam cells are generated from the massive 
uptake of modified LDLs and the intra-cytoplasmic accumulation of cholesteryl esters, a 
source of growth factors, pro-inflammatory and pro-atherogenic factors in all stages of 
atherosclerosis. All these factors contribute to smooth muscle cell proliferation, matrix 
production and actions of metalloproteases, leading to matrix degeneration (Dollery et 
al., 2006, Libby, 2008; Libby, 2009). The continued accumulation and subsequent 
apoptosis of plaque cells, leads to the formation of a necrotic core and results in the 
progressive narrowing of the arterial lumen. This can then trigger thinning of the fibrous 
cap and its disintegration, with plaque erosion or rupture, leading to thrombus formation 
and vascular occlusion underlying coronary syndromes, myocardial infarction, or stroke 
(Glass and Witztum, 2001, Libby, 2002, Hansson, 2005, Hansson and Libby, 2006, 
Libby, 2008; Weber et al., 2008).
1.6.2 The role of atherogenic biomarkers in atherosclerosis
Measurement of standard lipid cholesterol and TG and lipoproteins are vital for 
assessing the risk of CVD. These measurements are obtained routinely in clinical 
practice (Blaha et al., 2008). Lipoproteins are essential in the metabolism and 
redistribution of lipids such as cholesterol, phospholipids and triacylglycerol. There are 
several classes of lipoproteins, which are used to transport lipids throughout the body 
and range in density and content (protein/lipid ratio); chylomicrons (contain dietary 
lipids), intermediate low density lipoprotein (IDL), VLDL, LDL and the high density 
lipoprotein (HDL) (Acevedo, 2012). Lipoproteins contain small particles termed 
apolipoproteins that function as regulators of binding between lipoproteins and 
receptors. These proteins act as enzyme co-factors during lipid metabolism, helping to
41
stabilize lipoproteins during transportation from cell or tissue to its destination (Han, 
2004). Apolipoproteins are one of the key players in progression of atherosclerosis. 
Alaupovic (1971) first suggested that measuring apolipoproteins might be more 
valuable in predicting the risk of CVD than measurement of the lipid components or 
lipoprotein (Rainwater et al., 1999 and Mora, 2009; Jacobson, 2011). Furthermore, 
Cholesterol, TG and lipoproteins have been studied extensively for their effect and role 
in atherosclerosis. Recently, it has been suggested that studies should focus on other 
factors that have roles in atherosclerosis e.g, studies have investigated the role of 
oxLDL, fractions of HDL such as HDL2 and HDL3 and apolipoprotein (Parish et al., 
2009).
1.6.2.1 The role of oxLDL in atherosclerosis
Animal studies have provided evidence to support the role of oxidative stress in 
atherosclerosis, particularly through oxidative modification of LDL (Fraley and 
Tsimikas, 2006; Bossola et al., 2011). oxLDL is a useful marker for CVDs (Itabe et al, 
2011, Fraley and Tsimikas, 2006, Itabe and Ueda, 2007; Holvoet et al., 2008). The 
measurement of oxLDL correlates with CVDs and indicates that oxLDL is a potential 
prognostic marker for future health events (Itabe et al, 2011). oxLDL has the ability to 
stimulate a number of pro-atherosclerotic effects, including endothelial cell activation, 
smooth muscle proliferation and monocyte/macrophage recruitment (Ahmed et al.,
2009).
Berliner and co-workers (1990) stated that the oxidative modification of LDL, through 
co-culture with endothelial cells, had stimulatory effects on many cell types and that 
these effects were due to the oxidized phospholipids generated by oxLDL. For example, 
oxLDL and its free lipid constituents have been shown to promote monocyte 
recruitment and inhibit macrophage motility. The effect of oxLDL has been clearly seen 
through control of monocyte gene expression (Tontonoz et al., 1998). OxLDLs induce 
functional alteration of monocytic regulation of monocyte chemoattractant receptors, by 
inducing specifically differentiation of CCR2hlgh CX3CRllow monocytes to CCR2low 
CX3CRlhlgh macrophages that strongly adhere to CX3CL1+ expressed by primary 
human coronary artery smooth muscle cells (CASMCs) under static conditions (Barlic 
et al, 2006). This observation indicates that in atherogenesis, there is oxidized lipid- 
driven activation of macrophage PPARy in the intima which results in a pro-adhesive 
chemokine receptor switching CCR2 off, CX3CR1 on, causing cessation of CCR2-
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dependent migration and activation of CX3CR1-dependent retention mechanisms, 
which together promote macrophage accumulation in the vessel wall (Wong et al., 
2002; Lesnik et al, 2003). Moreover, oxLDL can increase migration of monocyte cells 
by enhancing VCAM-1 expression by endothelial cells, which leads to adhesion of 
these cells within the endothelial space (Calara et al., 199; Aikawa et al, 2002). In 
addition, oxLDL is recognized to induce foam cell formation and inflammatory 
responses, where it stimulates expression of a wide diversity of pro-inflammatory 
cytokines and chemokines in macrophages (Lee et al, 2000). Finally, it has a role in 
promoting endothelial cell expression of M-CSF leading to differentiation of monocytes 
to macrophages (Cushing et al, 1990 and Lee et al., 2000). OxLDL also helps to induce 
release of CCL2 from endothelial cells (reviewed by Pirillo et al, 2013). Although the 
pathological features of OxLDL have been well considered, the formation, distribution, 
and overall fate of OxLDL in vivo remains unclear (Itabe et al., 2011).
1.6.2.2 The role of Apo A l and HDL in atherosclerosis
Apolipoprotein Al is a protein (264 amino acids) that in humans is encoded by the 
APOA1 gene (Eriksson et al, 2009). It has a specific role in lipid metabolism, is a 
major protein constituent of HDL particles, has pleiotropic biological functions such as 
stimulating macrophage cholesterol efflux within artery walls, making the macrophage 
cells less likely to become fat overloaded, transform into foam cells, die and contribute 
to progressive atheroma. It also functions by motivating reverse lipid transport, 
inhibiting LDL oxidation and scavenging toxic phospholipids. Furthermore, it has the 
ability to improve pancreatic p-cell health and function, can act as an anti-thrombotic 
factor as well as having anti-inflammatory properties (Navab et al., 2011, Shah 2011). 
HDL cholesterol and its major protein constituent, (ApoAl), have been shown through 
clinical and epidemiological studies to have a strong inverse correlation with the 
development of atherosclerosis and myocardial infarction (reviewed by Chapman et al.,
2010).
HDL particles have multiple functions including cholesterol transport (Dastani et al.,
2006) and modulation vascular endothelial function by promoting the production of the
atheroprotective signalling molecule NO (Mineo et al., 2006), protection against LDL
particle oxidation and anti-inflammatory properties (Genest et al., 2003; Marcil et al.,
2004). Their role in reverse cholesterol transport, which is transport of cholesterol from
peripheral tissues to the liver for secretion into the bile for excretion, made HDL
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particles the most important protective factor against the development of atherosclerotic 
cardiovascular disease (Maeda et al, 2011). Two pathways are involved in these 
processes. A first pathway is the production of apoAl from liver and intestine which 
binds to the cellular ATP-binding cassette transporter (ABCA1) and forms of nascent 
HDL particles (Wang et al, 2008). Nascent HDL becomes mature HDL following 
loading by cholesterol from peripheral, extra-hepatic tissues, and arterial tissue 
(potentially including cholesterol-loaded foam cell macrophages of the atherosclerotic 
plaque). The esterification of free cholesterol in HDL occurs by lecithin-cholesterol acyl 
transferase (LCAT) leading to spherical HDL3 and HDL2 particle formation. These 
subfractions mediate transport of cholesterol to the liver for excretion (Natarajan et al,
2010). The second pathway is by the esterification of free cholesterol in HDL which is 
made by cholesterol ester transfer protein (CETP), exchanging the core cholesteryl 
esters of HDL for triglycerides to Apo B-containing lipoproteins mainly VLDL and 
LDL and then subsequent uptake primarily by hepatic LDL receptors or into the 
circulation (Kontush et al, 2006; Chapman et al, 2010). Therefore, defects in the gene 
encoding Apo Al are associated with HDL deficiencies (Alexander et al, 2009).
HDL can be separated by ultra-centrifugal methods into two main subfractions: lipid- 
rich HDL2 and lipid-poor HDL3. In addition, it is thought that one or both of the HDL 
fractions is more related to the risk of CVD than total HDL cholesterol (Bakogianni et 
al, 2001; Superko et al, 2012). Prospective studies were reported that lower HDL2 and 
HDL3 is predicted risk for CVD, one showed lower HDL2 cholesterol is powerful 
indicators of CHD (Williams et al, 2012). A low HDL level in subjects with insulin 
resistance primarily results from a decrease in the HDL2 and, to some extent, HDL3 
levels (Muth et al, 2010). However, suggestions that all subfractions of HDL particles 
display atheroprotection, through one or more mechanisms, are plausible (Superko et al, 
2012). Furthermore, high circulating levels of ApoAl of HDL have been shown to 
predict decreased risk of CHD (Chapman et al, 2010).
1.6.2.3 The role of Apo E in atherosclerosis
Apolipoprotein E (ApoE) is a glycoprotein (299 amino acids) and a constituent of 
chylomicrons, intermediate-density lipoprotein (ILD), LDL, HDL and VLDL. ApoE is 
encoded by APOE gene and mainly produced by the liver, monocytes and macrophage 
cells (Hara et al., 2009). It acts as a ligand for lipoproteins with receptors for clearance
of lipid from the circulation and for cholesterol metabolism (Singh et al, 2002).
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According to studies in mice lacking ApoE (Wu and Huan, 2007) there was 
accumulation of remnant lipoproteins (VLDL and chylomicron) with total plasma 
cholesterol levels exceeding 400 mg/dl, even though mice were fed on low fat chow 
(Kunjathoor et al, 1996). Similarly, in humans with deficiency in ApoE there is 
increased plasma cholesterol and triglycerides, which are the consequence of impaired 
clearance of chylomicron, VLDL and LDL remnants (Tennert et al, 2007).
The role of ApoE in atherosclerosis development relates to its synthesis and metabolism 
by macrophages within vessels (Rosenfeld et al, 1995), which has a local effect on 
cholesterol homeostasis and on inflammatory reactions in atherosclerotic vessels. In 
macrophages, the anti-atherogenic effects of endogenous and exogenous ApoE are the 
induction of cholesterol efflux, thereby stimulating reverse cholesterol transport 
(Greenow et al, 2005, Curtiss and Boisvert, 2000, Burt et al, 2008). An additional 
significant atheroprotective effect of ApoE in macrophages was observed through its 
inhibition of LDL-oxidation and stimulation of enzymes that are associated with 
lipoprotein metabolism (Walpola et al, 1993, Miyata and Smith, 1996). Furthermore, 
ApoE has anti-inflammatory actions by regulation of inflammation and cell 
proliferation, inhibiting expression of adhesion molecules, decreasing the migration of 
monocytes into the lesion (Stannard et al, 2001) and preventing the migration and 
proliferation of smooth muscle cells (Kothapalli et al, 2004; Zhu and Hui, 2003).
To assess the role of ApoE in atherogenesis, a number of approaches have been taken 
including: bone marrow transplantation and transgenic overexpression. Previous studies 
reported that transplanting bone marrow from mice with normal Apo E gene onto Apo 
E deficient recipients led to normalization of cholesterol level in the serum and 
prevented atherosclerosis. This was a result of an increase in ApoE in the serum 
enhancing lipoprotein clearance (Linton et al, 1995; Huang et al, 2013). Hepatic 
overexpression of ApoE in ApoE knockout mice prevented the development of 
atherosclerotic lesions, suggesting plasma ApoE has a role in protecting the arterial 
intima (Stevenson et al, 1995; Kashyap et al, 1995). This was noted through 
accumulation of ApoE within preexisting atherosclerotic lesions and also through the 
induction of morphological changes in lesions, including decreased foam cells and 
increased smooth muscle cells and extracellular matrix content (Tsukamoto et al, 1999).
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In further research, transplantation of ApoE-/- bone marrow onto C57BL/6 (B6) mice 
did not lead to changes in plasma lipid and lipoprotein levels, but increased 
atherosclerosis and foam cell formation compared to controls transplanted with 
ApoE+/+ bone marrow. The athors showed that the expression of ApoE in macrophages 
was responsible for the anti-atherogenic effect of transplanted bone marrow (Fazio et al, 
2002). Moreover, Shimano et al. (1995) established transgenic mice that expressed 
human ApoE in the vessel wall and identified a reduction in atherosclerotic lesions, in 
the absence of any change in plasma cholesterol. In addition, ApoEh/hLdlr_/“Mxl-cre 
mice develop spontaneous hyperlipidemia and atherosclerosis on a chow diet 
(Gaudreault et al., 2012) but following inducible repair of the hypomorphic ApoE 
alleles in these mice had decreased plasma lipids and ApoB lipoprotein levels, rise in 
plasma HDL-cholesterol and ApoAl levels (Eberle et al., 2013) supporting the role that 
of hepatic ApoE in the clearance of remnant lipoproteins in the absence of the LDL 
receptor (Linton et al., 1995) and in promoting HDL expansion and remodelling 
(Mahley et al., 2006).
1.6.2.4 The role of Apo B in atherosclerosis
Apolipoprotein B (ApoB) is a large protein (4536 amino acids) structural component of 
all lipoproteins including LDL, intermediate density lipoprotein (IDL), very low-density 
lipoprotein (VLDL), and LP (a) with the exception of HDL (Kappelle et al, 2011; Lee 
et al., 2011). ApoB is encoded by APOB gene and has two forms, ApoB-48 and ApoB- 
100. In humans, ApoB-48 is synthesized in the intestine, where it is complexes with 
dietary TG and free cholesterol, absorbed from the gut lumen, to form chylomicron 
particles. ApoB-100 is synthesized in the liver and is found in LDL, DDL and VLDL 
particles (Walldius and Jungner, 2004). In mice, both ApoB-48 and ApoB-100 are 
secreted from the liver (Dallinga-Thie, 2010). ApoB is absolutely required for formation 
of LDL and assist with binding to its receptor in different tissues, allowing cells to 
internalize LDL and thus absorb cholesterol (Parish et al., 2009).
Increasing evidence indicates that ApoB is a superior marker of vascular disease
compared with LDL cholesterol, as ApoB represents the total amount of potentially
atherogenic circulating lipoproteins (Walldius and Jungner, 2004, Barter et al., 2006,
Ley et al., 2010; Kappelle et al., 2011). Control studies for patients with CHD have
found plasma Apo B levels to be more characteristic of disease than other plasma lipids
and lipoproteins (Kwiterovich et al., 1992). A further study showed that ApoB was a
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stronger predictor of risk than LDL-cholesterol in both men and women (Walldius et al, 
2001). This study found that ApoB and the Apo B/Apo Al ratio should be taken into 
account as it is highly predictive in evaluating cardiac risk.
In recent years, several groups have used homologous recombination in mouse 
embryonic stem cells to generate Apo-E-deficient mice and LDL receptor-deficient 
mice (Maeda, 2011). Both of these targeted mutations interfere with the clearance of 
Apo-B-containing lipoproteins from the plasma; in both of these animal models, the 
plasma levels of the Apo-B-containing lipoproteins are elevated and there is increased 
susceptibility to the development of atherosclerosis. In Apo-B transgenic mice, the high 
levels of LDL in chow-fed mice were clearly due, at least in part, to the over-production 
of Apo-B in the liver (Linton et al, 1993). However, mice with modified ApoB-100 
had decreased, not increased, LDL particles, in part because of a reduced secretion of 
modified-ApoBlOO particles (Toth et al, 1996, Johnson et al, 2008).
The inconsistencies in the literature when considering Apo B as a good predictor risk of 
atherosclerosis may be due to the absence of standardised assays for measuring plasma 
ApoB levels and attempts to develop these methods are ongoing (Carmena et al, 2004; 
Contois et al, 2011).
1.6.2.5 The role of lipoprotein (a) in atherosclerosis
Lipoprotein (a) LP(a) is a protein that is encoded by LPA gene. LP(a) consists of an 
LDL-like particle and is bound to the highly glycosylated Apo(a) and Apo B in a 1:1 
molar ratio, through one or more disulphide bridges (Carmena et al, 2004 ). Apo (a) is 
detected in the liver where it is expressed by hepatocytes. The assembly of Apo (a) and 
LDL particles occurs at the outer hepatocyte surface (Saba and Oridupa, 2012). The 
half-life of LP (a) in the circulation is about 3 to 4 days, (Rader et al, 1993) and there is 
limited information about its metabolism. Similarly, the physiological function of LP (a) 
is largely unknown (Itabe et al, 2011).
LP(a) levels are genetically determined and are an independent risk factor for
atherosclerosis {Enas et al, 2006). Moreover, its level in serum has been found to be an
inherited risk factor for IHD (Dembinski et al, 2000) and myocardial infarction
(Kamstrup et al, 2008; Kamstrup et al, 2011). The relationship between elevated LP
(a) levels and CHD was confirmed by a number of retrospective case-control studies. A
meta-analysis of prospective studies showed that plasma LP (a) concentration is an
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independent risk factor for CHD in both men and women (Craig et al., 1998). Another 
prospective study found that LP (a) is an independent risk factor for MI and CHD in 
elderly men (Gaw et al., 2005).
However, four studies found no relationship between LP(a) and CVD (Seman et al., 
1999). These discrepancies may result from the lack of standardization and the failure of 
some immunoassays to measure all Apo (a) isoforms equally (Seman et al., 1999). 
However, this was finally clarified with the data obtained from Epidemiological Study 
of MI (PRIME) which included 9133 men with no history of CHD or use of 
hypolipidemic medicines, that indicated LP (a) as a strong predictor of CHD risk (Luc 
et al, 2002). In addition, Apo (a) in LP (a) has a similar structure to plasminogen and 
can compete with plasminogen for binding to the plasminogen receptor. This leads to 
inhibited conversion of plasminogen to plasmin. Plasmin decreases fibrin blood clots 
therefore with less plasminogen to degrade fibrin, the concentration of fibrin increases 
and promotes thrombogenesis (Caplice et al., 2001; Sofi et al., 2007). Because of the 
unique structure of LP(a) combined with the potential atherogenic risk associated with 
LDL particles and the thrombogenic risk attributed with Apo (a), LP(a) is considered as 
a risk factor for atherosclerosis and CVD (Nordestgaard, et al., 2010). Moreover, Lp(a) 
transports the more atherogenic pro-inflammatory oxidized phospholipids, which attract 
inflammatory cells to vessel walls (Gouni-Berthold et al., 2011; Tsimikas et al., 2008) 
and causes smooth muscle cell proliferation (Ichikawa et al., 2002).
1.6.3 The role of pro-inflammatory cytokines in atherosclerosis
Pro-inflammatory cytokines including IL-ip, IL-6, TNF-a and IFN-y together or 
individually play a role in development of atherosclerosis. These cytokines that are 
produced at a distance from adipose tissue or locally in the artery wall can affect 
atherosclerosis and potentially play a role in various stages of atherosclerosis 
(Kleemann et al., 2008). In the early stages, TNF-a and IFN-y can cause imbalance in 
barrier function of endothelial cells and promote leukocyte transmigration by changing 
the distribution of vascular endothelial cadherin-catenin complexes and, inhibiting the 
formation of F-actin stress fibres (Kleinbongard et al., 2010). TNF-a is able to 
transiently induce a rise in calcium and stimulation of myosin light chain kinase, which 
causes endothelial junction impairment (Komarova et al, 2010; Ait-Oufella et al.,
2011).
48
Pro-inflammatory cytokines can stimulate attraction of monocytes to endothelial cells 
by enhancing expression of adhesion molecule, such as ICAM-1 and VCAM-1 and 
enhancing the up-regulation of selectins and integrin ligands, which are part of the 
leukocyte adhesion cascade (Weber et al, 2008; Ait-Oufella et al., 2011). Furthermore, 
IL-ip, IL-6, (Bazan et al., 1997; Garcia et al., 2000), TNF-a (Ahn et al., 2004; Ollivier 
et al., 2003; Lesnik et al, 2003), IFN-y (Bazan et al., 1991, hnaizumi et al., 2000, 
Ollivier et al., 2003; Lesnik et al., 2003) mediate the migration of monocytes through 
endothelial cells by activating expression of chemokines (e.g. IL-8, CCL2 and 
CX3CL1) on endothelial cells, which bind to their receptors on monocytes and 
macrophages. Similarly, these locally synthesised cytokines, produce by macrophages 
cells, SMCs and ECs, can regulate and accelerate the transformation of macrophages 
into foam cells by increasing the expression of scavenger receptors and enhancing cell- 
mediated oxidation (Ait-Oufella et al., 2011). While IFN-y has the ability to amplify the 
expression of pro-inflammatory cytokines including TNFa and IL-ip by monocytes 
(Butler et al., 1994; Haworth et al, 1991) and macrophages (Mallat et al., 2001), TNF-a 
can trigger the release of IL-lp, IL-6, IL-8 from monocytes, macrophages and 
neutrophils (Le Page et al, 1999 and Hayes et al., 1995).
TNF-a, IL-6 and IL-lp strongly up-regulate PAI-1 expression at the protein and mRNA 
level in different cell types, including endothelial cells, smooth muscle cells and 
monocytes (Wiesbauer et al., 2002, Alessi et al., 2006, Dong et al., 2007). This effect is 
as a result of altering the fibrinolytic modulator of ECs, reducing the secretion of t-PA 
and increasing the production of PAI-1 (Kruithof et al, 2008). Thus, pro-inflammatory 
cytokines increase thrombus formation and stimulate the progress of acute coronary 
syndromes (Ait-Oufella et al., 2011). Furthermore, IFN-y and IL-lp can act as pro- 
atherogenic modulators through inhibition of the ATP-binding membrane cassette 
transporter Al (Yin et al., 2010), whereas IL-8 is considered as an important pro- 
atherogenic cytokine due to enhancing lesion formation by expediting leukocyte 
extravasation and EC adhesiveness (Gerszten et al., 1999).
In the advanced stage of atherosclerotic plaques, cytokines IL-1, TNF-a, and IFN-y 
stimulate apoptosis of SMCs, ECs and macrophages (Clarke et al., 2006, Stoneman et 
al., 2009; Ait-Oufella et al., 2011). Robaye et al. (1991) established apoptosis induction 
of ECs by TNF-a. LPS-induced apoptosis in macrophages is mediated mostly through
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the autocrine production of TNF-a (Xaus et al., 2000). The consequence of this is 
endothelial dysfunction and macrophage apoptosis, which leads to the accumulation of 
cellular debris contributing to an increase in the lipid core. Plaque SMC apoptosis leads 
to thinning in the fibrous cap, leading to its rupture (Mallat and Tedgui, 2000, Tabas et 
al., 2005; Clarke et al, 2006).
The involvement of pro-inflammatory cytokines in the pathogenesis of atherosclerosis 
is supported by their detection in human atherosclerotic plaques. Furthermore, high 
circulating levels of these factors in individuals with atherosclerosis reflect this 
association. Evidence also comes from the study of genetically modified mice (Ohta et 
al., 2005; Kamari et al., 2007) or mice with genetic mutations in these cytokine genes 
(Schieffer et al, 2004; Koga et al., 2007) which show inhibition of the atherosclerotic 
lesion stages. Anti-inflammatory cytokine, IL-10, can inhibit the production of these 
pro-inflammatory cytokines. IL-10 is synthesised by T lymphocytes and macrophages 
and has anti-atherogenic properties (Stoner et al., 2013). These facts are based on 
studies of atherosclerosis mouse models (Eefting et al., 2007), in which the expression 
of IL-10 increased in both coronary arteries in atherosclerosis (Satterthwaite et al.,
2005). Individuals with atherosclerosis have greater serum levels of IL-10 compared to 
healthy people. However, it is the balance between anti-inflammatory and pro- 
inflammatory cytokines which is as a major determinant of plaque stability (Tedgui et 
al., 2006).
1.6.4 The role of chemokines in atherosclerosis
During the process of vascular inflammation, chemokines play a central role, mediating 
the recruitment and activation of inflammatory cells (Keane et al., 2000; Liu and Jiang,
2011). Chemokines and their receptors can up-regulate selectins and integrin ligands, 
supporting leucocyte arrest, either directly or involving their presentation by binding to 
proteoglycans. In addition, they provide important anti-apoptotic survival cues to 
leucocytes (Weber, 2008; Zemecke and Weber, 2010). A number of chemokines are 
expressed by monocytes, macrophages, SMCs and ECs in response to inflammatory 
mediators in human atherosclerotic plaques (Lucas and Greaves, 2001; Braunersreuther 
et al., 2007).
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1.6.4.1 The role of CCL2 and its receptors CCR2 in atherosclerosis
CCR2 is a member of the G-protein coupled receptor family and is expressed on the cell 
surface of monocytes and macrophages (Singh and Sobhia, 2013). Two independent 
mouse models of atherosclerosis have illustrated the role of CCL2 in atherosclerosis 
(reviewed by Koenen and Weber, 2010). These animal models have a genetic deletion 
of CCL2 or its receptor CCR2 in atherogenic LDL receptor-deficient (LDLR-/- or 
apolipoprotein E-deficient (ApoE-/-), mice. These genetic deletions led to reduced 
atherosclerotic lesions, together with a decrease in macrophage infiltration (Dawson et 
al, 1999). In addition, CCL2 has been identified in macrophage-rich areas bordering 
the lipid core, on endothelial cells, SMCs in human and mouse atherosclerotic lesions 
(Yla-Herttuala et al., 1991, Nelken et al, 1991; Rayner et al, 2000). This was 
confirmed by other studies reporting that CCL2 and CCR2 interaction accounted for 
most of the macrophage accumulation in atherosclerotic arteries (Peeters et al, 2009). 
Blockade of CCL2-CCR2 interaction by using gene therapy in atherosclerosis-prone 
mice caused inhibition of the formation of fatty streak lesions and limited the 
progression of pre-existing plaques, without affecting serum lipid concentrations (Coll 
et al, 2007). Furthermore, the overexpression of CCL2 in ApoE'7' transgenic mice 
accelerated atherosclerosis by increasing the number of macrophages in artery lesions 
(Aiello et al, 1999).
In humans, numerous clinical studies have shown elevation of CCL2 levels in serum of 
patients with CVD (De Lemos et al, 2007, Martinovic et al, 2005, Arakelyan et al, 
2005; Herder et al, 2006). A positive correlation was observed between CCR2 
expression on circulating monocytes and serum CCL2 with carotid intima-media 
thickness and cardio-ankle vascular index, measures of atherosclerosis, in chronic 
haemodialysis patients (Okumoto et al, 2009). Other genetic human studies indicated 
that men with (SNP)-2518G (altematively-2578G) in the regulatory region of CCL2, 
which causes increased promoter activity, is associated with elevated, circulating levels 
of the CCL2 gene and increased risk of MI (McDermott et al, 2005; Szalai et al, 2001).
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1.6.4.2 The role of CX3CL1 and CX3CR1 in atherosclerosis
CX3CL1 is the only known chemokine expressed in both a soluble/shed and a 
membrane-tethered form. The soluble form of CX3CL1, cleaved from the membrane by 
the enzyme TACE (TNF-a converting enzyme), is involved in chemotaxis, while the 
membrane-anchored form promotes adhesion and retention of leukocytes (Fong et al, 
1998; Shah etal., 2011).
The expression of fractalkine and its receptor CX3CR1 which, is a G-protein coupled 
receptor, are up-regulated in atherosclerosic lesions (Umehara et al, 2001, Landsman et 
al, 2009, Wong et al, 2002; Combadiere et al, 2003). The importance of 
CX3CL1/CX3CR1 in atherosclerosis was supported by two common coding 
polymorphisms which are associated with a lower risk of CVD (Moatti et al, 2001; 
McDermott et al, 2001) while alternative study (Niessner et al, 2005) did not support 
these findings. However, the significance of CX3CR1 in atherosclerosis was clearly 
observed through reduction of plaque size and increased lesion stability after using an 
inhibitory antibody against CX3CL1 in animal models (Bursill et al, 2004). Deletion of 
the gene encoding CX3CR1 or CX3CL1 in mice prevented the formation of 
atherosclerosis and reduced monocyte infiltration in murine disease models 
(Combadiere et a l , 2003, Lesnik et al, 2003; Teupser et al, 2004; Saederup et al, 
2008).
According to epidemiologic studies, patients with CVD have increased expression of
CX3CR1 in peripheral blood mononuclear cells (PBMCs) (Fraticelli et al, 2001;
Damas et al, 2005) and elevated serum CX3CL1 levels (Damas et al, 2005). CX3CL1
levels in patients with unstable angina pectoris are even higher than in those patients
with stable angina pectoris (Ikejima et al, 2010). However, neither CX3CL1 nor
CX3CR1 have been found in normal mouse or human arterial wall (Barlic et al, 2007).
CX3CR1 expression has been found on numerous different cell types associated with
atherosclerosis, both in vivo and in vitro, including monocytes, macrophages, T cells,
NK cells, dendritic cells and vascular SMCs (Imai et al, 1997; Combadiere et al, 1998).
Its ligand, CX3CL1, is only detected in advanced lesions, where it is expressed by
SMCs, ECs and macrophages (Imai et al, 1997, Lucas et al, 2003, Cheng et al, 2007,
Wong et al., 2002; Lesnik et al, 2003). Therefore, CX3CL1 may act by attracting
macrophages that express CX3CR1; while CX3CR1 expressed by SMCs may facilitate
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the function of macrophages as well as the migration of SMCs towards endothelium that 
express high levels of CX3CL1 during atherosclerosis (Wong et al, 2002, Lesnik et al, 
2003; Liu and Jiang, 2011). Furthermore, the CX3CL1/CX3CR1 axis possibly leads to 
the development of atherosclerosis by stimulating monocyte recruitment, as well as 
enhancing pro inflammatory cytokine production and inducing SMC proliferation 
(Koenen and Weber 2011).
This interaction between CX3CL1 and CX3CR1 besides directly regulating migration 
and adhesion, also acts as a signal transduction pathway to coordinate the function of 
CX3CL1 and other cytokines (Liu and Jiang, 2011). Additionally, one study reported 
that soluble CX3CL1 stimulates extracellular signal-related kinases and stress-activated 
protein kinases to enhance the interaction between monocytes and vascular cells 
(Cambien et al, 2001). Landsman et al, (2009) found that the absence of CX3CL1- 
CX3CR1 interaction led to increased macrophage apoptosis and inhibited plaque 
development, which indicted that CX3CR1 is essential for macrophage survival.
1.6.5 Obesity and atherosclerosis
The number of atherosclerosis and CVD patients and their rate of death are increased 
among obese people. Moreover, excess weight was an independent predictor of CVD 
death and congestive heart failure, after adjusting to other known recognised risk factors 
(Sucharda, 2010; Rocha and Folco, 2011). The site of adipose tissue deposition such as 
central obesity also is important in the incidance of atherosclerosis and ultimately CVD 
(Kershaw and Flier, 2004). There are a number of mechanisms by which expansion in 
adipose tissue could critically affect the vessel wall. An enlargement in adipose tissue is 
associated with hypertension, IR, hyperglycaemia, lipid/lipoprotein metabolism changes 
and an inflammatory state, including macrophage infiltration. These conditions lead to 
increased pro-inflammatory and decreased anti-inflammatory profiles, which may 
contribute directly and indirectly to local (adipose tissue) and distant (artery wall) 
inflammation (Glass and Witztum, 2001; Lusis, 2000). These consequences of obesity 
are the main reason for atherosclerosis, causing endothelial dysfunction by several 
mechanisms leading to progression of CVD, stroke and myocardial infarction (Rocha 
and Folco, 2011).
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1.6.6 Low testosterone and atherosclerosis
The importance of studying the relationship between testosterone and the development 
of atherosclerosis and CVD is highlighted by: (a) the diversity between genders in the 
rate of CVD and atherosclerosis may be related to sex hormones as estrogen is 
protective factor (Ng et al, 2003). (b) the rate of mortality from these diseases is higher 
among men than in women (Jones and Saad, 2009) (c) A previous study reported that 
the incidence of death from heart disease was higher among patients with low 
testosterone compared to normal individuals (Nettleship et al, 2007). Others studies 
suggested that this increase in cardiovascular risk is not due to male gender, but is due 
to low testosterone levels associated with age (Jones and Saad, 2009) or obesity (Kelly 
and Jones, 2013). Undoubtedly, testosterone deficiency in men is accompanied with 
several cardiovascular risk factors including IR and MetS (Kapoor and Jones et al, 
2008). The features of these states including hyperglycemia, hypertension, an 
atherogenic lipid profile, inflammation, a pro-thrombotic fibrinolytic profile and 
hyperinsulinemia can be individually responsible for the development of CVD, 
atherosclerosis (Jones, 2010), congestive heart failure and stroke (Ma and Tong, 2010). 
Notably, some short-term studies found that testosterone replacement therapy (TRT) 
improved these conditions (reviewed by Jones and Saad, 2009). Furthermore, IR is 
linked to the classical cardiovascular risk factor, T2DM where the most diabetic patients 
are at risk of CVD (Hossain et al, 2007). Normalisation of testosterone after a period of 
treatment improved insulin sensitivity and T2DM via reduction of visceral adiposity and 
IR in diabetic patients (Kapoor et al, 2006). Testosterone treatment may exert its 
beneficial actions through an effect on cellular components and mediators of 
atherosclerosis and CVD.
Dyslipidemia is postulated as a mechanism linking low testosterone with CVD in men, 
Testosterone has a role in lipid and lipoprotein metabolism (Fahed et al, 2012). 
Previous cross-sectional studies reported that endogenous low plasma testosterone 
levels are associated with increased total and LDL cholesterol (Saad et al, 2008; Barud 
et al, 2002). Epidemiological studies also indicated that testosterone levels in serum are 
inversely linked with the serum concentrations of triglyceride and LDL-C (Wu, 2003) 
while other studies found no notable link to TG (Isidori, 2005). Interestingly, 
testosterone treatment was shown to reduce total cholesterol in 27 hypogonadal men 
who were at risk of CHD and who were treated with statins (Jones and Saad, 2010).
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Testosterone therapy in earlier studies reduced the levels of total and LDL cholesterol, 
(Saad et al, 2007; 2008). In contrast, a positive relationship was seen between 
testosterone level and HDL level and Apo Al in healthy and diabetic men (Uyanik et al, 
1997; Van et al, 2003). Contradictory results related to this association have also been 
reported. For example, Malkin et al, (2004a) and Kapoor et al, (2006) detected no 
change in HDL, whereas other studies showed a decrease in HDL with testosterone 
supplementation in hypogonadal men with and without T2DM (Wittert et al, 2003; 
Jones et al, 2009). Another study reported that the different doses of testosterone had 
no effect on plasma lipids and apolipoproteins, only the highest dose of testosterone 
(600 mg/wk) was associated with a reduction in plasma HDL and Apo Al in young, 
healthy men (Singh, et al, 2002) and in serum HDL, HDL2, and HDL3 in elderly men 
(Herbst et al, 2003). Testosterone treatment has also been shown to reduce Lp (a) level 
in normal men (Zmunda et al, 1997).
In animal studies, hypotestosteronemia and hypertestosteronemia increased significantly 
the total LDL cholesterol, TG, and Apo B while physiological levels of testosterone had 
a beneficial effect on serum lipids, lipoproteins, and apolipoproteins in castrated rabbits 
(Qiang, 2003). Similar beneficial effects were observed in the testicular feminization 
mouse (Tfm) model, which is considered a model of atherosclerosis, where testosterone 
treatment decreased the plaque area and aortic intimal thickness (Nettleship et al, 2007). 
A recent study indicated that the physiological concentration of 5a-dihydrotestosterone 
(5a-DHT) reduced the progression of atherosclerosis via inhibiting intimal foam cell 
formation from macrophages in a New Zealand white rabbit model (Qiu et al, 2010). 
Physiological testosterone treatment also attenuated atherosclerosis in orchidectomised 
LDL'7' mice and significantly attenuated aortic cholesterol accumulation in 
orchidectomised male rabbits fed a pro-atherogenic diet for 120 days (Nathan et al, 
2001). Despite differences in the association of testosterone treatment with lipid, 
lipoprotein and apolipoprotein levels in human studies, animal experiments offer 
important data on the protective effect of testosterone on these parameters. The 
mechanism by which testosterone acts is unclear. The effect of testosterone on 
atherogenic factors may be by reducing the lipid uptake through inhibiting lipoprotein- 
lipase (LPL) activity in adipocytes and activating lipolysis through increasing the 
number of lipolytic beta-adrenergic receptors (Divers et al, 2010). Furthermore, 
testosterone can also inhibit the differentiation of adipocyte precursor cells (Shiyama
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and Adrian, 2004). Moreover, as a result of obesity-related testosterone decline, the 
liver is exposed to products of adipocyte metabolism, FFAs, in high concentrations and 
may induce metabolic disorders due to perturbation of lipid metabolism of the liver 
(Kelly and Jones 2012). Elevated plasma FFA enhances TG synthesis, leading to 
hypertriglyceridemia and high level of VLDL. Additionally, testosterone has a role in 
regulation of hepatic lipoprotein lipase (HLP) activity which catalyses the hydrolysis of 
triacylglycerols and phospholipids, mediating the removal of lipoproteins from plasma 
such as LDL, HDL, HDL2 and HDL3 (Herbst et al, 2003). Hypogonadism causes 
dysregulation in the processes of lipoprotein metabolism and increases atherogenic risk 
(Deeb et al., 2003).
Testosterone, as mentioned previously, has an inhibitive effect on some pro- 
inflammatory cytokines and chemokines, associated with atherosclerosis. Especially in 
vitro human and muose studies, reduction of TNF-a, IL-6, IL-1 and IFNy and increase 
in IL-10 production was seen after incubation of vascular cells such as monocytes (Li, 
1993), macrophages (D’Agostino, 1999), and endothelial cells (Hatakeyama, 2002) with 
testosterone. In in vivo studies, the production of TNF-a was augmented after LPS 
administration into castrated male mice, which was attenuated by testosterone treatment 
(Spinedi et al, 1992). Testosterone replacement also significantly reduced TNF-a and 
CRP and increased IL-10 in a cohort of hypogonadal men with coronary heart disease 
(Malkin et al, 2004a).
1.7 Summary
Obesity is associated with elevated pro-inflammatory modulators such as cytokines and 
chemokines, reduction in anti-inflammatory factors such as adiponectin and IL-10 and 
dyslipidemia. These alterations link obesity with other disorders such as T2DM, 
atherosclerosis and testosterone deficiency in men. The latter condition, which increases 
with age, also causes central obesity in men (figure 1.10). However, improvements have 
been seen in T2DM and atherosclerosis conditions after normalizing testosterone levels, 
using testosterone replacement treatment. Some studies report that, testosterone displays 
beneficial effects on levels of pro-inflammatory cytokines and chemokines, while others 
showed a positive effect on reduction in body composition or reduced dyslipidemia by 
changes in lipid profile including lipoprotein and apolipoprotein.
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Figure 1.10: Association of obesity and hypogonadism with risk factors of T2DM 
and atherosclerosis. Obesity can cause low testosterone leading to hypogonadism (red 
line) and hypogonadism is associated with abdominal obesity which contributes to risk 
factor for atherosclerosis, CVD and IHD, whether through a direct effect of pro- 
inflammatory factors on the vasculature or through increasing the prevalence of further 
risk factors of atherosclerosis such as, IR, T2DM, dyslipidemia and endothelial 
dysfunction (blue line). T2DM: type 2 diabetes mellitus, CVD: cardiovascular disease, 
IHD: ischemic heart disease, IR: insulin resistance.
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Although several pharmacological blockers of different testosterone receptors have been 
used to identify the mechanisms behind these beneficial effects, this is still not fully 
elucidated. Therefore, there needs to be further work to elucidate the beneficial role 
played by testosterone as a potential treatment of T2DM and atherosclerosis in obese 
men.
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1.8 Aims of this thesis
The aim of the research is to investigate the effect of testosterone on biomarkers of 
diabetes, atherosclerosis and obesity and to elucidate the mechanisms controlling these 
interactions.
A combined in vitro and in vivo strategy was taken with the following objectives:
1. Investigate the effects of physiological testosterone replacement on body 
composotion, biomarkers and parameters associated with inflammation using two 
clinical patient cohort studies, one short term and one long term.
2. Investigate whether testosterone modulates the expression of anti/ pro-inflammatory 
markers and anti-atherogenic factors in liver tissue from animal model of low 
testosterone.
3. Investigate the effects of testosterone on the modulation of inflammatory and 
adipocyte drived associated proteins in cell culture models of macrophages and 
adipocytes, respectively.
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Chapter 2
The effect of testosterone treatment in hypogonadal men with T2DM in short and 
long-term studies
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2.1 Introduction
The association of low testosterone with T2DM and CVD is well recognized 
(Muraleedharan and Jones, 2010; Kelly and Jones, 2013). Epidemiological studies have 
indicated that up to 40% of men with T2DM have testosterone deficiency (Corona et 
al, 2006, 2009, Ding et al, 2006; Kapoor et al, 2007a). Furthermore, it is clear that the 
prevalence of diabetes increases following induction of a hypogonadal state during 
treatment for prostate cancer (Keating et al, 2010).
Other studies established that endogenous testosterone (total and free) was lower in 
subjects with MetS compared with those without (Brand et al, 2010, Corona et al,
2011). In addition, low testosterone is associated with impaired insulin sensitivity, 
increased percentage of body fat, truncal obesity, dyslipidaemia, hypertension and CVD 
(Wang et al, 2011). Decrease in biologically available testosterone in aging men could 
be associated with the increased prevalence of CVD. This evidence suggests that TRT 
for hypogonadal men, with diabetes or CVD may be favourable in decreasing the risk or 
the consequence of these diseases. One of these risk factors is increased inflammatory 
factors and decreased anti-inflammatory factors in serum in T2DM and atherosclerosis 
as a result of obesity. Pro-inflammatory cytokines such as TNFa, IL-1 and IL-6 have an 
essential role in T2DM and atherogenesis development, while IL-10 and adiponectin are 
anti-diabetic and anti-atherogenic factors (Malkin et al, 2004a; Saad, 2009). 
Testosterone has immunomodulatory actions, and current in vitro evidence indicates 
that testosterone could suppress the expression of pro-inflammatory cytokines TNF-a, 
IL-lp, and IL-6 and promote the expression of the anti-inflammatory cytokine IL-10 
(Malkin et al, 2004a; Corrales et al, 2006).
However, inflammation and infection decrease testosterone concentration as a 
consequence of the inhibitive action of inflammatory cytokines on the hypothalamic- 
pituitary-testis axis (Saad, 2009; Muraleedharan and Jones, 2010). The effective role of 
testosterone within the immune system is clearly documented, where the higher rate of 
immune-mediated disease in women and androgen deficient men has been associated 
with the immunosuppressive action of androgens compared with estrogens (Cutolo and 
Wilder, 2000). Furthermore, administration of testosterone to hypogonadal men with 
CHD reduced serum TNFa and IL-lp, but not IL6 levels and raised levels of IL-10 
(Saad, 2009). In testosterone deficient men suffering from T2DM, baseline testosterone
levels were inversely correlated with IL-6 and CRP levels (Kapoor et al, 2007).
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Dyslipidaemia is another important risk factor which has an impact on atherosclerosis 
development and is a consequence of diabetes and obesity (Kelly and Jones, 2013). 
Lipid profiles including total cholesterol and TG and lipoproteins play a central role in 
the development of atherosclerotic cardiovascular disease in humans. The plasma 
concentrations of lipoproteins and their metabolic fates are regulated by apolipoproteins 
on the surface lipid-rich particles (Davignon et al., 1988). The HDL-C and HDL2-C 
levels are known to increase in response to the elimination of obesity and smoking, the 
adoption of habitual exercise, and alcohol consumption (reviewed from Moriyama et 
al, 2014). The suggestion has been made that investigations in LP (a), apolipoproteins 
A-I and B (Apo A-I, ApoB), or HDL density subfractions may identify improved drug 
treatment and lifestyle changes to lower lipid levels, prevent atherosclerosis and limit 
the consequence of T2DM.
Strong evidence has been provided by several studies for a relationship between plasma 
lipoprotein and their apolipoproteins, and development of atherosclerosis (Olofsson et 
al., 2007). In addition, diabetic dyslipidemia is characterized by hypertriglyceridemia; 
increased LDL, decreased HDL, high Apo B and low ApoAl, which can be the most 
important cause of atherosclerosis in diabetic patients (Hashemi et al, 2012). 
Furthermore, previous studies suggest that Apo B might be of greatest value in the 
diagnosis and treatment of persons with normal or low concentrations of LDL 
cholesterol (Walldius et al, 2001) For example, patients with T2DM frequently have 
hypertriglyceridemia together with hyper-apo B, an atherogenic lipid profile that is 
often unrecognised because of concomitant low or normal levels of LDL cholesterol 
(Sniderman et al, 2001). The lack of Apo E in the Apo E-deficient mouse model leads 
them to develop lesions ranging from lipid-laden fatty streaks to advanced 
fibroproliferative lesions by the age of 30 weeks (Candido et al, 2002). Increased levels 
of Lp (a) is an associated with coronary atherosclerosis (Armstrong et al, 1986) and are 
as an independent risk factor of atherosclerosis. Therefore, it is thought that the one 
mechanism of testosterone as a protective therapy would be its beneficial influence on 
serum apolipoproteins as androgens are known to affect lipid metabolism. In addition, 
because the effects of TRT on apolipoprotein levels in both atherosclerotic and diabetic 
patients are not yet defined, the effects of testosterone on lipid and its carrier 
lipoproteins, generally and apolipoprotein especially remain controversial. Therefore, an 
investigation of the effect of testosterone on inflammatory factors on the one hand and
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on apolipoprotein on the other, could be important to point out by which mechanism 
testosterone treatment has improved T2DM conditions and prevents atherosclerosis.
This part of the study involved two patients groups. (1) A double-blinded placebo- 
controlled group of hypogonadal men with T2DM treated with intramuscular 
testosterone injection, compared to a control group of patients who received a placebo; 
this study was a short-term study over 6 months. (2) A group of hypogonadal men with 
T2DM treated with testosterone in a longitudinal study. For the data analysis these 
patients were divided into 3 groups 1) normal testosterone, 2) low testosterone without 
testosterone treatment, 3) low testosterone with testosterone treatment. In addition, for 
some analyses the patients were divided into four subgroups according to the patient 
IHD status at initial diagnosis.
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2.1.1 Aims
This study had two key aims:
1. To investigate the effects of physiological TRT on body composition (BMI, WC, 
W/HR), anti/pro-inflammatory cytokines (adiponectin, IL-lp, IL-6, IL-10, CRP and 
TNFa) and atherogenic factors (HDL, HDL2, HDL3, HDL2/HDL3 ratio, ApoAl, ApoB, 
ApoE and LP(a)) in serum of hypogonadal men with T2DM at risk of CVD in a short 
duration placebo-controlled study (6 months).
2. To investigate the difference between groups of diabetic patients (normal testosterone, 
low testosterone no treatment, low testosterone with treatment +/- IHD) by measuring 
body composition (BMI, WH, WHR), anti/pro-inflammatory cytokines (adiponectin, 
IL-lp, IL-6, IL-8, IL-10, IFNy and TNFa), atherogenic factors (HDL, HDL2,HDL3, 
HDL2/HDL3 ratio, ApoAl, ApoB, ApoE and LP(a)) levels in serum in a longitudinal 
observational study (follow up after 5-6 years).
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2.2 Materials and methods
2.2.1 Patients of the double-blinded placebo-controlled study
Testosterone therapy was given to group of hypogonadal men with T2DM in a 
randomized, double-blind, placebo-controlled study. This study was conducted at the 
Andrology Outpatient Department, Sheffield Cardiology Research Department, Royal 
Hallamshire Hospital Sheffield (RHH) and the Centre for Diabetes and Endocrinology, 
Barnsley District General Hospital, Barnsley, UK. The study included a total of 24 male 
patients, over the age of 40 years (range, 52-73 years; mean ± SEM 59.6 ± 11.9 years) 
with T2DM at risk of CVD. The local regional ethics committee approved the protocol 
(05/Q2308/140), and the patients provided their written informed consent. The inclusion 
criteria were Type 2 diabetic men with HbAlc (the term HbAlc refers to glycated 
haemoglobin) up to 9.5%, reflecting no significant symptoms of hyperglycaemia. 
Hypogonadism was defined as the total testosterone level <12 nmol/1 and bioavailable 
testosterone < 4 nmol/1 with symptoms of hypogonadism. Hypogonadal men were 
referred to the andrology clinic; they were androgen deficient and androgen replacement 
was deemed clinically indicated by a consultant endocrinologist. Patients were excluded 
if they had current or previous breast or prostate cancer or an elevated prostate specific 
antigen (PSA) or irregular digital rectal examination suspicious for prostate cancer. 
Other exclusion criteria were strict symptoms of benign prostatic hypertrophy, treatment 
with testosterone in the 3 months prior to the trial, investigational drug treatment in the 
3 months prior to the trial and known allergy to Sustanon or peanuts. Participants were 
also excluded who had peripheral vascular disease defined as either confirmed in a 
previous diagnostic assessment by a specialist vascular surgeon or an ankle brachial 
pressure index (ABPI) less than 0.92 and ischaemic leg pain or distal complications 
such as ulceration or gangrene.
2.2.1.1 Randomisation and drug treatment
The participants were randomly selected by a computer-generated assignment to 
testosterone treatment or placebo. 11 patients received a total of 12 testosterone 
injections intramuscularly over 6 months, (i.m. injection was given once every 2 
weeks). Testosterone was given as 0.8 ml Sustanon 250 injection (200mg testosterone 
esters; Organon Laboratories Ltd, Cambridge, UK). This regimen is commonly used as
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a standard physiological TRT in men with androgen deficiency. The same protocol was 
followed with 13 control patients who were given placebo. The placebo was 0.8 ml of 
0.9% normal saline. Drugs were drawn in identical syringes and were prepared by 
research staff in a separate clinical room away from the patient and the doctor assessing 
the patients.
2.2.1.2 Assessment of patients and sample collection in double-blinded placebo- 
controlled study
Blood samples were taken from all participants at baseline, 3 and 6 months. All patients 
and controls were required to complete a detailed questionnaire recording their medical 
history and their current medications at the screening visit in the morning before 10.00 
am and in the fasted state at screening/ baseline, 3 and 6 months, having only taken 
water to drink since midnight the night before. Smokers were asked not to smoke on the 
morning of an assessment visit. All patients were instructed to follow their usual diet 
and physical activity as well as taking supplements including anti-diabetic treatment, 
anti-hypertensive and lipid-lowering medications, without dose adjustment for the 
duration of the study. Their height and weight were recorded and the BMI was 
calculated using the equation (BMI = weight (kg)/height (m)2. The waist circumference 
was measured; a waist was defined as the point midway between the iliac crest and the 
costal margin (lower rib). Glucose level, HbAlc and blood pressure were available from 
the research database. ^
2.2.2 Patients of the longitudinal study
This study involved 120 men with T2DM who had testosterone levels determined at
RHH between 2002 and 2005. Subjects were allocated to two groups based on the
Endocrine Society Guidelines recommended cut-off level: i) Total testosterone levels
<10.4 nmol/1 and ii) Total testosterone >10.4 nmol/1. This study involved participants
who were assessed and managed routinely within the district-wide diabetic retinopathy
screening clinic, as well as the hospital diabetic clinic, and provided a representative
sample from the general community. In addition, patients were identified with T2DM
from the hospital database. The study was approved by the South Yorkshire Research
Ethics Committee (05/Q2308/140). For the purpose of data analysis carried out in the
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current study this group were divided into patients with normal testosterone, low 
testosterone without treatment and low testosterone plus TRT. All the patients were 
initiated and monitored within the routine clinics in the diabetes and endocrinology 
department at RHH. There were a number of reasons for patients with low testosterone 
not receiving testosterone treatment, including patient choice, or the patient declined to 
attend for further clinical assessment, however all patients still remained in contact with 
the clinic, and responded when requested to provide a follow-up sample. For the present 
analysis this group of patients was also divided into 4 subgroups based on IHD status 
into normal testosterone, IHD with normal testosterone, IHD with low testosterone not 
receiving testosterone treatment and IHD with low testosterone treated with testosterone.
2.2.2.1 Drug treatment
TRT was given to men with testosterone levels less than the local laboratory normal 
assay range (<8.4 nmol/1) without a concomitant diagnosis of prostate cancer or other 
contra-indications to TRT. This group received testosterone treatment as 2% gel 
testosterone, (average treatment time 5.8±1.3 years). The choice of initial therapy was 
based on the combined decision between patient and doctor. Doses were adjusted to 
achieve testosterone levels within the mid to upper normal range (>18nmol/l). The 
duration of treatment and dosage were based on each individual patients and their needs.
2.2.2.2 Assessment of patients and sample collection in longitudinal study
All blood samples were taken between 0800 and 1100 am. Baseline data on age, height, 
weight, BMI, smoking, glycaemic control (HbAlc), CVD were obtained from the 
hospital records.
2.2.3 Determination of pro and anti-inflammatory biomarkers in patients of 
double-blinded placebo-controlled study by Bead Cytometric Array Assay
BD™ Cytometric Bead Array (CBA) is a flow cytometry application assay that offers a 
powerful approach to quantify a variety of soluble proteins simultaneously in a single 
sample. This applies the principles of flow cytometry and considerably decreases 
sample requirements and time to results. The method uses the same principle as ELISA 
and applies it to uniquely identifiable antibody-coated beads. These beads are coated
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with specific antibody for a single analyte and have an unique fluorescence intensity 
(http://www.bdbiosciences.com/research/cytometricbeadarray/formats/index.jsp).
In addition, the beads have an internal colour with two different fluorescent dyes (red 
and infrared). Different concentrations of red and infrared dyes are used to generate up 
to 100 distinct bead regions by flow cytometry. Each defined bead is conjugated to a 
specific target analyte followed by binding with a biotinylated detection antibody and a 
reporter dye, streptavidin-conjugated phycoerythrin. Following incubation and 
subsequent washing, the samples are analysed on a flow cytometer where these beads 
are transported in a fluid stream in the cytometer to the laser beam for interrogation. 
The optics system consists of lasers to illuminate the particles in the sample stream and 
optical filters to direct the resulting light signals to the appropriate detectors. These 
detectors convert light signals that can be processed by the computer, to electronic 
signals (voltages) and then are assigned a channel number in an appropriate position on 
a data plot. List mode data are collected on each particle of bead or event. This data can 
be analysed to provide information about subpopulations within the sample (Figure 2.1) 
by using the FCAP Array analysis software that gates on each individual bead 
population and defines the median fluorescence intensity (MFI) for each analyte in the 
array. It creates a standard curve and allows interpolation of sample concentrations 
compared to the standard curve and creates an analysis report in tabular format.
Method
All reagents were obtained from BD Biosciences (UK). All sample and reagent 
preparations were performed on the day and stored at 4°C until used. Suspension of the 
capture bead stock solutions by vortex was carefully performed. The preparation of 
capture bead working solutions was made by adding capture bead reagent (by using 
each bead for target analyte ILlp, IL-6, IL-10 and TNF-a) to the capture bead diluent. 
This was in accordance to the number of standards and samples to be tested and to the 
volume required for each reaction well (25 pi). Similarly, these processes were followed 
in the preparation of working solution of the PE detection reagent by using PE detection 
reagent for each target analyte and detection reagent diluent based on required volume 
(lpl) per reaction and the number of test samples (standard and samples) to generate an 
ultimate volume of 25pl per well.
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Figure 2.1: Cytometric Bead Array (CBA) principle. The steps of flow Cytometric Bead 
Array start by adding capture beads which have a distinctive fluorescence intensity and coated 
with capture antibody specific for the target analyte in a single tube (1) to different beads with a 
sample or standard and a mixture of detection antibodies (2) that are conjugated to Phycoerythrin 
(PE). This reaction leads to the formation of a complex of capture bead with PE, conjugated 
detector antibody and single target analyte (3). Following incubation and consequent washing 
steps (4), the samples are acquired and analysed (5) on a flow cytometer by the FCAP Array 
analysis software gates on each distinct bead population and illustrates the median fluorescence 
intensity (MFI) for each single analyte in the array. It creates a standard curve and determines 
sample concentrations compared to the standard curve. Adopted and modified from 
(http://www.bdbiosciencescom/research/cytometricbeadarray/fonnats/index.jsp).
69
Following reconstituting the standards with 4 ml of assay diluent and leaving for 15 
minutes, serial dilution of standards (0, 10, 20, 40, 80, 156, 312.5, 625, 1250, and 2500 
pg/ml) were prepared to create a standard curve for each single bead or multiplex assay.
Micro-plates of 96 wells were pre-wetted by the addition of lOOpl of wash buffer into 
each well, which was then immediately removed. 25 pi of capture bead stock was added 
per well and then followed by 25 pi of standard (IL-6 IL-ip, IL-10 and TNF-a) and 
samples. Plate were then mixed by digital shaker for 5 minutes at 500 rpm and 
incubated for 1 hour at room temperature (RT). 25 pi of PE detection reagent was 
pipetted into each assay well and mixed by a digital shaker for 5 minutes at 500 
rpm and then incubated at RT for 2 hours. Aspiration of buffer in the plate was made 
and all wells were further drained by vacuum. For bead suspension, 300pl of wash 
buffer was added to each well and mixed as before. Following insertion of the micro- 
plate into the BD FACS Array™ flow cytometer, data was acquired and analysis was 
performed by FCAP Array™ software.
2.2.4 Determination of pro and anti-inflammatory biomarkers in 
patients of longitudinal studies by Enhanced Sensitivity CBA
The above principle of CBA flow cytometric assay is a standard method to detect target 
proteins down to 2-10 pg/ml, while, CBA Enhanced Sensitivity Master Buffer Kits are 
applicable for difficult to detect very low concentrations. The working assay can detect 
as low as 0.274 pg/ml concentration (from 274 to 200.000 fg/ml) by using a two-step 
detection system of PE detection reagent (a) and (b). This ensures binding and detection 
further target analyte and offers reliable quantification and a highly sensitive method for 
generating accurate results (http://www.bdbiosciences.com/research/cytometricbeadarr 
ay/formats/enhanced.j sp).
Method
All reagents were obtained from (BD Biosciences, UK). The principle of this method 
was as described in the previous section (2.2.3). Following reconstituting the standards 
with 4 ml of assay diluent for 15 minutes, serial dilution of standards (0, 274, 823, 
2,469, 7,407, 22,222, 66,667, 200,000 fg/ml) were prepared to create a standard curve 
for each analyte. Furthermore, the same steps such adding capture bead and PE
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detection reagent were performed as in previous section (2.2.3) (by using each bead and 
PE detection for target analyte, TNF-a, IFN-y, IL-1 (3, IL-6, IL-8 and IL-10). An 
additional step in this method was made by adding 1 OOpl of the Enhanced Sensitivity 
Detection Reagent (Part B) to each assay well. Mixing the plate for 5 minutes at 500 
rpm using a digital shaker was performed and the plate was incubated at RT for 1 hour. 
For bead suspension, 200pl of wash buffer was added twice to each well in plate and 
mixed on a digital shaker for five minutes at 500 rpm. The assay thenfollowed the same 
protocol as previously described.
2.2.5 Determination of adiponectin by ELISA in patients on both of 
double-blinded placebo-controlled and longitudinal studies
Enzyme-Linked Immuno-Sorbant Assay (ELISA) is utilized to distinguish a specific 
antigen in the target analyte by employing the quantitative sandwich enzyme 
immunoassay technique. This technique depends on the specificity of antigen-antibody 
type reaction. Due to the high degree of its sensitivity and specificity, it is considered a 
fast and accurate method to investigate the concentration of antigen in a sample. The 
binding of two antibodies with the target antigen is usually performed with serial steps 
of adding multiple liquid reagents, incubations, washes, which are followed by a visual 
change in the colour of liquid (figure 2.2A). The primary antibody is adsorbed (capture 
antibody) to the micro-well, the sample to be analysed is added and then after 
incubation, unbound materials are washed away. Then the second antibody is added and 
binds to the primary antibody producing an antibody-antigen-antibody complex. The 
second antibody is attached to an enzyme (horseradish peroxidase) following a wash to 
remove any unbound antibody-enzyme reagent, a substrate solution is added which 
produces colour in proportion to the amount of antigen present in the sample. The 
colour development is stopped by stop solution and the intensity of the colour is 
measured by spectrophotometry on a microplate reader. The antigen concentrations in 
the samples can be determined by creating a standard curve.
Method
Adiponectin was investigated by using the Human total adiponectin/Acrp30 Quantikine 
ELISA kit (R&D Systems, UK). The plate was pre-coated with a mouse monoclonal 
antibody against adiponectin antigen. Serum samples were diluted to 100-fold dilution
with buffered protein base (Calibrator Diluent RD6-39). 100 pi of assay diluent 
(Calibrator Diluent R1DW) was added to each well followed by 50pl of different 
adiponectin standards (0, 3.9, 7.8, 15.6, 31.2, 62.5, 125 and 250 ng/ml). Test samples 
were pipetted into the wells in duplicate and incubated for 2 hours at RT. Following 
aspiration and washing each well four times with 400 pi wash buffer, the plate was 
inverted and blotted against clean paper towels. 200pl of adiponectin antibody-enzyme 
conjugate was added to each well and the plate incubated for 2 hours at RT. After that 
washing was repeated and then 200 pi of substrate solution (Tetramethylbenzidine, 
TMB) was added to each well and the plate incubated and protected from light for 30 
minutes at RT. Following adding 50 pi of stop solution (Sulphuric Acid) per well to end 
the reaction, the plate was read in a microplate reader (Wallac victor2 1420 multilabel 
counter, UK) at 450 nm after 30 minutes.
2.2.6 Determination of CRP by ELISA in patients of double-blinded 
placebo- controlled
Method
All reagents and 96 well microplate contained in the Human total CRP Quantikine 
ELISA kit (R&D Systems, USA) were brought from 4°C to RT. The microplate was 
pre-coated with a mouse monoclonal anti-body against CRP antigen. Serum samples 
were diluted 100-fold with buffered protein base (Calibrator Diluent RD-P). 100 pi of 
assay diluent (Calibrator Diluent RD1F) was added to each well followed by 50pl of 
CRP standards (0, 0.78, 1.56, 3.12, 6.25, 12.5, 25 and 50 ng/ml) and test samples were 
pipetted into the appropriate wells in duplicate and then the plate incubated for 2 hours 
at RT. The assay followed the same protocol as described above for adiponectin.
2.2.7 Determination of TNF-a by High Sensitivity ELISA in patients of 
double-blinded placebo-controlled
The principle of this kit is the same as the standard ELISA that was previosly described 
however, there was a further step for the improvement of sensitivity (figure 2.2B). This 
is for the detection of low protein concentrations from serum or cell culture
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Figure 2.2: The principle of standard ELISA and high sensitivity ELISA method.
Capture antibody (1, A&B) (primary antibody) binds to antigen in the target analyte (2, 
A&B). Biotinylated detection antibody (3, A&B) with streptavidin (4, A&B). In the 
standard ELISA method detection substrate is then added (5, A) and absorbance measured 
(6, A). In the high sensitivity ELISA method, following the addition of biotin-streptavidin- 
HRP as amplification reagent I and further streptavidin-HRP and amplification (6, B) is 
added to bind to the additional biotin tyramide sites (5, B). Substrate detection is added (7, 
B) following washing steps to measure absorbance reading (8, A&B) by microplate 
reader. Modified from http://www.ebioscience.com/knowledge-center/product- 
line/elisa/high-sensitivity-elisa kits.htm.
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samples, by further enhancing the signal obtained from conventional HRP-based 
ELISA. The signal amplification step uses biotinylated Tyramide resulting in an 
increased sensitivity without loss of resolution or increase in background. This assay 
detects low cytokine concentrations < 1.0 pg/ml with reliable quantification.
Method
All reagents and 96 well microplate contained in the Human TNF-a High Sensitivity 
ELISA kit (eBioscience, UK) were brought from 4°C to RT. The TNF-a microplate was 
coated with monoclonal antibody to human TNF-a antigen. Serum samples were diluted 
to 100-fold dilution with buffered protein base. lOOpl of TNF-a standards (0, 0.031, 
0.063, 0.125, 0.250, 0.500, 10.0 and 20.0 pg/ml) were added to appropriate wells. 50 pi 
of sample diluent added to wells and then 50 test samples were pipetted into the 
appropriate wells in duplicate. Biotin- conjugated anti-body was added to all wells and 
the plate incubated for 2 hours at RT on a shaker (100 rpm). Following aspiration and 
washing each well six times with 400 pi wash buffer, the plate was inverted and blotted 
against clean paper towels. lOOpl of streptavidin-HRP was added to each well and the 
plate incubated for 1 hour at RT on a shaker. Washing steps were then repeated and then 
100 pi of Amplification Solution I (biotin tyramide) was added to each well and 
protected from light for 15 minutes at RT on a shaker. Plate was washed again and 100 
pi of Amplification Solution II (streptavidin-HRP) was added to each well and protected 
from light for 15 minutes at RT on a shaker (100 rpm). Washing steps were then 
repeated and then 100 pi of substrate solution (TMB) was added to each well and 
protected from light for 10 minutes at RT. Following adding 100 pi of stop solution 
(phosphoric acid) per well to end the reaction, the plate was subjected to a microplate 
reader at 450 nm during 30 minutes.
2.2.8 Determination of apolipoprotein by ELISA in patients of double­
blinded placebo-controlled and longitudinal studies
2.2.8.1 Apo A1 ELISA 
Method
All reagents and microplate of 96 well contained in the apolipoprotein A1 Human
ELISA kit (abeam, UK) were brought from 4°C to room temperature. The ApoAl 
microplate was pre-coated with a mouse polyclonal antibody against the Human Apo 
A1 antigen. Serum samples were diluted 400 fold with buffered protein base. 25pi of 
ApoAl standards (0, 0.625, 1.25, 2.50, 5, 10, 20 and 40 pg/ml), biotinylated antibody 
and test samples were pipetted into the appropriate wells in duplicate and the plate 
incubated for 2 hours at RT. Following aspiration and washing each well five times with 
200 pi wash buffer, the plate was inverted and blotted against paper towels. 50pl of 
enzyme conjugate was added to each well and the plate incubated for 30 minutes at RT. 
Washing steps were then repeated and then 50 pi of substrate solution (TMB) was 
added to each well and protected from light for 10 minutes at RT. Following adding 50 
pi of stop solution (hydrochloric acid) per well to end the reaction, the plate were 
subjected to a microplate reader at 450 nm during 30 minutes.
2.2.8.2 Apo B ELISA 
Method
All reagents and microplate of 96 well contained in the MaxDiscovery apolipoprotein B 
ELISA kit Manual (BIO SCIENTIFC, USA) were brought from 4°C to RT. the 
Apolipoprotein B microplate was pre-coated with an antibody to the Human Apo B 
antigen. Serum samples were diluted 10.000-fold with buffered protein base. lOOpl of 
Apo E standards (0, 3, 6, 12, 24, 50, 100 and 200 ng/ml) and test samples were pipetted 
into the appropriate wells in duplicate and the plate incubated for 1 hour at 37°C. 
Following aspiration and washing each well five times by 250 pi wash buffer, the plate 
was inverted and blotted against paper towels. lOOpl of ApoB antibody-enzyme 
conjugate was added to each well and the plate incubated for 1 hour at 37 °C. After this 
point the assay followed the same protocol as described as before.
2.2.8.3 Apo E ELISA 
Method
All reagents and 96 well microplate contained in the apolipoprotein E Human ELISA 
kit (abeam, USA) were brought from 4°C to RT. The Apolipoprotein E microplate was 
pre-coated with a mouse polyclonal antibody against the Human Apo E antigen. Serum
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samples were diluted 400-fold with buffered protein base. 50pl of different Apo E 
standards (0, 0.031, 0.063, 0.125, 0.250, 0.500, 10.0 and 20.0 pg/ml) and test samples 
were pipetted into appropriate wells in duplicate and incubated for 2 hours at RT. 
Following aspiration and washing each well five times with 200pl wash buffer, the plate 
was inverted and blotted against paper towels. 50f.il biotinylated antibody was added to 
each well and the plate was incubated for lhour at RT. Washing steps were then 
repeated and then 50pl of enzyme conjugate was added to each well and the plate 
incubated for 30 minutes at RT. After this point the assay followed the same protocol as 
described as before.
2.2.8.4 Lp (a) ELISA 
Method
All reagents and 96 well microplate contained in the Human Lp (a)/ Apo A1 ELISA kit 
(DRG instruments GmbH, Germany) were brought from 4°C to RT. Lp (a) microplate 
was pre-coated with a mouse monoclonal anti-Apo (a). Samples of serum were diluted 
to 1: 202 with Sample Buffer (provided as part of the kit). 25 pi of Lp(a) Calibrator (0, 
0.32, 1.1, 2.8, 4.4 U/L) and test serum were pipetted into the suitable wells in duplicate 
and then 50pl of enzyme conjugate mouse monoclonal anti-Apo(a) was added and the 
plate incubated on shaker for 1 hour at RT. After this point the assay followed the same 
protocol as described above for adiponectin.
2.2.9 Determination of HDL subfractions in serum from patients of 
double-blinded placebo-controlled and longitudinal studies
To measure the level of HDL3 and HDL2 with HDL2/HDL3 ratio in serum, this firstly 
required determination of the level of total HDL in serum. Secondly, a single 
precipitation procedure for selectively separating HDL3 from both the apo B-containing 
lipoproteins and HDL2 is needed. Heparin, manganese chloride (MnCk) and dextran- 
sulphate (DS) are usually used for precipitating lipoprotein and HDL2 in the 
supernatant (Hirano et al, 2008).
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2.2.9.1 Precipitation method with Heparin/MnC12/DS to separate HDL3 and 
HDL2 patients serum of double-blinded placebo-controlled and longitudinal 
studies
Method
All reagents and samples were brought from 4°C to RT before using. For preparing the 
precipitation reagent heparin (Sigma Aldrich, UK) (8.25 mg/ml), MnCk (Sigma 
Aldrich, UK) (98.7 mg/ml), and DS (Sigma Aldrich, UK) (12 mg/ml) were mixed 
together in 1ml of dfUO. After that, 15pL of the precipitation reagent was added to 
75pL of serum and incubated at RT for 30 min, and then centrifuged at 10,000g for 10 
min at 4°C. After the centrifugation step the pellet contained the HDL2 and the HDL 3 
remained in the supernatant which was then ready for measurement by the method 
below (2.2.9.2).
2.2.9.2 Determination of total HDL and HDL3 subfraction by using Amplex Red 
cholesterol assay
Method
Following preparation of the supernatant containing HDL3, all reagents of the 
Amplex® Red Cholesterol Assay Kit, (Invitrogen™, UK) were brought from 4°C to RT. 
Serial dilutions of standards were made (0, 2, 4, 6, and 8pg/ml) to create the standard 
curve. In duplicate, 50pl of standard, control and samples of total HDL and fractionated 
HDL3 serum were pipetted into each a 96 well microplate (Fisher Scientific, UK) and 
incubated with 50pl of Amplex Red reagent /HRP/cholesterol oxidase/cholesterol 
esterase working solution for 30 minutes at 37°C. This working solution was 300pM 
Amplex® Red reagent containing 75pl of Amplex® Red reagent stock solution, 50pl of 
the HRP stock solution, 50pl of the cholesterol oxidase stock solution and 5 pi of the 
cholesterol esterase stock solution, which was added to 4.82 ml of Reaction Buffer. 
Following incubation, the plate was read in a microplate reader at 570nm within 30 
minutes. The HDL3 values were multiplied by 1.2 to correct for dilution by the 
precipitation reagent. HDL2 was calculated by subtracting the HDL3 value from the 
total HDL value. Moreover, the ratio of HDL2/HDL3 was calculated by dividing HDL2 
by HDL3.
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Number 24 120
Type of 
treatment
intramuscular testosterone 
injection
Gel treatment
Period for 6 months 5-7years
Investigated
parameters
Body composition, 
apolipoproteins, TNF-a, IL-6, IL- 
1 p, IL-10, adiponectin, CRP and 
HDL3, HDL2 and HDL2/HDL3
Body composition, I 
apolipoproteins, TNF-a, IL- 
6, IL-lp, IL-10, IFN-y 10, 
adiponectin, IL-8 and HDL3, 
HDL2 and HDL2/HDL3
Assay
technique
ELISA, Cytometric Bead Array 
and Amplex Red cholesterol 
assay
ELISA, Cytometric Bead 
Array and Amplex Red 
cholesterol assay
Table 2.1: Summary table of human in vivo study. The details of samples patients, 
analysis method, target parameters, period and of type treatment used in this study
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2.2.10 Statistical analysis of assay data
Data is presented as mean ± SEM, unless otherwise stated. In a short-term study, the 
data were analysed with a statistical software package (SPSS version 20, SPSS Inc, 
Chicago, Illinois USA), Prism Graphpad 5 software and StatsDirect. Comparison 
baseline data for treatment groups (placebo and testosterone) was analysed by using t- 
test. Generalized Linear Model (GLM) was used to compare the difference between 
groups for data followed by a post-hoc Tukey's test. Mest was also used to compare the 
mean change from 0 to 3 and 6 months between groups. Two way ANOVA was used 
with a post-hoc Tukey's test for HDL and its fraction. In the longitudinal study, the 
normal distribution of data was assessed by the D’Agostino test for normality. Kruskal- 
Wallis test was used for non-parametric data followed by a post-hoc Conover-Inman 
test. All results were considered as statistically significant at P < 0.05.
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2.3 Results
2.3.1 Patients in double-blinded placebo-controlled study
The baseline clinical characteristics are displayed in Table 2.2. The study population 
included a group of 24 hypogonadal men with T2DM treated with testosterone (n=ll) 
and a group treated with placebo (n=13). The baseline data of the treatment group and 
the placebo-treated groups were not statistically different by using the t test.
2.3.1.1 Analysis of change in body composition in the double-blinded placebo- 
controlled study patients
No significant change in BMI, WC and W/H R was seen in either treatment group 
during the study. There was not significant diffference in BMI, WC and W/H R in 
patients with testosterone treatment compared to patients with placebo from baseline to 
6 months (Table 2.3A) (Table 2.3B).
2.3.1.2 Analysis of pro and anti-inflammatory biomarkers by CBA assay
The results measuring IL-lp, IL-6, IL-10, and TNF-a from CBA method were all under 
the detection limit. Therefore, they were not available for analysis.
2.3.1.3 Analysis of adiponectin by ELISA in the double-blinded placebo-controlled 
study patients
There was a reduction but not significant in the level of adiponectin in both groups from 
baseline to 6 months. However, there was a significant difference in adiponectin levels 
in patients with testosterone treatment, which were lower after 3 months compared to 
the placebo treated group (2978.10 ± 672 vs 5452.48 ± 836 P=0.03) (Table 2.4A) and 
the reduction in adiponectin with testosterone by analysis of thechange of levels over 
time remained significant (-16.90±11.33 vs. 9.85±6.85 ng/ml; P=0.04) (Table 2.4B).
2.3.1.4 Analysis of TNF-a by high Sensitivity ELISA in the double-blinded 
placebo-controlled study patients
Testosterone treatment tended to lead to a decrease in TNF-a level in serum from
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Age year 61.7 ± 11.8 56.6 ±11.9
BMI Kg/m2 32.65 ±1.1 34.36 ± 1.5
W/H (cm) 1.06 ±0.01 1.07 ± 0.01
WC (cm) 115.96 ±3.6 119.12 ±3.4
Adipo (ng/mL) 5502.28 ±1186 3800.87 ± 764
CRP (ng/mL) 5685.43 ±741 4271.96±621
TNF-a (pg/ml) 0.56 ±0.11 0.55 ±0.11
LP(a) (U/L) 41.14 ±8.1 57.14 ±13
ApoB (mg/ml) 1.08 ±0.17 1.21 ±0.11
Apo A1 (pg/ml) 753 ±120 482 ± 87
Apo E (pg/ml) 123.2 ±8.8 131.9 ±11
HDL mmol/l 0.91 ± 0.06 0.94 ± 0.06
HDL2 (mmo/I) 0.791 ± 0.06 0.742 ± 0.08
HDL3 (mmol/l) 0.138 ±0.02 0.197 ±0.03
HDL2/HDL3 Ratio 5.731 ± 1.2 5.7 ± 1.6
HbA1c (%) 7.82 ±1.52 7.46 ±1.12
Glucose (mmoi/1) 8.85 ± 4.42 10.64 ± 4.59
Systolic BP (mmHg) 138.4 ±20.7 135.7 ±16.3
Diastolic BP 
(mmHg) 70.8 ±10.0 72.6 ± 9.6
Table 2.2: Baseline characteristics (mean ± SEM) of hypogonadal men with T2DM 
administered testosterone treatment or placebo groups. The baseline values of each 
parameter between the placebo and testosterone groups were not statistically different. 
BMI: body mass index. WC: waist circumference. W/H R: waist to hip ratio. Adipo: 
adiponectin. CRP: C-reactive protein. TNF-a: tumour necrosis factor. LP (a): 
Lipoprotein (a). Apo B: apolipoproteins B. Apo Al: apolipoprotein Al. HDL: Hig 
density lipoprotein cholesterol. HblAlc: glycated haemoglobin. Bp: blood pressure. 
SEM: Standard error mean.
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Parameter
Placebo (n=13) Testosterone (n = ll)  Baseline
_________ Mean ± SEM Mean ± SEM_______________ comparison
Baseline 3 6 Baseline 3 6 P-value
BMI Kg/m2 32.65 ±1.1 32.74 ±1.2 32.64 ±1.3 34.36 ±1.5 34.65 ±1.6 34.82 ± 1.6 0.3
W/H (cm) 1.06 ±0.01 1.06 ±0.01 1.06 ±0.01 1.07 ±0.01 1.08 ±0.01 1.07 ±0.02 0.7
WC (cm) 115.96 ±3.6 115.20 ±3.6 115.12± 3.9 119.36 ±3.4 119.72 ±3.6 120.04 ±3.9 0.4
Table 2.3A: Comparison of the effect of placebo and testosterone treatment on 
body composition in hypogonadal men with T2DM at baseline, 3 and 6 months.
BMI: body mass index. WC: waist circumference. W/H R: waist to hip ratio. SEM: 
Standard error mean. GLM: generalized linear model. Baseline comparison analysed by 
/-test.
Placebo (n=13) Testosterone (n=l 1)
Parameters % change % change p-value p-value
Mean ± SEM Mean ± SEM (0-3) (0-6)
(0-3) (0-6) (0-3) (0-6)
BMI Kg/m2 0.72 ±0.46 0.33 ± 0.84 0.86 ±0.48 1.31 ±0.52 0.8 0.6
W/H (cm) 0.38 ±0.40 0.41 ±0.44 0.94 ±0.71 0.37 ±0.97 0.4 0.9
WC (cm) 0.72 ±0.46 0.41±0.85 0.25±0.30 0.45 ± 0.69 0.5 0.9
Table 2.3B: Comparison of the effect of placebo and testosterone treatment on 
body composition in hypogonadal men with T2DM at 3 and 6 months expressed as 
percentage from baseline. BMI: body mass index. WC: waist circumference. W/H R: 
waist to hip ratio. SEM: Standard error mean. Group comparison analysed by /-test.
82
baseline to 6 months. There was no significant difference in TNF-a levels in the 
testosterone group compared to placebo treated group at any time point (Table 
2.4A)(Table 2.4B).
2.3.1.5 Analysis of CRP by ELISA in the double-blinded placebo-controlled study 
patients
The serum levels of CRP increased from baseline to 6 months in the testosterone-treated 
group whereas it decreased in the placebo-treated. However, there was not a significant 
difference between the two groups at any time point (Table 2.4A) (Table 2.4B).
2.3.1.6 Analysis of apolipoproteins by ELISA in the double-blinded placebo- 
controlled study patients
Neither serum LP (a) nor Apo B concentration changed during the course of the study 
in either treatment group, and values for the testosterone-treated group were not 
significantly different from the placebo-treated group. Similarly, no significant change 
was seen in level of Apo Al and Apo E in patients treated with testosterone, compared 
to the placebo treated patient from baseline to 6 months (Table 2.4A) (Table 2.4B).
2.3.1.7 Analysis of HDL subfractions by Amplex Red cholesterol assay in the 
double-blinded placebo-controlled study patients
There was no effect of testosterone on level of HDL2, HDL3 and HDL2/HDL3 ratio in 
both groups from baseline to 6 months and in patients with testosterone treatment 
compared to patients with placebo over six months (Table 2.5A) (Table 2.5B).
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Parameters
Placebo: (n=13) 
Mean ± SEM
Testosterone (n=ll) 
Mean ± SEM
Baseline
comparison
Baseline 6 Baseline 6 (P)
HDL ( mmol/l) 0.91 ±0.06 0.97 ± 0.08 0.94 ± 0.06 0.91 ± 0.06 0.7
HDL2 (mmol/l) 0.791 ±0.06 0.820 ± 0.09 0.742 ± 0.08 0.743 ± 0.07 0.6
HDL3 (mmol/l) 0.138 ±0.02 0.168 ±0.02 0.197 ±0.03 0.156 ±0.07 0.2
HDL2/HDL3 Ratio 6.98 ±1.2 5.38 ± 0.6 5.77 ±1.6 5.5 6± 0.94 0.5
Table 2.5A: Comparison of the effect of placebo and testosterone treatment on 
serum of HDL and its fractions in hypogonadal men with T2DM at baseline and 6 
months. HDL: High density lipoprotein. SEM: Standard error mean. P: P-value. Two 
way ANOVA. Baseline comparison analysed by Mest.
Parameters
Placebo: (n=13) 
% change 
Mean ± SEM
Testosterone (n = ll)  
% change 
Mean ± SEM p-value
(0-6) (0-6)
HDL ( mmol/l) 5.62± 4.91 -2.80 ±2.94 0.1
HDL2 (mmol/l) 0.90 ±5.13 5.65 ± 7.43 0.6
HDL3 (mmol/l) 32.02 ±13.99 4.77 ± 20.47 0.2
HDL2/HDL3 Ratio -13.49 ± 12.89 84.51 ±65.91 0.1
Table 2.5B: Comparison of the effect of placebo and testosterone treatment on 
serum of HDL and its fractions in hypogonadal men with T2DM at 6 months 
expressed as percentage from baseline. HDL: High density lipoprotein. SEM: 
Standard error mean. Group comparison analysed by Mest.
86
2.3.2 Patients in longitudinal study
Table 2.6 shows the baseline characteristics of the 120 diabetic males included in the 
longitudinal study with an average age of 66 years (range 40-79 years). This group was 
divided based on the baseline level of serum testosterone into normal testosterone 
participants (n=76), low testosterone participants without testosterone treatment (n=29) 
and low testosterone with testosterone treatment participants (n=15). Within the groups 
these were also divided into four subgroups according to IHD status. Patients with IHD 
and normal testosterone (n=14), IHD with low testosterone without testosterone 
treatment (n=6) and others had IHD and treated with testosterone therapy (n=4) 
compared to a further subgroup of patients with normal testosterone without IHD 
(n=52) and used as untreated (no testosterone) control group.
2.3.2.1 Analysis of change in body composition in the longitudinal study patients
There was no significant difference in BMI, W/H ratio and WC between patients with 
low testosterone and patients with low testosterone treated with testosterone compared 
to control samples who had normal testosterone (Table 2.7). Likewise, no significant 
difference was seen in body composition in IHD subgroups compared to untreated 
control samples who had normal testosterone without IHD (Table 2.8).
2.3.2.2 Analysis of pro and anti-inflammatory biomarkers by Enhanced Sensitivity 
CBA in the longitudinal study patients
The level of IL-ip, IL-6, IL-8, IL-10, TNF-a and IFN-y in serum of patient in this study 
was measured by Enhanced Sensitivity CBA assay. The data for IL-8 was reliable (the 
coefficient of variation between sample measures was below 10%), however the 
obtained data for IL-ip, IL-6, IL-10, TNF-a and IFN-y were not reliable and excluded, 
due to the much higher variability among these data.
2.3.2.3 Analysis of IL-8 levels by Enhanced Sensitivity CBA assay in the 
longitudinal study patients
No significant difference was observed in the mean serum IL-8 level in patients with 
low testosterone either with or without treatment compared to untreated control samples
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Age year3 56.13 ±1.00 56.55 ±1.68 57.13±1.19
BMI Kg/m23 32.22 ±0.71 33.16 ±1.05 35.03±1.12
W/H (cm)3 0.62 ± 0.01 0.64± 0.01 0.66 ± 0.01
WC (cm)3 108.97 ± 1.68 112.32 ±2.58 116.85±2.46
HbAlcac 7.19± 0.15 7.21 ±0.19 7.61±0.31
IHDb,c 26.31% 24.13% 13.3%
Insulin treatmentb’c 34.21% 24.14% 60%
Metformin15’c 60.52% 41.37% 40%
Table 2.6: Baseline characteristics for patients and untreated controls groups in 
the longitudinal study. BMI: body mass index. W/H R: waist to hip ratio. WC: waist 
circumference. aMean with standard error of mean, dum ber as a percentage, c data 
were obtained from the hospital records. IHD: ischemic heart disease.
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P aram eter NT (n=76) 
Mean ± SEM
LT (n=29) 
Mean ± SEM
LT+TRT(n=15)
Mean ± SEM
BMI Kg/m2 32.42 ±0.8 32.91 ±1.0 34.19 ± 1.4
W/H R(cm) 0.56 ±0.01 0.54 ± 0.02 0.59 ± 0.02
W C (cm) 97.73 ± 2.4 99.01 ±4.2 104.4 ±3.7
Table 2.7: Comparison in body composition between patients and untreated 
controls with normal levels testosterone at the end of the longitudinal study. NT:
normal testosterone. LT: low testosterone. LT+TRT: low testosterone with testosterone 
replacement treatment. BMI: body mass index. W/H R: waist to hip ratio. WC: waist 
circumference. SEM: Standard error mean. Kruskal-Wallis test.
Parameter NT (n=52) 
Mean ± SEM
IHD+NT (n=14) 
Mean ± SEM
IHD+LT (n=6) 
Mean ± SEM
IHD+TRT (n=4) 
Mean ± SEM
BMI Kg/m2 32.06 ±0.9 31.6 ± 1.4 29.9 ±1.8 33.55 ± 2.5
W/H R(cni) 0.55 ± 0.01 0.55 ± 0.02 0.50 ± 0.03 0.57 ±0.04
WC (cm) 95.9 ± 2.9 96.29 ± 4.6 83.9 ± 5.8 98.03 ± 7.7
Table 2.8: Comparison in body composition between IHD patients and untreated 
controls with normal levels of testosterone at the end of the longitudinal study. NT:
normal testosterone. IHD+NT: ischemic heart disease with normal testosterone. 
IHD+LT: ischemic heart disease with low testosterone. IHD+TRT: ischemic heart 
disease with testosterone replacement treatment. BMI: body mass index. W/H R: waist 
to hip ratio. WC: waist circumference. SEM: Standard error mean. Kruskal-Wallis test.
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(Table 2.9). Similarly, there was no significant difference in levels of IL-8 among all 
IHD subgroups compared to untreated control samples (p>0.05) as shown in table 2.10.
2.3.2.4 Analysis of adiponectin levels by ELISA in the longitudinal study patients
As shown in table 2.9, no significant change was seen in mean serum levels of 
adiponectin between patients with low testosterone with or without treatment and 
untreated control samples. In the same way, there was no significant difference in 
adiponectin level between the 3 subgroups and untreated control samples (Table 2.10).
2.3.2.5 Analysis of apolipoprotein factors by ELISA in the longitudinal study 
patients
There was no significant difference in all apolipoprotein concentrations (Apo Al, Apo 
B, Apo E and LP (a)) between patients with low testosterone who were treated with or 
without testosterone therapy as seen in table 2.9. Similarly, no significant change was 
seen in the level of these apolipoprotein among all IHD subgroups compared to 
untreated control samples as shown in table 2.10.
2.3.2.6 Analysis of HDL subfractions by Amplex Red cholesterol assay in 
longitudinal study
As shown in table 2.11, the mean serum level of HDL (p=0.05) in patients with low 
testosterone was approaching significantly lower than in the untreated control group. 
Although not statistically significant, an increase in the level of HDL was seen in 
patients treated with testosterone compared to patients with low testosterone. In contrast, 
no significant difference was observed in the mean serum HDL2 levels in patients with 
low testosterone and the untreated control group, whilst the mean serum HDL2 levels in 
patients treated with testosterone was approaching significantly (p=0.06) higher than in 
the untreated control group. There was a significant increase in the level of HDL2 
(p=0.01) in patients treated with testosterone compared to patients with low 
testosterone. It is worthy to note that while there was no a significant difference in the 
level of HDL3 in patients with low testosterone and the untreated control group, there 
was significant reduction in its level (p=0.004) in patients treated with testosterone
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Param eter NT (n=76) 
Mean ± SEM
LT (n=29) 
Mean ± SEM
LT±TRT (n=15) 
Mean ± SEM
Adipo (ng/ml) 10731 ±941.8 10812± 1460 10220± 1847
IL-8 (pg/ml) 1.96 ±0.26 2.40 ± 0.68 2.51 ± 0.33
LP(a) (U/L) 175.28 ±25.3 209.1 ±51.1 144.7 ±53 .5
Apo B (mg/ml) 1.59 ±0.69 1.69 ±0.11 1.49 ± 0 .16
Apo A1 (pg/ml) 1725 ±104.1 1734 ± 131.2 1549 ± 136.6
Apo E (pg/ml) 121.3 ±7.8 119.2 ± 11.97 112.9 ± 13.34
Table 2.9: Comparison of adiponectin, IL-8 and apolipoprotein between patients 
and untreated controls with normal levels testosterone in the longitudinal study.
NT: normal testosterone. LT: low testosterone. LT+TRT: low testosterone with 
testosterone replacement treatment. IL-10: interleukin 10. IL-8: interleukin 8. LP (a): 
lipoprotein. Apo: apolipoprotein. SEM: Standard error mean. Kruskal-Wallis test.
91
Param eters NT (n=52) 
Mean ± SEM
IHD+NT (n=14) 
Mean ± SEM
IHD+LT (n=6) 
Mean ± SEM
IHD+TRT(n=4) 
Mean ± SEM
Adipo (ng/ml) 11559± 1241 8836± 1281 14134 ±2984 13813 ± 5928
IL-8 (pg/ml) 1.52 ± 0.22 1.67 ± 0 .26 2.51 ± 0.73 2.07 ± 0.60
LP(a) (U/L) 194.9 ±31.82 181.1 ± 68.09 198.8 ± 142.8 329.8 ± 147.6
Apo B (mg/ml) 1.62 ± 0.07 1.56 ± 0.17 1.44 ± 0.28 1.85 ± 0 .53
Apo A 1 (pg/ml) 1835± 133 1649 ± 227 1803 ± 268 2 061± 798
Apo E (pg/ml) 110.5 ±7.1 140.4 ± 25.9 107.6 ± 23.6 123.2 ±45.1
Table 2.10: Comparison of adiponectin, IL-8 and apolipoprotein between IHD 
patients and untreated controls with normal levels testosterone in the longitudinal 
study. NT: normal testosterone. IHD + NT: ischemic heart disease with normal 
testosterone. IHD + LT: ischemic heart disease with low testosterone. IHD+TRT: 
ischemic heart disease with testosterone replacement treatment. IL-8: interleukin 8. LP 
(a): lipoprotein (a). Apo: apolipoprotein. SEM: Standard error mean. Kruskal-Wallis 
test.
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Param eters NT (n=76) 
Mean ± SEM
LT (n=29) 
Mean ± SEM
LT+TRT (n=15) 
Mean ± SEM
HDL(mmoI/I) 1.40 ± 0 .02 1.31 ± 0.04 1.38 ± 0.05
HDL2 (mmol/l) 1.09 ±0 .02 1.01 ± 0.05 nn1.17 ± 0 .05
HDL3 (mmol/l) 0.31 ± 0.01 0.30 ± 0.03 0.21 ± 0.02*
HDL2/HDL3 Ratio 4.24 ± 0.25 4.07 ± 0.34 ** nn 5.90 ± 0.50 ’
Table 2.11: Comparison of HDL, HDL2, HDL3 and HDL2/HDL3 ratios between 
patients untreated controls with normal levels testosterone in the longitudinal 
study. NT: normal testosterone. LT: low testosterone. LT+TRT: low testosterone with 
testosterone replacement treatment. HDL: High density lipoprotein cholesterol. SEM: 
Standard error mean. * P< 0.05, ** PO.Ol vs NT, DD PO.Ol vs LT. Kruskal-Wallis 
test.
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compared to the untreated control group. In addition, there was an almost significant 
decrease in concentration of HDL3 (p<0.05) in patients treated with testosterone 
compared to patients with low testosterone. No significant difference was seen in the 
HDL2/HDL3 ratio between patients with low testosterone and the untreated control 
group. Conversely, there was a significant increase in the HDL2/HDL3 ratio in patients 
treated with testosterone (p=0.003) compared to the untreated control group and 
(p=0.01) compared to the patients with low testosterone. As shown in table 2.12, no 
significant change was seen in levels of HDL in all IHD subgroups. A significant 
decrease was only seen in the level of HDL2 (p=0.02) in IHD patients with normal 
testosterone compared to the untreated control group. However, no significant 
difference was seen in levels of HDL3 and H2/H3 ratio in all IHD subgroups compared 
to the untreated control subjects.
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Param eters NT (n=52) 
Mean ± SEM
IHD+NT (n=14) 
Mean ± SEM
IHD+LT (n=6) 
Mean ± SEM
IHD+TRT (n=4) 
Mean ± SEM
HDL ( mmol/l) 1.43 ±0.01 1.36 ±0.04 1.37 ± 0.11 1.29 ± 0.12
HDL2 (mmol/l) 1.12 ±0.02 1.02 ±0.04* 1.07 ±0.09 1.08±0.11
HDL3 (mmol/l) 0.31 ± 0.02 0.34 ± 0.03 0.30 ± 0.05 0.21 ±0.06
HDL2/HDL3 Ratio 4.31 ±0.30 3.60 ± 0.51 4.11 ±0.61 6.15 ± 1.80
Table 2.12: Comparison of HDL, HDL2, HDL3 and HDL2/HDL3 ratios between 
IHD patients and untreated controls with normal levels testosterone in the 
longitudinal study. NT: normal testosterone. IHD + NT: ischemic heart disease with 
normal testosterone. IHD + LT: ischemic heart disease with low testosterone. 
IHD+TRT: ischemic heart disease with testosterone replacement treatment. HDL: High 
density lipoprotein cholesterol. SEM: Standard error mean. * p < 0.05 vs NT. Kruskal- 
Wallis test.
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Body composition NC NC NC
Adiponectin Reduction after 3 months NC NC
TNF-a NC NR NR
CRP NC NI NI
IL-8 NI NC NC
Apolipoprotein NC NC NC
HDL NC NC NC
HDL2 NC Increased NC
HDL3 NC Decreased NC
HDL2/HDL3 Ratio NC Increased NC
Table 2.13; Summary of results the effect of testosterone treatment on serum 
factors in hypogonadal men with T2DM in Double-blinded placebo-control and 
longitudinal studies. NC: no change, NR; no result, NI=not investigated, IHD: 
ischemic heart disease, Adipo: adiponectin, CRP: C-reactive protein, TNF-a: tumour 
necrosis factor, IL-8: interleukin 8, HDL: high density lipoprotein.
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2.4 Discussion
2.4.1 Patients in double-blinded placebo-controlled study
This study investigated the effect of testosterone replacement therapy over a six 
month period in men with low testosterone and T2DM.
2.4.1.1 The effect of testosterone on body composition in patients in a double­
blinded placebo-controlled study
All of the patients were suffering from obesity as defined by the baseline of BMI 
criteria and central adiposity, as defined by waist or waist-hip ratio. No significant 
changes in BMI, WC and W/HR following TRT were found in this study. In a similar 
study, no significant changes in BMI or waist circumference were observed in diabetic 
Japanese men, following administration of the testosterone enanthate for 6 months 
(Ueshiba, 2013). Furthermore, no significant changes were observed in the BMI of 
diabetic patients following 6 months of testosterone treatment (Kapoor et al, 2007). 
Similar results were obtained in a study by Frederisen et al. (2012) in that, there was no 
change in visceral fat mass in aged men with low testosterone levels following 6 months 
of transdermal testosterone treatment, However, subcutaneous fat mass was 
significantly reduced in both the high and the abdominal areas when analysed by MRI. 
A further study found that testosterone treatment for 8 months in 23 middle aged, 
abdominally obese men was followed by a decrease in visceral fat mass, without 
changes in body mass, subcutaneous fat and lean body mass (Marin et al, 1992a).
The beneficial effects of testosterone on body composition have been reported in other 
studies. Rebuffe-Scrive et al (1991) showed a reduction in the W/HR in 9 of 11 middle 
aged men who were moderately obese, after intramuscular injection of testosterone over 
a 6 weeks period. Furthermore, Saad et al. (2009) reported that a decline in WC was 
observed in both groups treated with a high dose testosterone undecanoate (TU; 1000 
mg) and testosterone gel (50 mg/day) for 9 months in two cohorts of elderly men with 
late-onset hypogonadism. In a study by Kapoor et al. (2006, 2007) testosterone therapy 
(200mg sustanon) for 3 months reduced WC and W/HR, improved IR and glycemic 
control in men with testosterone deficiency and T2DM. Moreover, testosterone therapy 
for 52 weeks reduced visceral fat accumulation in proportion to the increase in
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testosterone levels in 60 non-obese aging men (Allan et al, 2008). Other studies have 
similarly demonstrated an improvement in WC (Saad et al, 2007, 2008) and decreased 
fat mass (Agledahl et al, 2008) with TRT.
The dose, duration of treatment, route of administration of testosterone and design of 
study (Alexandersen and Christiansen, 2004, Jones and Saad, 2009; Traish and Kypreos 
., 2011; Kapoor et al, 2007) or the way of measuring regional distribution of fat such as 
ultrasound, which may not give reliable result (Frederiksen et a l, 2012a) are known 
factors which impact on any change in body composition in response to testosterone.
The latter points may demonstrate why TRT did not show beneficial effects on BMI, 
WC and W/RH in the current study. However, the mechanisms by which testosterone 
decreases body composition are still poorly understood, improved understanding of how 
testosterone is associated with beneficial effects in T2DM is needed.
2.4.1.2 The effect of testosterone on adiponectin in patients in a double-blinded 
placebo-controlled study
It was found that testosterone treatment reduced serum adiponectin levels significantly 
after three months of treatment, in comparison to levels in samples from those with the 
placebo. This agrees with findings by Kapoor et al. (2007) who reported a significant 
reduction in the level of adiponectin after 3 months testosterone treatment in men with 
T2DM. Similarly, two other studies found that testosterone treatment reduced 
adiponectin plasma levels following 6 months, in young hypogonadal non-diabetic men 
(Lanfranco et al, 2004) and in ageing men with low to normal testosterone levels 
(Frederiksen et al, 2012). Furthermore, it has been reported that the percentage 
composition of the high molecular weight (HMW) fraction of adiponectin was reduced 
by TRT in both animal models (mice) and hypogonadal men (Xu et al, 2005). A 
previous study that induced low testosterone levels in normal men experimentally, 
resulted in an increase in adiponectin levels following a supplement of testosterone this 
increase was prevented (Page et al, 2005b). This was strongly supported by an animal 
study whereby castration of mice was associated with an increase in adiponectin which 
was reversed following TRT in both sham-operated and castrated mice (Nishizawa et 
al, 2002). According to Kapoor et al. (2007), the suppressive action of testosterone on 
the adiponectin levels is thought to be as a result of a reduction in body fat composition 
related to TRT, which led to a decrease in adiponectin production from adipocytes. In
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support of this hypothesis, previous studies reported that plasma adiponectin levels 
showed a more significant correlation with the amount of visceral adipose tissue than 
the subcutaneous adipose tissue (Yatagai et al, 2003; Park et al, 2004; Kwon et al, 
2005), while another study stated that the subcutaneous adipose tissue was 
independently correlated with the HMW adiponectin levels in aging men (Fujikawa et 
al, 2008). A further study provides contrasting evidence supporting the beneficial effect 
of testosterone on body composition without affecting the level of adiponectin (Page et 
al, 2005a). The latter studies reported opposite findings to this current study with no 
significant change in body composition being seen in patients treated with testosterone. 
Moreover, Heufelder et al. (2009) found that testosterone therapy in combination with 
diet and exercise in T2DM men resulted in increase in adiponectin, demonstrating that 
other factors in addition to testosterone can contribute to a positive outcome. However, 
the mechanism involved in this action is not fully understood. Therefore, further studies 
important to determine the mechanism through which this occurs.
2.4.1.3 The effect of testosterone on pro-inflammatory factors in patients in the 
double-blinded placebo-controlled study
The present study showed no effect of TRT on patient serum CRP levels for 6 months. 
Similar findings were observed in several studies with different types of testosterone 
treatment. One of these demonstrated that treatment with anastrozole, which inhibits the 
conversion of testosterone to estradiol, did not significantly affect inflammatory 
markers CRP or IL-6 in elderly men with mild hypogonadism (Dougherty et al, 2005), 
this study demonstrates that when testosterone is acting via the AR no change in these 
markers is seen. Additional studies reported that there were no effects on CRP levels at 
any dose of testosterone in young eugonadal men, who received an analogue of 
gonadotrophin-releasing hormone to block gonadal steroid production, followed by 
supplementation with graded doses of testosterone (Singh et al, 2002). Similarly, no 
change was seen in levels of CRP and IL-6 following 3 months of androgen treatment 
with either dihydrotestosterone or recombinant human chorionic gonadotropin in elderly 
healthy men with partial androgen deficiency (Ng et al, 2002). At the level of the gene 
in vivo, Corcoran and co-workers, (2010) found that both physiological and 
supraphysiological concentrations of testosterone had no effect on macrophage CRP 
mRNA expression in older men. Additionally, a significant inverse correlation between 
baseline CRP and total testosterone was observed in diabetic men (Kapoor et al, 2007)
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while in a second study, free testosterone had a negative correlation with CRP in older 
age males (Yang et al, 2005). Haider et al. (2007) found that ADT was associated with 
an unfavourable increase in CRP levels in diabetic men with advanced prostate cancer. 
However, in the present study the short time of treatment (6 months) might explain the 
lack of effect of testosterone on anti-inflammatory actions, and long-term treatment 
would be required to clarify the effect of testosterone on CRP.
In this current study, testosterone had no effect on serum levels of TNF-a patients, this 
is consistent with the data reported in human and animal studies that testosterone did 
not show an effect on TNF-a levels (Kapoor et al., 2007; Kelly et al, 2012). In contrast, 
Malkin et al. (2004) indicated that testosterone treatment induced a small but significant 
reduction in TNF-a in hypogonadal men, compared with the placebo group. Similarly, 
another study found that transdermal testosterone reduced serum TNF-a but not IL-6 in 
normal elderly men (Khosla et al, 2002). A further study stated that while TRT caused 
a decrease or complete abolition of spontaneous ex vivo production of IL-1, IL-6 and 
TNF-a by antigen-presenting cells in diabetic patients with partial androgen deficiency, 
testosterone, in in vitro, had no effect on the secretion of inflammatory cytokines by 
these cells after stimulation with LPS plus IFN-y this suggests that APCs preserve their 
constitutive machinery to produce inflammatory cytokines under androgen treatment 
(Corrales et al, 2006). In support of testosterone as an anti-inflammatory agent, 
induction of acute hypogonadism in normal elderly men performed by administration of 
GnRH which led to the contrary effect, where this increased the circulating levels of 
TNF-a and IL-6. In this regard, testosterone showed immune modulatory action through 
its effects on different inflammatory diseases including rheumatoid arthritis and 
systemic lupus erythematous, in which androgens have improved the clinical status and 
decreased inflammatory factors (Cutolo et al, 1991).
However, the lack of change in TNF-a and CRP levels after TRT might be as a result of 
the lack of influence of testosterone on the mean BMI, WC and W/HR in the group 
treated with testosterone. The present study data indicated a high degree of obesity 
among thesis patients, which did not change with testosterone treatment, and obesity is 
known to be correlated positively with these inflammatory factors.
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2.4.1.4 The effect of testosterone on atherogenic factors in patients in double­
blinded placebo-controlled study
Testosterone treatment had no significant effect on HDL, or its fractions HDL2, HDL3 
and HDL2/HDL3 ratio. Similarly it had no effect on serum apolipoproteins levels 
including Apo Al, Apo B, Apo E and LP (a). This is supported by previous findings, 
where Agledah et al. (2008) found that after normalising for testosterone levels in 
elderly men with subnormal testosterone levels, no significant change in levels of HDL 
was noted. Further studies reported that testosterone treatment, for one month, did not 
affect triglycerides or HDL, in 27 hypogonadal men (Malkin et al, 2004a). Similarly, 
two other studies in which men with Leydig cell insufficiency, firstly as a result of 
cytotoxic chemotherapy (Howell et al., 2001) and secondly as a result of age > 65 years 
of age (Snyder et al, 2001) were treated with transdermal testosterone replacement, 
reported no change in HDL. These studies showed that the route of administration is a 
vital factor, because transdermal testosterone seemingly did not affect plasma 
lipoproteins in healthy elderly men. Others thought that TRT in hypogonadal and 
elderly men may have a beneficial effect on lipid metabolism, through decreasing total 
cholesterol and the atherogenic fraction of LDL, without significant alterations in HDL 
levels or its subtractions HDL2 and HDL3 (Zgliczynski et al, 1996). However, other 
studies showed contrasting findings with regards to HDL or its fractions following 
testosterone treatment. An increase (Ozata et al, 1996), or reduction (Bagatell et al, 
1992, Behre et al, 1994, Lapauw et al, 2009, Bagatell et al, 1994; Herbst et al, 2003) 
in HDL and its fraction have both been reported. Hence, although testosterone treatment 
had no clear effect on HDL and their fractions, it also did not associate negatively with 
their levels. Especially, as there were previous data related to the inhibiting effect of 
testosterone treatment on HDL (Frederikse et al, 2012a) in men causing concern for 
using testosterone as therapy.
Similarly, controversial data have been stated for LP (a) which is considered as risk 
factor for CVD. Previous studies reported an increase in LP (a) levels with testosterone 
treatment (Berglund et al, 1996; Von Eckardstein et al, 1997) while a control study 
(Snyder et al, 2001) found no link between testosterone and LP (a). Similarly, two 
studies reported no change in LP (a) after testosterone treatment in hypogonadal men 
(Ozata et al, 1996) and in elderly obese men (Herbst et al, 2003). An uncontrolled 
study established a 25-59% decline in Lp(a) following testosterone injection in men
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with a LP(a) concentration less than 25 nmol/1, but no effect on LP (a) when the level 
was above 25 nmol/1, prior to testosterone administration (Marcovina et al, 1996). A 
further study indicated that a decrease in LP (a) levels was associated with GnRH 
analogue therapy in patients with prostate cancer (Arrer et al, 1996). However, more 
recently, in a double blind, placebo controlled study over a 6-month period, transdermal 
testosterone treatment was associated with favourable effects on IR, total and LDL- 
cholesterol, and LP(a), in hypogonadal men with T2DM and/or MetS (Jones et al, 
2011)
Regarding Apo B, while two studies found no alteration in levels of Apo B (Herbst et 
al, 2003; Tan et al, 1998), others found that androgens were associated with decreased 
ApoB levels and LDL cholesterol (Dickerman et al, 1996). In an animal study, 
Zhongguo and Li, (2000) showed testosterone, at physiological serum levels, had a 
positive effect on lipid profiles, lipoprotein, ApoB, in rabbits whilst 
hypotestosteronemia and hypertestosteronemia have a negative effect. Testosterone 
treatment had no effect on ApoE. Similarly, Snyder et al. (2001) found no change in 
ApoE after testosterone administration. However, at the level of the gene in vitro, 
testosterone therapy increased ApoE mRNA in the liver of Tfin mice (Kelly et al, 
2012a) and in human macrophages (Kelly et al, 2012b). Limited information is 
available regarding ApoE and correlation with testosterone treatment.
In most of the previous studies, there was a reduction in both the lipid profiles and body 
composition (Malkine et al, 2004, Saad et al, 2008; 2009) whereas in the present 
study, there was no change in body composition based on the average BMI and W/HR, 
this may explain why testosterone had not effect on HDL and its fraction or in 
apolipoprotein. However, these studies were also for a longer time period than the 
present study or used route of administration of testosterone different from in the 
current study. This may explain the difference results found in the current study.
2.4.2 Patients in the longitudinal study
This part of the study was conducted on 120 men between the ages of 40 and 79 who 
had T2DM and received gel or intramuscular testosterone treatment. These patients 
were initially assessed and diagnosed between 2002 to 2005 years, then followed up 
6-7 years later when a serum sample was taken, this sample was analysed in the
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current study. In the current study 120 men were divided into a normal testosterone 
group and groups with low testosterone with or without testosterone treatment. This 
was based on the testosterone levels at the time of the original assessment (2002-
2005). Additionally, these groups were divided based on IHD status into 4 subgroups; 
normal testosterone subject, normal testosterone subject with IHD, low testosterone 
subject with IHD with and without testosterone treatment.
2.4.2.1 The effect of testosterone treatment on body composition in patients in the 
longitudinal study
The results demonstrated that at the end of the period of study there was no significant 
difference in body composition (BMI, W/HR ratio and WC) between subgroups treated 
with testosterone compared to untreated control subjects. This was similar to the 
findings in the double-blinded placebo-controlled study where six months testosterone 
intramuscular injection had no effect. In the similar way, two studies did not find a 
change in VAT after treatment with a transdermal testosterone patch for 1 year in 
nonobese aging men (Allan et al, 2008) and in elderly men (Svartberg et al, 2008). 
This involved non-obese patients in the first study and measured regional distribution of 
fat by computed tomography (CT) in the second study, which may not give reliable 
results, this may explain the lack of effect of testosterone on VAT. This is despite the 
fact that in previous studies, an inverse correlation between the total testosterone levels 
of 110 men and accumulation of visceral fat, but not other fat deposition, was seen after 
a 7.5-year follow-up (Tsai et al, 2000). In long term studies (5-6 years) using a high 
dose of parenteral testosterone undecanoate 1000 mg, reduction in WC and BMI was 
observed in obese men with testoserone deficiency (Saad et al, 2013; Yassin et al, 
2013), in obese hypogonadal men with T2DM ( Haider et al, 2013, 2014) and in ageing 
men with metabolic syndrome (Francomano et al, 2014). Therefore, the contrast of the 
current data with the above studies may be attributed to differences dose/duration of 
treatment and in age of men in these studies.
2.4.2.2 The effect of testosterone treatment on adiponectin in patients in the 
longitudinal study
The mean serum adiponectin level was not affected by testosterone treatment in
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patients with low testosterone with or without treatment compared to untreated 
control group. There was also no difference in adiponectin levels between IHD 
subgroups. This is in agreement with a previously published study in which 200mg 
testosterone enanthate had no effect on adiponectin levels over 36 months period in 
older men (Page et al, 2005a). This was in contrast to the effect of intramuscular 
testosterone treatment for 3 months that decreased the level of adiponectin in diabetic 
patients in a double-blinded placebo-controlled study in this thesis. Similarly, 
Frederiksen et a l (2012a) reported that gel testosterone treatment over 6 months 
significantly decreased adiponectin levels in aging men and suggested this action was 
as result of reduction in subcutaneous fat in the abdomen and on the lower extremities. 
However, in both groups, testosterone treatment as intramuscular injection or gel had 
no effect on body composition. Thus, it could be beneficial to investigate the effect of 
testosterone treatment on adiponectin gene expression in vitro.
2.4.2.3 The effect of testosterone treatment on IL-8 levels in patients in the 
longitudinal study
There was no effect of testosterone on the level of IL-8 in patients treated with 
testosterone compared to the untreated control group and between all IHD subgroups. 
IL-8 acts as a pro-inflammatory factor and has a role in progression of atherosclerosis 
(Boekholdt et al, 2004) and inflammation in adipose tissue (Trayhum et al, 2004). 
Therefore, testosterone did not show modulation of other inflammatory factors. 
Furthermore, there is limited evidence on the role of testosterone on IL-8 thus; it is 
difficult to explain the lack effect of testosterone treatment on IL-8.
2.4.2.4 The effect of testosterone on atherogenic factors in patients in the 
longitudinal study
Testosterone treatment increased the level of HDL, but not significantly, compared to 
patients with low testosterone without treatment. Testosterone significantly increased 
HDL2, and the HDL2/HDL3 ratio compared to patients with low testosterone without 
treatment. In addition, testosterone significantly decreased HDL3 in the low 
testosterone group compared to the untreated control group and tended to decrease it 
compared to patients with low testosterone who were not treated with testosterone. This 
decrease appeared to be due to the effects of testosterone, as the HDL3 levels in both
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the untreated groups (normal and low testosterone) were very similar, whereas the 
levels in the treated group were lower. Additionally, testosterone treatment was not 
associated with any change in HDL and its fractions between all IHD sub-groups. 
However, it was recognized that both total HDL and HDL2 levels have inverse 
associations with the risk of acute myocardial infarction and may thus be protective 
factors in IHD, whereas the role of HDL3 remains unclear (Salonen et al., 1991). 
Another recent study suggested that subjects with higher HDL2 levels were better 
protected from atherosclerosis, while a shift towards HDL3 was reported in T2DM and 
MetS. This shift might be due to defect in production of HDL3 or in LCAT which is 
responsible for convertion of HDL3 to HDL2 (Maeda et al, 2011). Moreover, the 
HDL2/HDL3 ratio is correlated positively and strongly with the HDL-C level, but 
negatively and moderately with BMI, WC, and TG (Moriyama et al., 2014). Therefore, 
the result of the current study demonstrating an increase in HDL2 and HDL2/HDL3 
ratio and a decrease in HDL3 in patients treated with testosterone may reflects the anti­
atherogenic action of testosterone. An additional study found that androgens 
significantly increased the level of HDL2 with no change in HDL and HDL3 (Ozata et 
al, 1996). Moreover, Tan (1998) found that there was a reduction in HDL3 sub­
fractions and a decrease in HDL, after treatment with testosterone as a parenteral 
testosterone ester for 4-weeks.
In the current study, there was no significant change in HDL even though there was a 
numerical increase in HDL in patients treated with testosterone, compared to untreated 
patients with low testosterone. Further a single-blind, randomised design study without 
placebo control, with patients either receiving diet and exercise advice alone, or diet and 
exercise advice in conjunction with 50mg testosterone gel once daily was conducted by 
Heufelder and colleagues (2009) in men with T2DM. In that study, testosterone 
significantly increased levels of HDL and decreased LDL and TG compared with diet 
and exercise advice alone. In Tfin mice, physiological testosterone replacement 
augmented HDL levels and this effect was independent of the androgen receptor or 
ERa-dependent pathways after conversion of testosterone to 17p-estradiol (Nettleship et 
al, 2007a). Saad et al. (2008) reported that testosterone undecanoate decreased the 
levels of cholesterol and LDL and increased HDL in men with sexual dysfunction and 
MetS.
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In studies carried out by Singh et al. (2002), the highest dose of testosterone (600 
mg/wk) caused a reduction in plasma levels of HDL and Apo Al in healthy young men. 
Suppression of testosterone with GnRH antagonists increased plasma HDL, HDL2 and 
HDL3. A meta-analysis indicated that intramuscular testosterone injection to 
hypogonadal men caused a small, dose-dependent decrease in HDL (Whitsel et al., 
2001). Androgens were associated with decreases in HDL cholesterol and ApoAl levels 
in 12 competitive bodybuilders who used anabolic steroids (Dickerman et al., 1996). 
According to Tan (1998), this reduction might come as a result of the effect of 
testosterone predominantly on hepatic lipase activity. For this, it concluded that the 
effects of androgen on HDL and its fraction, nevertheless, depend on the formulation 
and type of androgen used, and the dose and route of administration. Supraphysiological 
doses of androgens, especially orally administered, nonaromatizable, androgen steroids, 
will decrease plasma HDL levels significantly (Schwarcz et al, 2010).
In the present study, testosterone had no effect on the levels of LP (a) in patients with 
low testosterone who were treated with testosterone compared to the untreated patients 
with low testosterone or untreated control group. This is supported by previous studies 
(Ozata et al., 1996 and Herbst et al, 2003). In contrast to the current data, testosterone 
treatment has been shown to decrease the levels of LP (a) (Klentze et al., 2005 and 
Lapauw et al., 2009). No significant change was seen in the levels of ApoAl, ApoB, 
and ApoE in low testosterone patients with or without testosterone treatment, compared 
to untreated control group with normal testosterone. Similarly, testosterone treatment 
had no effect on levels of any apolipoproteins in the IHD subgroups. However, as in the 
double-blinded placebo-controlled patient study, testosterone did not associate with a 
change in level of apolipoprotein in diabetic patients. This might be due to the lack of 
the effect of testosterone treatment on body composition.
2.5 Limitations of the study
Limitations of this study include the small number of patients in both studies and the 
short duration of treatment in the double-blinded placebo-controlled study which may 
limit in the benefit of testosterone treatment, thus using a longer study period both 
before and after treatment would better control more variables, match for age, body 
composition, stage of disease and interaction with other medications e.g. statins,
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metformin. An additional factor limiting the ability of the trial to detect changes in 
inflammatory cytokines, following testosterone treatment, was the lack results of these 
parameters by using CBA array assay, therefore alternative methods of assessing these 
parameters will be considered for future studies.
2.6 Summary
The short term double-blinded placebo-controlled patients study extended previous 
findings by providing further support for the notion that testosterone therapy decreases 
adiponectin levels as seen in diabetic patients after three months. However, no alteration 
in body composition, levels of pro-inflammatory factors or apolipoproteins after 
testosterone therapy was found in this group of patients. Similarly, testosterone did not 
affect HDL levels and its fractions, whereas previous studies found a decrease. In the 
longitudinal study, testosterone treatment also was not associated with any changes in 
body composition, the level of pro-inflammatory factors and apolipoproteins in diabetic 
patients. Beneficial effects on HDL fraction were seen in patients with low testosterone 
were treated with testosterone, but not in IHD subgroups. However, the effect of 
testosterone supplementation may be elucidated when larger populations and longer 
study period of testosterone treatment trials are carried out in double-blinded placebo- 
controlled studies patients or using the same group of patients both before and after 
treatment in a longitudinal study, as well as for estimating the longer term outcome of 
testosterone treatment.
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Chapter 3
The effect of testosterone treatment on the expression of metabolic markers in the 
liver of the Tfm mouse model
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3.1 Introduction
Animals have been used to study the causes, impact and complications of many diseases 
affecting humans including T2DM and heart disease related to obesity and have been 
widely used as models of metabolic syndrome, obesity and androgen insensitivity 
(Jones and Saad, 2009). These studies have relied on various approaches to explore the 
mechanisms by which diseases develop or to discover the appropriate strategies that 
may help protect against these diseases (Malkin et al, 2004). Animal studies have 
employed different approaches such as using varying degrees of reduction or an 
increase in nutrition, pharmacological methods, genetic manipulation or surgical 
techniques to produce useful animal models (Bertram and Hanson, 2001). The ability to 
modify the genetic make-up of mice and to create ‘transgenic’ or ‘knockout’ mice has 
allowed the progress of several interesting and suitable obesity, T2DM and CVD 
models (Gajda et al, 2007). Additionally, to achieve a better understanding of human 
obesity, rabbits, rats and mice are used as models as they readily gain weight when 
supplied with a high-fat diet and this increases/also other risk factors related to MetS. 
Moreover, atherosclerotic lesions comparable to those established in humans can be 
developed after longer feeding times in Testicular feminized mice (Tfm) which are 
considered as a model of effect of testosterone.
3.1.2 Testicular feminization identification
An inherited syndrome of testicular feminization has been described in several species 
in addition to man, including the cow, the rat and the mouse (He et al, 1991). It is also 
called androgen insensitivity syndrome (AIS). This syndrome was initially termed 
testicular feminization but this name at present is used for animals, while androgen 
resistance or androgen insensitivity is used for humans (Howden, 2004). It is identified 
as a syndrome resulting from unresponsiveness of the target cell to the action of 
androgenic hormones due to mutations in the androgen receptor genes (Hughes et al.,
2006). The first proof that AIS was caused by AR mutations was published in 1989 by 
Brown and his group. The androgen receptor is a high-affinity androgen-binding protein 
that mediates the effect of testosterone and dihydrotestosterone by functioning as a 
trans-acting inducer of gene expression (Brown et al, 1989).
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3.1.3 Tfm mice
Tfin mice are totally insensitive to androgen due to a single base deletion in the N- 
terminal domain of the androgen receptor, resulting in a frame shift mutation creating a 
premature, stop codon at amino acid 412 and the expression of non-functional truncated 
androgen receptors (Rizk et al., 2005, He et al., 1991, Monks et al., 2007; Chang et al., 
2013). Furthermore, AR binding is greatly decreased in various tissues. Therefore, Tfin 
in these mice is considered an X-linked genetic disorder in which males carrying the 
mutation in the AR gene have female phenotypic characteristics (Gilbert et al., 2000). In 
addition, the lack of functional ARs results in complete infertility of the Tfin male mice 
(Rizk et al., 2005). Moreover, the testes of these mice are very small and cryptorchid 
(Reddy and Ohno, 1981).
The physiological consequence of the genetic disorder and histological structure of the 
testes in these mice is a low testosterone level in the circulation. The reduction of 
biosynthesis and production of testosterone are due to reduction in 17a hydroxylase, 
which is the main enzyme of the steroidogenesis process. The reduction of 17a 
hydroxylase may be as result of the placement of testes in the intra-abdominal area and 
a lack of action of testosterone in utero. In addition, these mice have high levels of LH 
hormone which is due to AR dysfunction and the low levels of testosterone. Both AR 
dysfunction and low testosterone lead to the absence of the negative long loop feedback 
mechanism of testosterone on the activation of pituitary ARs.
Recent studies have used this type of mouse as a model of atherosclerosis. These studies 
found that Tfin mice exhibited a significant increase in aortic root lipid deposition 
compared to littermates, following feeding with a high-fat diet. Furthermore, this fatty 
streak formation was significantly decreased after physiological testosterone 
replacement therapy (TRT). The effect was independent of the classic AR androgen 
receptor and was mediated in part by activation to 17p-estradiol (Nettleship et al., 2007). 
Similarly, Kelly and colleagues in 2012b reported that the beneficial effect of 
testosterone (both AR-dependent and AR independent) was seen on reduction of fatty 
streak formation in the Tfin mice (Kelly et al., 2012b).
However, recent studies also found that Tfm mice can be used as models for studying 
the relationship of low testosterone with hepatic glucose and lipid homoeostasis (figure 
3.1). For instance, Kelly et al., (2012a) reported that a high-cholesterol diet induced
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significant hepatic lipid accumulation in Tfin mice compared to wild-type mice, and 
intramuscular TRT considerably abolished this effect, suggesting AR-independent 
effects on hepatic steatosis and lipid metabolism in these mice. It is known that, the 
liver is the most important active metabolic organ together with adipose tissue and 
muscle. The liver has a role in glucose and lipid metabolism (Emanuelli et al, 2014).
3.1.4 Molecules involved in hepatic metabolism
The regulation of glucose and lipid metabolism is the under the control of a number of 
hormones including insulin and testosterone which led to elevated glucose oxidation by 
increasing significantly mRNA expression of the receptor in the Chang human liver cell 
line (Parthasarathy et al., 2009). In an animal study, castration of mice was associated 
with elevation of blood glucose, reduced insulin levels and decreased glucose uptake. 
Furthermore, testosterone deficiency plays a key role in induction of IR in the liver by 
its association with increased adiposity, which leads to the flow of FFA from adipose 
tissue to liver and a consequent decrease in insulin sensitivity (see figure 3.1) (reviewed 
by Kelly and Jones, 2013). FFA can stimulate NFkB, JNK, and IKK activation through 
TLR-4 in hepatocytes, some of which suppress insulin signalling. Activation of these 
kinases leads to increase in pro-inflammatory cytokines and chemokine genes 
expression (Ota et al, 2012). Chemokine-mediated macrophage infiltration into the 
liver might therefore be related to the pathology of IR. Chemokines such as CCL2- 
CCR2 (Panee et al, 2013) as well as CX3CL1-CX3CR1 (Shah et al, 211) connect 
inflammation with IR. PAI-1 is another factor which can be induced in the liver by 
inflammation (Lagoa et al, 2005). It was noted that the liver of obese mice 
overexpresses PAI-1 (Westerbacka et al, 2007). PAI-1 is known as a regulator of the 
fibrinolytic system in blood by inhibiting both urokinase-type and tissue-type 
plasminogen activators. High levels of PAI-1 are found in patients with T2DM or 
atherosclerosis, which is associated with imbalance in glucose and lipid homeostasis 
(Dimova and Kietzmann, 2008; Kietzmann and Andreasen, 2008). In general, IR can 
impair glucose and lipid metabolism in the liver by different pathways. Increased levels 
of FFAs transported from adipose tissue to the liver induce gluconeogenesis and VLDL
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Figure 3.1: The association of low testosterone with inflammation and insulin 
resistance in adipose tissue and liver. Testosterone deficiency leads to increase 
adiposity with IR causing fat accumulation and hyperglycaemia. Adipose tissue 
expansion stimulates the release of FFAs via lipolysis into the circulation, increased 
pro-inflammatory factors (IL-6, TNF-a, CX3CL1 and CCL2) and decreased anti­
inflammatory factors (adiponectin and PPAR5/p). FFAs, IL-6 and TNF-a induce IR in 
the liver, leading to impairment in glucose metabolism, glycogen synthesis, 
gluconeogenesis, lipogenesis and ultimately to hepatic steatosis and hyperglycaemia. 
FFA, free fatty acid. IL-6, interleukin 6. TNF-a, tumour necrosis factor alpha. PPAR5, 
Peroxisome proliferator-activated receptor delta (Adapted and modified from Kelly and 
Jones, 2013).
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synthesis, that leads to inhibition of lipolysis of chylomicrons and promotes 
hypertriglyceridemia and decreased of HDL. The latter and the formation of small, 
dense LDL particules are linked to a higher risk of CVD (Chapman et al., 2010).
The plasma concentration of HDL-cholesterol is to a large extent determined by the 
production and catabolic rates of its principal apolipoprotein, Apo Al. The plasma 
concentration of ApoAl on average reflects the corresponding concentration of HDL- 
cholesterol (Jung and Choi, 2014). Therefore, Apo Al is also a powerful predictor of 
CVD in men, since its role is in reverse transport of cholesterol from peripheral tissues 
to the liver for clearance. In addition, Apo E is structurally close to Apo Al (Getz et al, 
2009). The liver is the important source for Apo E in plasma (Getz et al., 2009). Apo E 
has a vital role in the receptor-mediated uptake of lipoprotein by the liver and therefore 
acts in regulating lipoprotein metabolism (Kolovou et al, 2009). It has also been 
previously found that ApoE deficient mice accumulate large amounts of triglyceride in 
their livers (Kuipers et al, 1996). Therefore, hepatic Apo E production is thought to 
contribute to secretion of VLDL-TG. Notably, the plasma levels of triglycerides are key 
molcules in the pathogenesis of atherosclerosis (Talayero and Sacks, 2011)
Adiponectin also has a role in lipid and glucose metabolism where it increases lipid 
catabolism by decreasing TG storage and FFA levels and augmenting HDL 
concentration in the liver. This leads to improved insulin sensitivity and reduced IR and 
T2DM (Vazquez-Vela et al, 2008). An additional function of adiponectin is to inhibit 
the effects of TNF-a, suppressing expression of adhesion molecules in vascular 
endothelial cells, thus lowering atherogenic risk. The effects of adiponectin are 
mediated by its receptors, AdipoRl and AdipoR2 that are expressed located in mouse 
liver (Kadowaki et al, 2005). It is found that the adiponectin levels are decreased in 
obesity, T2DM and atherosclerosis. Administration of adiponectin in mice improves 
these conditions (Chandran et al, 2003).
PP ARp/5 is another beneficial factor regulating the expression of specific target genes 
involved in lipid metabolism, insulin sensitivity, energy homeostasis, obesity, and 
inflammation. In addition, PP ARp/5 acts as an anti-inflammatory mediator through 
reducing, TNF-a, adhesion molecules, decreasing triglycerides and increasing HDL 
(Fan et al, 2008, Karpe et al, 2009; Di Paola et al, 2010). The use of newly developed 
selective agonists and genetic approaches showed the substantial association of 
PPARp/5 in lipid homeostasis and IR (Kaipe et al, 2009).
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Therefore, in this chapter, cDNA samples of liver tissue from Tfin mice with and 
without testosterone treatment were investigated. The effect of testosterone treatment on 
expression of anti-inflammatory modulators (adiponectin, PP ARp/5), pro-inflammatory 
factors (CX3CL1, CX3CR1, CCL2, CCR2 and PAI-1) and anti-atherogenic parameters 
(Apo A-l and Apo E) was assessed in these mice due to all these factors being 
implicated in MetS, T2DM and atherosclerotic conditions. Samples of cDNA from Tfin 
mice treated with placebo and XY littermate mice were used as controls.
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3.1.5 Aim
To investigate whether testosterone modulates the expression of anti and pro- 
inflammatory markers (adiponectin, PPARp/8, PAI-1, CX3CL1, CX3CR1, CCL2, and 
CCR2) and anti-atherogenic factors (Apo A-l and Apo E) in liver tissue from Tfm mice 
fed a high-cholesterol diet.
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3.2 Materials and Methods
Tfin and littermate mice were used at age 8 weeks at which time point they were fed on 
a high fat diet for a period of 28 weeks, ad libitum. This diet contained 42% butterfat 
and 1.25% cholesterol, along with 0.5% cholate, which is required for cholesterol 
absorption in the mouse (Special Diet Services, UK).
Prior to receiving this high-cholesterol diet for the duration of the study, treated Tfin 
mice with testosterone, control Tfin mice and littermate received a normal chow diet. 
This part of the study was performed by Dr. Daniel Kelly at University of Sheffield. All 
procedures were carried out under the jurisdiction of UK Home Office personal and 
project licences (project licence number 40/3165, personal licence number 60/11754), 
governed by the Animals Scientific Procedures Act 1986. Mice received intramuscular 
injections of testosterone or saline treatment. A sterile 0.3mL 30G needle (BD, UK) was 
introduced at a right angle to the skin surface into the centre of the muscle mass and 
lOpL of either Sustanon® 100 (20mg/mL testosterone propionate,40mg/mL 
testosterone phenylpropionate, 40mg/mL testosterone isocaproate; equivalent to 
74mg/mL testosterone) or physiological saline was injected. Mice were injected once 
fortnightly, from 7 weeks of age, alternating the leg injected to minimise discomfort or 
irritation (Kelly et al., 2012b).
Hepatic complementary DNA (cDNA) samples from Tfin mice were obtained from 
animals sacrificed at 36 weeks. The steps of extraction of RNA and synthesis of cDNA 
were performed by Dr. Daniel M Kelly and Sarnia Akhtar. 20 cDNA samples were 
from Tfin mice that were treated with testosterone, 4 cDNA samples were from Tfin 
mice that were treated with placebo and 12 cDNA samples were from XY littermates 
controls.
3.2.1 Molecular investigation of gene expression in liver tissue of Tfm 
mice using semi-quantitative real-time reverse transcription 
polymerase chain reaction (qRT-PCR)
Real-time reverse transcription quantitative PCR (qRT-PCR) results are based on 
several steps, including cell processing, RNA extraction, RNA storage and assessment
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of RNA concentration, cDNA synthesis and selection of an appropriate constitutively 
expressed control gene.
qRT-PCR is a development of the basic polymerase chain reaction (PCR), which is used 
for amplifying a DNA sequence specific to a particular gene, into multiple DNA copies 
in a quantitative manner. The cDNA can be run on an agarose gel to assess the size and 
purity of the sample. PCR involves three-steps which are denaturation, annealing and 
extension, known as a cycle that is repeated a specified number of times in a thermal 
cycler. The PCR reaction usually includes four phases that are shown in the 
amplification plot (figure 3.2) the linear-ground phase, the exponential phase, the linear 
phase and the plateau phase. Through the ground-linear phase, only background 
fluorescence is detected. The cycle at which the amplification fluorescence exceeds a 
chosen threshold above the background fluorescence is called the Cycle threshold or Ct 
value and this indicates the initial exponential phase. During the exponential phase, the 
amount of DNA is theoretically doubled with each cycle and it is at this point that 
measurements are made, i.e. when the CT value is obtained. Once the plateau phase is 
reached, all of the reagents are consumed and no further product is generated.
3.2.1.1 qRT-PCR using SYBR® Green dye methodology
RT-PCR monitors the amplicon amount as the reaction take place. Commonly, the 
amount of product is directly related to the fluorescence of a reporter dye. Since it 
distinguishes the amount of product as the reaction develops, RT-PCR offers a wide 
linear dynamic range, reveals high sensitivity and is quantitative. The preliminary 
amount of template DNA is inversely related to a parameter measured for each reaction 
and the Ct value. SYBR Green-based detection is the least expensive and flexible 
procedure available for RT- PCR (Wang et al, 2006). Other methods (such as TaqMan) 
need an expensive third primer labelled with a dye and a quencher (Bustin et al., 2005). 
SYBR Green dye binds to all double-stranded DNA present in the sample by inserting 
between base pairs (Wang et al., 2006). Signal is generated during the PCR cycle at the 
end of either the annealing or the extension stage, when the highest amount of double­
stranded DNA product is generated. Therefore, the result is an increase in fluorescence 
intensity proportional to the amount of PCR product created, (figure 3.3).
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Figure 3.2: Amplification plot of qRT-PCR. Four phases are displayed in the 
amplification curve the linear-ground phase, the exponential phase, the linear phase and 
the plateau phase. In the exponential phase the level of fluorescence can be detected 
whereas the linear phase represents the doubling of PCR product every cycle and 
plateau phases indicate the end of the reaction. The orange horizontal line represents the 
threshold above background fluorescence; the cycle at which the amplification 
fluorescence crosses this line is termed the cycle threshold or Ct value.
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A) Reaction setup: The SYBR Green I dye fluoresces when bond to double-stranded DNA.
__________________________________________________
B) Denaturation: when the DNA is denatured, the SYBR Green I dye is released and 
the fluorescence is drastically reduced.
C) Polymerization: During extension, primers anneal and PCR product is generated.
Forward primer
3 E 1
Reverse primer
D) Polymerization completed: When polymerization is completed. SYBR Green I dye 
binds to the double-stranded product resulting in a net increase in fluorescence 
detected by 7900HT PCR system.
Figure. 3.3: Shows the principle of SYBR Green dye detection in qRT-PCR assay.
The steps from A-D demonstrate the action of SYBR Green I dye in three phases of the 
PCR reaction which are annealing, extension and denaturation. The signal is only 
detectable during annealing and extension, since the denaturation step contains 
predominantly single-stranded DNA. It was adapted and redrawn from 
http://www.lifetechnologies. com/uk/en/home/lifescience/pcr/real-time-pcr/qpcr-
education/what-can-you-do-with-qpcr/introduction-to-gene-expression.html.
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Method
Each 20pl PCR reaction contained 1 Ojj.1 of SYBR green PCR master mix (Qiagen, UK), 
5 pi of a 1:10 dilution of cDNA of the sample or control, 1 jul of target primer 
(PrimerDesign, UK) and 4 pi of RNAse free water. All of these amounts were pipetted 
in duplicate for each sample into 96 well-plates (Applied Biosystems, UK) on ice. 
Plates were covered with an adhesive film, centrifuged to ensure that all solutions were 
collected at the bottom of the wells. The analysis of these samples was performed by 
using the 7900HT PCR system or StepOne™ real-time PCR system (Applied 
Biosystems, UK) which was according to the cycles below.
Initialization 95°C for 5 min
Denaturation 94°C for 15 seconds
Annealing 60°C for 30 seconds ~ 40 cycles
Final elongation 72°C for 30 seconds J
Hold 4°C
Melt curve 
95°C 60 seconds
55°C for 30 seconds increasing in 10°C increments.
3.2.1.2 Selection of endogenous control reference genes
In qRT-PCR, the selection of the housekeeping gene is important for the normalization
of quantitative gene expression results. The candidate housekeeping gene is usually
used as reference in qRT-PCR assays to control for error between samples and to
measure variations in the levels of a target gene mRNA compared to a housekeeping
gene. The level of reference gene expression has to be stable in the same tissues or cell
types under the defined experimental conditions. Genes most generally used as internal
controls in qRT-PCR studies include: beta actin (ACTB), glyceraldeyde-3-phosphate
dehydrogenase (GAPDH), beta glucuronidase (GUSB), hypoxanthine guanine
phosphoribosyl transferase (HPRT1) and ribosome small subunit (18S) ribosomal RNA
(Choesmel et al., 2007). However, some studies have reported these classical
housekeeping genes as appearing to give irregular expression levels in diverse
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experimental states (Ohl et al, 2005; Silver et al, 2008). Therefore, it is essential that 
reliable control genes are specific for the sample group and does not alter under 
different experimental treatments under investigation. Validation of the control avoids 
misinterpretation of gene expression data and identifying the most stable housekeeping 
gene has to be performed from a set of tested candidate reference genes. For this 
identification, a comprehensive range of bioinformatically validated assays such as 
geNorm (Vandesomple et al, 2002); NormFinder (Andersen et al, 2004) and 
BestKeepe (Haller et al, 2004) software programs for housekeeping genes can be used.
Method
RT-PCR was applied to 12 mouse housekeeping genes (ACTB, SDHA, RPL13, ATPSB, 
EIF4A, 18S, YWHAZ, CYC1, B2M, CANX, UBC, and GAPDH) (PrimerDesign, UK) 
on 8 biological samples with different experimental conditions used in this study. Each 
reference gene was tested with each sample in duplicate. This was done by mixing in 
each well of a 96 well-plates on ice (lpl of 1:10-dilution of sample or control cDNA, 
lpl of target reference gene primer, 8pl of RNA free water and lOpl of SYBR Green 
master mix). Threshold (Ct) values were used for the expression ratio that was 
calculated by the comparative Ct method (Livak and Schmittgen, 2001). These values 
were imported into the GeNorm software (Vandesompele et al, 2002), which 
determines the most stable housekeeping genes. A gene expression stability measure (M 
value) was determined for each housekeeping gene. The housekeeping gene with an M 
value less than 1.5 was identified as the most stable one.
3.2.1.3 Amplification efficiency of PCR primers determination
It is important to determine the amplification efficiency of the qRT-PCR assay to 
obtain accurate data. This means that during the logarithmic phase of the reaction, the 
PCR product of the target gene is doubling with each cycle. Perfect amplification 
efficiency is 100%, (Livak et al, 2001). Amplification efficiency between 90 and 110% 
is considered as acceptable. 100% PCR efficiency demonstrates a change of 3.3 cycles 
between 10 fold dilutions of template. This is achieved by a 10-fold serial dilution of 
the template cDNA ranging (from 1:1 to 1:1000 in RNA free water) for obtaining 
primer efficiencies. The Ct values obtained for all target and reference genes are plotted 
against log dilution factor on the graph. A linear trend line was applied, with the slope
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of the line used to calculate the percentage efficiency of each primer by the following 
equation:
Efficiency = 10 <‘l/slope)- l
The R-squared value >0.95 of linear correlation demonstrates that the Ct values 
adequately correspond to the trend line fitted.
Method
To determine the primer efficiency, template cDNA was diluted in a series (neat, 1:10, 
1:100 and 1:1000); each PCR reaction was carried out in duplicate for the target gene 
and reference gene. The Ct values obtained were plotted by using logio of dilution of the 
cDNA sample against the Ct values, to create the graphical and linear curve at R2 > 0.95 
by Microsoft Office Excel.
3.2.1.4 Validation of primer targets by electrophoresis
Validation can be done for the amplified products of the SYBR® Green qRT-PCR 
analysis by running each amplified target on an agarose gel for visualisation. A single 
and sharp band should be observed demonstrating that only one specific sequence has 
been amplified.
Method
7pi of qRT-PCR product for each target gene was mixed with 3pi of lx loading dye 
(Promega, UK) and loaded onto a 1.5% agarose gel (Invitrogen, UK) and separated at 
110V for 30min. A 200bp ladder (Promega, UK) was also loaded onto the gel. The 
agarose gel was made from 0.75g of agarose powder (Bioline, UK) was dissolved in 
50ml IX TAE as electrophoresis buffer (Beckman Coulter, UK) and then stained with 
3pl ethidium bromide (lOmg/ml) (Sigma-Aldrich, UK). Bands were visualised using a 
UVP bioimaging system (BioRad, UK) and appeared as a single and sharp band 
referring to specific target gene.
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3.2.1.5 Relative quantification analysis of qRT-PCR data
By measuring the Ct values in qRT-PCR analysis, determination of the relative 
expression of a target gene in the test sample using a reference gene(s) as the normalizer 
is calculated by using the 2“AACT method (Livak et al., 2001; Schmittgen and Livak, 
2008) as follows:
Normalizing the CT of the target gene to that of the reference (Saunders and Lee, 2013) 
gene, for both the test sample and the calibrator sample is calculated as follows:
ACT (test) = CT (target, test) -  CT (ref, test)
ACT (calibrator) = CT (target, calibrator) -  CT (ref, calibrator)
Then normalizing the ACT of the test sample to the ACT of the calibrator is by:
AACT = ACT (test) -  ACT (calibrator)
Calculation of the expression ratio is by:
2~a a c t
This method is usually used when the target and reference genes have similar and 
approximately 100% amplification efficiencies. However, if the target and the reference 
genes do not have similar amplification efficiencies the Pfaffi method can be used 
(Pfaffl, 2006) which leads to modification of the 2-AACT method by replacing the 2 in the 
equation by the actual amplification efficiency as follows:
Ratio = (E target) ACT, target (calibrator-test)
(Eref) ACT, ref (calibrator -  test)
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Number 12 4 20
Type of 
treatment
None placebo testosterone
Investigated
parameters
Adiponectin, PAI-1, 
PPARp, Apo A l, ApoE, 
CX3CL1 and CX3CR1, 
CCL2 and CCR2
Adiponectin, PAI-1, 
PPARp, Apo Al, 
ApoE, CX3CL1 and 
CX3CR1, CCL2 and 
CCR2
Adiponectin, PAI- 
1, PPARp, Apo Al, 
ApoE, CX3CL1 
and CX3CR1, 
CCL2 and CCR2
Assay
technique
qRT-PCR qRT-PCR qRT-PCR
Table 3.1: Summary table of Tfm mice in vivo study. The details of Tfm mice 
samples, target genes, analysis method used in this study
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3.2.2 Statistical Analysis
Data is presented as mean ± SEM. All statistical tests and applications were performed 
by using Prism 5 Graph pad software and Stats Direct. Statistical differences between 
groups were analysed by one way ANOVA or Kruskal-Wallis test to analysis 
parametric and nonparametric data, respectively. When the tests, (one way ANOVA or 
Kruskal Wallis test) revealed significant differences, multiple comparisons of groups 
were performed using Tukey's test or Conover-Inman post hoc, respectively. All 
comparisons were two tailed and p  values less than 0.05 were considered statistically 
significant.
125
3.3 Results
3.3.1 Selection of endogenous control reference genes
12 mouse housekeeping genes were tested (ACTB, SDHA, RPL13, ATPSB, EIF4A, 
18S, YWHAZ, CYC1, B2M, CANX, UBC, and GADH) on 8 samples with different 
experimental conditions using qRT-PCR. GADPH was the most stable housekeeping 
gene, where its M value was less than 1.5. Therefore GADPH was used as the internal 
control for calculation of relative expression ratios and comparison with the target genes.
3.3.2 Primer efficiency
Following 10-fold serial dilution of the template cDNA ranging (from 1:1 to 1:1000 in 
RNase free water) primer efficiencies were determined. The Ct values for each dilution 
were collected during the exponential phase of the PCR, log-transformed and plotted 
with the slope of the regression line representing the sample’s amplification efficiency. 
The results related to a slope and percentage efficiencies of target genes and reference 
gene where some were in the ideal range and others had primer efficiencies less than 
90% as seen in (figure 3.4 and table 3.2). Therefore, Pfaffi method was used to 
determine the relative expression of target genes in this study.
3.3.3 Validation of primer targets
Primer products for target genes and reference genes from the qRT-PCR assay were run 
on 1.5% agarose gel electrophoresis. As shown in (figure 3.5a, b) a single product was 
visible and sizes of primers was as excepted between (83-129bp) for all target and 
reference genes for both Tfm mice (A) and XY littermate mice (B).
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GADPH 1.968 96.84
Adiponectin 1.941 94.08
PPARp/6 1.863 86.33
PAI-1 1.931 93.04
CX3CL1 1.863 86.33
CX3CR1 1.92 91.99
CCL2 1.896 89.57
CCR2 1.86 86.32
APO Al 2.00 99.66
APOE 1.941 94.08
Table 3.2: Primer efficiencies of target and reference genes. Calculated primer 
efficiency percentage was determined by using E = io('1/slope)-l. These should be in the 
range of 100 ± 10% for optimal PCR.
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Figure 3.4: Standard-curve plot for calculation of primer efficiency genes. The efficiency of 
amplification of target genes and internal control (GADPH) was determined using real-time 
PCR and SYBR Green detection. The Ct values for each dilution were used to calculate slope of 
the line representing the log of their amplification efficiencies. An ideal slope should be -3.32 
for 100% PCR efficiency.
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Figure 3.5: Amplification of qRT-PCR products on 1.5% agarose gel 
electrophoresis for the liver of Tfm mice (A) and XY littermates mice (B). L-
Ladder, Lane 1- GADPH Lane 2- Adiponectin, Lane 3- PPARp/5, Lane 4- PAI-1, Lane 
5- CX3CL1, Lane 6- CX3CR1, Lane 7- CCL2, Lane 8- Apo Al, Lane 9- Apo E, Lane 
10- CCR2. All PCR products obtained were between 83 and 129bps which matched the 
expected sizes as provided by the supplier, PrimerDesign.
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3.3.4 Analysis of adiponectin mRNA expression in the liver by qRT- 
PCR
There was a significant increase (p=0.04) in the expression of adiponectin in the 
testosterone treated Tfm mice (n=20) compared to the placebo treated Tfm mice (n=4). 
There was no significant difference in adiponectin expression in either Tfm mouse 
group compared to XY littermate mice (n=12) (figure 3.6).
3.3.5 Analysis of PPARp/S mRNA expression by qRT-PCR
A significant increase was seen in the expression of PP ARp/8 (p=0.04) in Tfm mice 
treated with testosterone (n=20) compared to Tfm mice with placebo treatment (n=4). 
Whilst, there was a trend towards an increase in expression of PPARp/5 in Tfm mice 
treated with testosterone relative to XY littermate mice (p=0.08), no significant change 
in expression of hepatic PPARp/5 in Tfm mice treated with placebo compared to XY 
littermate mice (n=12) was observed (figure 3.7).
3.3.6 Analysis of PAI-1 mRNA expression by qRT-PCR
In figure 3.8, it can be seen that there was a significant decrease (p=0.03) in expression 
of PAI-1 in the liver in Tfm mice treated with placebo (n=4) compared to XY littermate 
mice (n=12) while no significant change in the liver of Tfm mice was seen with 
testosterone treatment (n=20) compared to the XY control group. In contrast, 
testosterone treatment increased considerably (p=0.01) expression of hepatic PAI-1 in 
Tfm mice relative to Tfm mice treated with placebo.
3.3.7 Analysis of CX3CL1 mRNA and its receptors CX3CR1 
expression by qRT-PCR
The expression of CX3CL1 was not significantly different in the liver in Tfm mice 
treated with testosterone (n=20) or with placebo (n=4) compared to XY littermate mice 
(n=12) (figure 3.9a). There was a decrease in expression of CX3CR1 in the liver of Tfm 
mice treated with testosterone, compared to the liver of Tfm mice treated with placebo 
and XY littermate mice, although this did not reach statistical significance (figure 3.9b).
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Figure 3.6: Expression of hepatic adiponectin mRNA by qRT-PCR in Tfm mice 
and XY littermate. A significant increase in its expression in Tfin T compared to Tfm 
P (Tfm mice with placebo, n=4) whilst, no significant difference was seen in expression 
of Adiponectin in Tfm T (Tfin mice with testosterone, n=20) compared to XY mice 
(XY littermate mice, n=12) One Way ANOVA, (n=3). #<0.05 Tfin P vs Tfm T.
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Figure 3.7: Expression of hepatic PPARp/S from qRT-PCR in Tfm mice and XY 
littermate. A significant increase was observed in its expression compared to Tfm P 
(Tfm mice with placebo, n=4) whereas no significant change was seen in expression of 
PPAR in Tfm T (Tfin mice with testosterone, n=20) compared to XY mice (XY 
littermate mice, n=12), Kruskal-Wallis, (n=3). #P<0.05 vs Tfm P.
PAI-1
1.8
o‘5 1.6RJi_ 1.4Co'55 1.2(Aok. 1aXa> 0.8a> 0.6
s(0 0.40)& 0.2
0
# #
*
I11
XY TFM P
,
TFM T
Figure 3.8: Expression of hepatic PAI-1 from qRT-PCR in Tfm mice and XY 
littermate. A significant reduction was observed in expression of PAI-1 in Tfin P 
(Tfm mice with placebo, n=4) compared to XY Tfm (XY littermate mice, n=12). A 
significant increase was seen in Tfm T (Tfm mice with testosterone, n=20) 
compared to Tfin P (Tfm mice with placebo, n=4). Kruskal-Wallis, (n=3). 
*P<0.05vs XY mice, ## P<0.01 vs Tfm P.
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Figure 3.9: Expression of hepatic CX3CL1 (A) and CX3CR1 (B) by qRT-PCR 
in Tfm mice and XY littermate. No significant change was seen in expression of 
CX3CL1 (A) and CX3CR1 (B) in Tfm T (Tfm mice with testosterone, n= 20) 
compared to Tfm P (Tfm mice with placebo, n= 4) and XY mice (XY littermate 
mice, n= 12), One way ANOVA, (n=3).
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3.3.8 Analysis of CCL2 mRNA and its receptors CCR2 mRNA 
expression in the liver by qRT-PCR
No significant change was seen in expression of CCL2 in the liver Tfm mice treated 
with testosterone (n=20) or with placebo (n=4) compared to XY littermate mice (n=12) 
(figure 3.10a). There was a trend to decrease the hepatic expression of CCR2 in Tfin 
mice with testosterone compared to Tfin mice treated with placebo and XY littermate 
mice, but this effect did not reach statistical significance (figure 3.10b).
3.3.9 Analysis of apolipoprotein mRNA expression (Apo aland Apo E) 
in the liver by qRT-PCR
There was a slight increase in expression of Apo Al in the liver of Tfin mice treated 
with testosterone (n=20), but this alteration did not reach statistical significance 
compared to Tfin mice treated with placebo (n=4) and XY littermate mice (n=12) 
(figure 3.11a). There was no significant differencea in the expression of Apo E in the 
liver of both Tfin mice treated with testosterone or with placebo compared to XY 
littermate mice, as shown in (figure 3.1 lb).
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Figure 3.10: Expression of hepatic CCL2 (A) and CCR2 (B) by qRT-PCR in 
Tfm mice and XY littermate. No significant change was notable in expression of 
CCL2 (A) and CCR2 (B) in Tfm T (Tfm mice with testosterone, n= 20) compared 
to Tfm P (Tfm mice with placebo, n= 4) and XY mice (XY littermate mice, n= 12), 
Kruskal-Wallis, (n=3).
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Figure 3.11: Expression of hepatic Apo Al (A) and Apo E (B) by qRT-PCR 
in Tfm mice and XY littermate. No significant change was seen in the 
expression of Apo Al and Apo E in Tfin T (Tfm mice with testosterone, n=20) 
compared to Tfm P (Tfm mice with placebo, n=4) and XY mice (XY littermate 
mice, n=12), One way ANOVA, (n=3).
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Parameters TFM+T
Adiponectin Increased
PPARp/8 Increased
PAI-1 Increased
CX3CL1 NC
CX3CR1 NC
CCL2 NC
CCR2 NC
ApoE NC
Table 3.3: Summary of results the effect of testosterone treatment on mRNA gene 
expression of all parameters in Tfm mice study. Tfm: testicular feminization mice, 
T: testosterone, NC: no change, PPAR: Peroxisome proliferator-activated 
receptor, PAI-1 Plasminogen activator inhibitor-1, Apo: apolipoprotein.
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3.4 Discussion
This part of the study, investigated the gene expression of anti-inflammatory 
(adiponectin, PPARp/5), anti-atherogenic factors (Apo A-l and Apo E) and pro- 
inflammatory factors such as PAI-1 and chemokines with their receptors, (CX3CL1, 
CX3CR1, CCL2 and CCR2) mRNA was qualified using liver tissue following 
testosterone treatment in Tfin mice compared to XY littermate and placebo Tfin mice 
controls where all these groups were fed on high fat diet.
As previously mentioned, Tfin mice have low testosterone besides having a non­
functioning AR, so they cannot respond to the classical genomic signalling pathways 
(Monks et al., 2007). Therefore, it was hypothesised that testosterone treatment for 
these mice may show, firstly whether testosterone can influence the target genes and 
secondly, whether testosterone is acting via mechanisms other than through the AR.
The first finding was that PCR confirmed the expression of the target genes in hepatic 
cDNA samples from Tfin mice and XY littermate mice. Secondly, testosterone 
replacement did have an effect either positively or negatively, on some of the target 
genes which indicate that testosterone has the ability to act via ER or non-genomic 
signalling pathways.
3.4.1 The effect of testosterone treatment on hepatic adiponectin 
mRNA expression in Tfm mice
The current study demonstrated that testosterone significantly increased hepatic mRNA 
expression of adiponectin in Tfin mice compared to Tfin mice treated with placebo. 
This is in contrast with the study by Nishizawa et al. (2002) reporting that castration in 
mice increased plasma adiponectin and testosterone treatment reversed this effect 
without changes in the mRNA and protein levels of adiponectin in the adipose tissue. 
These results suggste: 1) changes in adiponectin mRNA expression do not always 
correspond to changes in plasma adiponectin concentrations, (Combs et al, 2003; Behre 
et al., 2007). 2) This observation supports the proposal that post-transcriptional and 
post-translational mechanisms in adiponectin production are differentially regulated 
(Swarbrick and Havel, 2008).
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However, the increase in hepatic mRNA expression of adiponectin may be related to the 
Tfin mice condition, because it is well recognized that there is an inverse relationship 
between testosterone and adiponectin (Lanfranco et al, 2004, Page et al, 2005a, Bai et 
al, 2011; Frederikse et al, 2012) even though both have anti-inflammatory and anti­
atherogenic actions (Malkin, et al, 2003; Lanfranco et al, 2004), where adiponectin 
can improve insulin sensitivity and prevent T2DM by promoting the ability of insulin to 
suppress glucose production by hepatocytes. Recent studies established that adiponectin 
increased fatty acid oxidation (Fruebis et al, 2001), increased insulin action in the 
muscle and liver and additionally improved IR in lipoatrophic and genetically obese 
mice, both of which had hypo-adiponectinemia (Yamauchi et al, 2001; Berg et al, 
2001).
In comparison, testosterone treatment of patients with T2DM in the present study 
reduced significantly the serum adiponectin concentration after 3 months (chapter 2). 
Testosterone did not show the same effect on adiponectin expression in the liver of 
these mice. Further clinical studies on the influence of testosterone therapy have 
reported a reduction in adiponectin levels in men with T2DM (Kapoor et al, 2007) and 
in aging men using supraphysiological doses of testosterone (Page et al, 2005a), while 
no changes were observed in adiponectin levels in aging men treated with physiological 
doses of testosterone (Page et al, 2005b). The mechanism of the diminution in 
adiponectin concentration during testosterone therapy is unclear. It is suggested that, the 
negative effect of testosterone therapy on adiponectin levels may be mediated by factors 
that are responsible for adiponectin production or synthesis at the same time as their 
activity is modulated by testosterone. However, this reduction was not observed in the 
present study with Tfin mice suggesting that testosterone acted by ER or non-genomic 
pathway. In a study using rats fed a high-fat diet and treated with testosterone it was 
found that testosterone treatment reduced adiponectin levels in the serum. In this study 
testosterone decreased fat accumulation in these rats even though they had body weight 
higher than untreated rats with the same food (Nikolaenko et al, 2013). Tfin mice in the 
current study had no significant difference in body weight compared to Tfin mice with 
Placebo or XY mice (Kelly et al, 2012). However, although not statistically significant, 
Tfin mice receiving testosterone replacement were observed to be heavier and gained 
more weight over the 28 week experimental period than saline-injected Tfin mice and 
XY littermates. However, fat accumulation was not investigated in that study by Kelly 
et al. (2012). Further investigations in these mice are needed to explain why under
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certain circumstances, testosterone increases mRNA expression of adiponectin in liver 
of these mice.
3.4.2 The effect of testosterone treatment on hepatic PPARp/5 mRNA 
expression in Tfm mice
A significant increase in hepatic mRNA expression of PPARp/5 was seen following 
testosterone treatment in mice compared to those treated with placebo. To the best of 
current knowledge no studies have been performed on the effect of testosterone on 
PPARp/5 compared to another isoforms of PPAR. For example, testosterone treatment 
increased the sensitivity of PPAR-a receptors in patients with T2DM (Nieschlag et al, 
2012). On the contrary, Kilby and colleagues (2013) found that testosterone treatment 
did not associate with any change in hepatic expression of PPARa and PPARy in the 
same mice with the same condition. In an alternative study, testosterone has recently 
been shown to inhibit PPARy activity in a transcriptional activity (Du et al, 2009).
PPARp/5 ligands have been shown to reduce triglyceride accumulation (Tanaka et al, 
2003) glucose and lipid metabolism (Billin et al, 2008). According to the anti­
inflammatory and anti-atherogenic role of PPARp/5 in different tissues in the animal 
models and humans, therefore, the increase of this factor by testosterone may reflect the 
role of testosterone via AR-independent pathway as anti-inflammatory and anti­
atherogenic factor in reduction of atherosclerosis development and T2DM.
3.4.3 The effect of testosterone treatment on hepatic PAI-1 mRNA 
expression in Tfm mice
Data reported here shows an increase in mRNA PAI-1 expression in the liver following 
testosterone therapy in Tfin mice, compared to Tfin mice treated with placebo. It is 
known that PAI-1 has a significant role in the development of coronary heart disease 
(CHD). Additionally, high levels of PAI-1 are associated with IR and lipid 
abnormalities, (Gruzdeva et al, 2013). Therefore, several studies were conducted to 
investigate whether testosterone influences the level of PAI-1 in serum or its gene 
expression in human and mice (Goglia et al, 2010). Cross sectional studies have 
reported a negative association between testosterone levels and PAI-1 and fibrinogen 
(Rosano et al, 1999; Webb et al, 1999). Replacement of testosterone in hypogonadal
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men and treatment of normal men with dehydroepiandrosterone (DHEA) reduces PAI-1 
serum levels (Bavenholm et al, 1998). In addition, Philips et al, (1994) studied the 
association between testosterone levels and fibrinolytic factors in men with CAD. 
Results showed that the testosterone levels were correlated negatively with CAD and 
PAI-1. An additional study investigated the relationship between testosterone levels, 
fibrinolytic activity and lipid levels, in hyperlipidaemic men (Glueck et al, 1993). It 
was found that testosterone was inversely associated with PAI-1 activity and fibrinogen 
levels (Glueck et al, 1993). Similarly a potentially beneficial effect of testosterone on 
coagulation was reported in men in the period after an acute MI (Pugh et al, 2002). 
Moreover, there was an increase in fibrinogen, PAI-1 and tPA in diabetic prostate 
cancer patients during androgen deprivation therapy (Haidar et al, 2007). Former 
studies using DHT (Norata et al, 2006) or testosterone (Jin et a l , 2007) found that the 
reduction of PAI-1 association with androgen was via AR pathway. This was clearly 
after blocking these receptors by bicalutamide or flutamide in human endothelial cells, 
respectively. Therefore, since Tfm mice in the current study have a non-functional AR, 
the increase in mRNA PAI-1 expression of liver might be as result of an AR- 
independent pathway, in a similar way to the effect on adiponectin mentioned above.
In contrast, Smith and colleagues (2005) found that physiological testosterone 
replacement did not affect the coagulation system such as PAI-1 and fibrinogen level in 
men with CHD. PAI-1 has the ability to inhibit fibrinolysis processes via suppresses 
tPA and urokinase (uPA).
The source of PAI- 1 levels in plasma in humans or mice includes: adipocytes, liver 
cells and endothelial cells (Bastard and Picroni, 1999). Previous reports have revealed 
that PAI-1 mRNA expression per total RNA mass in adipose tissue was higher in 
rodents made obese, either genetically or by lesioning the ventromedial hypothalamus, 
than in their lean counterparts, (Shimomura et al, 1996; Sierra-Honigmann et al, 1998). 
This finding suggests that the contribution of the mass of adipose tissue is at least as 
important as upregulation of PAI-1 synthesis in the increase in circulating PAI-1 levels 
observed in obese mice (Morange et al, 2000). As previously mentioned, Tfin mice 
with testosterone in the current study were heavier and gained more weight over the 28 
week experimental period than Tfm mice with placebo and XY littermates even though 
this was not statistically significant. Consequently, this could explain the increase in 
expression of PAI-1 in these Tfin mice regardless of testosterone treatment. However,
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evidence from other studies showed that plasma PAI-1 levels are more closely related to 
fat accumulation and PAI-1 expression in the liver than in adipose tissue in obese mice 
(Alessi et al, 2003). Therefore, investigation of fat accumulation in the livers of these 
mice could be valuable in explaining the increase in mRNA PAI-1 expression.
In rat study, results showed that the modifications of aortic expression of PAI-1 were 
associated with castration and expression returned with the administration of a 
physiological amount of testosterone but not with a pharmacological dose of the same 
hormone (Goglia et al, 2010). Supraphysiological doses of testosterone therapy caused 
a decrease in fibrinogen and PAI-1 activity, (Anderson et al, 1995). Nevertheless, Smith 
et al. (2000) suggested that no changes in the levels of PAI-1 following a physiological 
dose of testosterone therapy were due to the low dose compared to the effect of 
supraphysiological doses of testosterone therapy in the previous study. In contrast, 
Goglia et al. (2010) found that the higher doses of testosterone or DTH resulted in an 
increase in mRNA for PAI-1 in endothelial cells of both young men and in 
premenopausal women.
The conflicting results of testosterone increasing simultaneously PAI-1, adiponectin and 
PPARp/8 in the liver are hard to explain. It is known that a negative correlation between 
PAI-1 and both PPARp/8 and adiponectin is seen in obesity (Garg et al, 2012). 
Obesity-induced inflammation is associated with increase in PAI-1 and a decrease in 
both adiponectin and PPARp/8 in the obese (Dandona et al, 2004; Stienstra et al, 
2006). It may be expected therefore, that testosterone treatment would reduce PAI-1 
and increase adiponectin and PPAR5/p, however the PAI-1 results do not follow this 
expectation, this finding may be specific to Tfm mice.
3.4.4 The effect of testosterone treatment on hepatic CX3CL1 and 
CCL2 mRNA and their receptors expression in Tfm mice
In the present study, testosterone treatment also did not associate with any change in
hepatic mRNA gene expression of CX3CL1 and CCL2 or their receptors. Several
hepatic cell populations, including hepatocytes, Kupffer cells, sinusoidal endothelial
cells and hepatic stellate cells, can secrete chemokines upon activation (Karlmark et al,
2008). Weisberg et al. (2006) studied the role of CCR2 and established that mice
lacking CCR2 had decreased adipose tissue macrophage infiltration, decreased hepatic
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steatosis, reduced inflammatory profiles and enhanced systemic insulin sensitivity 
(reviewed by De Luca and Olefsky, 2008). Furthermore, the CX3CL1/CX3CR1 
interaction can moderate chronic inflammatory diseases, including atherosclerosis; 
independent of CCL2/CCR2 (Yao et al, 2014). In addition, Shah et al, (2011) 
demonstrated that CX3CL1-CX3CR1 is a novel inflammatory adipose chemokine 
system that moderates monocyte adhesion to adipocytes and is accompanied by obesity, 
IR, and T2DM. Furthermore, Kanda and co-workers (2006) found that expression of 
CCL2 receptor, CCR2, was detected in the liver and inhibition of CCL2 function 
ameliorated both IR and hepatic steatosis as well as reduced the extent of macrophage 
infiltration into adipose tissue of obese mice.
These data offer evidence for CX3CL1-CX3CR1 as a diagnostic and therapeutic target 
in cardio-metabolic disease. Furthermore, Kanda et al, (2006) demonstrated that 
overexpression of CCL2 in adipose tissue caused hepatic steatosis along with adipose 
tissue inflammation, while systemic deletion of CCL2 inhibited HFD-induced steatosis.
However, a previous study reported that CX3CL1 and its receptor were detected in 
plaque regions of artery walls of Tfin mice, fed a high fat diet, but were not influenced 
by testosterone or AR function (Kelly et al, 2012b). In the same study, CCL2 
concentrations were significantly elevated in XY littermate and Tfin mice following a 
high-cholesterol diet compared to normal diet-fed XY littermate, but concentrations of 
CCL2 were not significantly different in serum of Tfin mice treated with testosterone 
compared to placebo-treated Tfin mice and XY littermates. Studies investigating the 
effects of testosterone therapy on chemokines and their receptors in animal models have 
been limited. However, it is actually difficult to conclude whether testosterone treatment 
has the ability to influence these receptors and ligands as anti-inflammatory modulator. 
Therefore, the results presented here are not able to confirm an effect of testosterone.
3.4.5 The effect of testosterone treatment on hepatic Apo A l and Apo 
E mRNA expression in Tfm mice
This study has found no significant effect of testosterone therapy on mRNA expression 
of Apo Al and ApoE. Both apolipoproteins have anti-atherogenic actions. It is 
hypothesised that as testosterone has anti-atherogenic action thus testosterone may lead 
to increase the expression both of Apo Al and Apo E.
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Animal experiments indicated that testosterone influences apo Al gene activity in 
inbred strains of mice (Tang et al, 1991), while the outcome of cell culture studies 
demonstrate that the hormone acts by antagonizing the actions of estrogen, and that 
androgens have no direct effect on gene transcription in human hepatoma cells (Tang et 
al., 1991; Tam et al., 1986). However, the outcome of cell culture is not the same as 
outcomes from whole liver tissues. Pharmacologic doses of estrogen hormone used to 
treate rodents resulted in larger concentrations of Apo Al mRNA and gene transcription. 
While these actions should lead to higher levels of Apo Al protein, the hormone also 
had post-transcriptional effects which reduced the abundance of the protein (Seishima et 
al., 1991; Tang et al., 1991). Clinical studies demonstrate that the mechanism of 
estrogen increasing the concentration of Apo Al in post-menopausal women was by 
inhibiting the activity of hepatic triglyceride lipase (HTGL) (Applebaum-Bowden et al., 
1989; Colvin et al., 1991) or by stimulating lipoprotein synthesis (Schaefer et al, 1983; 
Sacks etal., 1995).
However, the effect of androgens on Apo Al expression, especially in animal models is 
uncertain as a result of the lack of information. In human studies, Singh and colleagues 
(2002) found that a 600mg dose of testosterone enanthate, which was associated with 
extremely supraphysiological testosterone concentrations, reduced HDL and Apo Al 
levels in healthy young men while Tan and co-workers (1998) found that a minimum 
effective dose of testosterone replacement in the form of parenteral testosterone ester 
given 4-weekly significantly decreased levels of ApoAl. In line with our findings, 
previous studies report neither the serum HDL cholesterol nor the ApoAl 
concentrations altered following transdermal testosterone treatment in healthy young 
men (Berglund et al., 1996; Arrer et al., 1996) and following gel testosterone treatment 
in older men (Rubinow et al, 2012). Nevertheless, other studies found physiological 
testosterone treatment increased both HDL cholesterol and ApoAl levels in 
hypogonadal, elderly men (Zgliczynski et al., 1996) and in normal men (Bagatell et al., 
1992).
Testosterone treatment did not show an effect on hepatic mRNA Apo E expression gene 
in Tfin mice. It is known that Apo E deficient mice (ApoE-/-) mice are severely 
hypercholesterolemia and develop advanced atheroma independent of diet. These mice 
are clear evidence of the importance of Apo E as the atheroprotective factor against
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atherosclerosis development. Furthermore, injection of cetrorelix, which is used to 
reduce gonadotropins and sex steroids in treatment of prostate carcinoma and ovarian 
cancer, into ApoE deficient mice (ApoE-/-) suggests that the associated suppression of 
testosterone leads to increased atherosclerosis, despite lower cholesterol levels in the 
male mice (Von Dehn et al., 2001). On the other hand, in female ApoE-/- mice, the 
reduction in testosterone leads to reduction in estradiol, insulin and HDL levels without 
effects on atherosclerosis (Von Dehn et al., 2001).
It is recognized that some factors moderate Apo E synthesis such as hormones, dietary 
cholesterol and fat. Estradiol enhances VLDL production from rat hepatocytes and the 
VLDLs contain Apo E. Regulation of Apo E gene expression by estradiol occurs both at 
the transcriptional and post-transcriptional level in rats (reviewed by Ajit et al., 1997). 
Previous studies report that increases in Apo E synthesis were also observed in castrated 
C57/BL6 mice given either physiological or pharmacological replacement doses of 
estradiol, but not testosterone, suggesting that the effect of estradiol was specific to the 
distribution of Apo E mRNA in the translationally active polysomal pool (Srivastava et 
al., 1997).
In human macrophage cells, cells were exposed to testosterone 10-8 M for 24, 48 and 
72h to investigate expression of the LXR-target gene APOE and Apo E gene. LXR- 
target gene Apo E is responsible for encoding the protein Apo E, involved in binding 
cholesterol following its removal from the cell. The results showed that testosterone 
stimulated expression of LXRa and APOE in human macrophages. This suggests that 
firstly, testosterone activates LXR acting through this nuclear receptor to control the 
expression of ApoE to aid cholesterol efflux. Secondly, this could explain the role of 
testosterone as an anti-atherogenic factor (Kilby et al., 2012). However the increase in 
ApoE seen in other studies compared to the lack of change seen in the currrent study 
may be due to differenes in the models used for aplication the presene or absence of 
androgen receptors and the targets studied (transription fators or RNA).
3.5 Limitations of the study
The small sample size of Tfin mice in the present study might be associated with the 
lack of a clear conclusion. Using adipose tissue samples would be useful to explain the
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influence of testosterone on the above genes. Fat distribution was not measured in these 
mice which made it difficult to draw conclusions on the changes in expression of some 
genes related to obesity. The absence of receptor blockers for ER or aromatase 
inhibitors in this study made it difficult to determine the mechanisms by which 
testosterone exerted its effect.
3.6 Summary
The present study showed that testosterone treatment did not induce significant changes 
in hepatic expression of mRNA for CX3CL1, CCL2 and their receptors CX3CR1 and 
CCR2 and atherogenic factors Apo Al and Apo E in Tfin mice following a high- 
cholesterol diet compared to placebo controls and XY littermates. However, 
testosterone showed a beneficial effect by significantly increasing mRNA expression of 
adiponectin and PPARp/8 suggesting an effect via the AR-independent pathway. On the 
other hand, this finding was contradicted by the result for the inflammatory factor PAI-1, 
where testosterone increased its expression in the liver which was also mediated by the 
AR-independent pathway. It is possible that more definitive results for the effect of 
testosterone in Tfin mice may be found with larger numbers of animals thus further 
work should be performed.
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Chapter 4
The in vitro effect of testosterone treatment on THP-1 macrophages and 3T3L1 
adipocytes
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4.1 Introduction
4.1.1 Monocyte/macrophage cell recruitment in atherosclerosis
Increased understanding of the mechanisms underlying atherosclerosis has highlighted 
prospective targets for new therapeutics. One of these mechanisms involves the 
contribution of chemokines to inflammation and migration of immune cells into the 
arterial wall, which is a consequence of interaction between chemokines within the 
endothelium and their receptors on infiltrating immune cells. Recently, therapeutic 
approaches to target inhibition of these interactions, with the aim of stopping the 
recruitment of immune cells into the tissue have been reported (Koenen and Weber, 
2011).
The specific immune cells implicated in atherosclerosis are monocyte cells. These cells 
differentiate into macrophage-derived foam cells, which are the core of the detectable 
fatty streak in the earliest atherosclerotic lesions in the sub-endothelial space (Zemecke 
and Weber, 2010). These cells, with their inflammatory mediator production (IL-1 p, IL- 
6, IL-8, TNF-a and IFNy) can be associated with inflammation in the arterial wall while 
anti-inflammatory cytokines (IL-10) can reduce the inflammatory condition (see chapter 
1). Macrophage cells also have the ability to secrete these factors in the same way, also 
in the arterial wall. These factors are present in all stages of atherosclerosis. They can 
(except IL-10) cause dysfunction in endothelial cells and promote leukocyte 
transmigration into the endothelial space by stimulating secretion of chemokines from 
immune cells. TNF-a and IFNy can activate macrophages to secrete TNF-a and IFNy 
and other pro-atherogenic factors including IL-8 and CCL2. IL-8 is produced by several 
different immune cells but mainly by macrophages. It has the ability to attract 
monocytes at an early stage and accumulate macrophage cells in advancement of 
atherosclerotic lesions. IL-6 (reviewed by Fernandez and Kaski, 2002) and IL-1 p 
(Dinarello et ah, 2010) have a role in atherosclerosic events by stimulating the 
migration and differentiation of the activated macrophages. They also act by triggering 
the synthesis of metalloproteinases and the expression of LDL receptors in the 
macrophages, as well as an increase in LDL capture and the secretion of 
chemoattractants, such as CCL2 and adhesion molecules. However, IL-10 which acts as 
an anti-inflammatory molecule is also secreted from macrophages. This cytokine has a 
role in the inhibition of inflammatory cytokines such as TNF-a, IL-6, and IL-1 p, and
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has been found at high levels in individuals with atherosclerosis in response to the pro- 
inflammatory environment of atherosclerosis (Huang et al, 2004; Szodoray et al., 2006).
Monocytes and macrophages also express a number of chemokine receptors including: 
CX3CR1 and CCR2. Each receptor binds its ligand, CX3CL1 and CCL2 respectively, 
which are secreted from endothelial, and smooth muscle and macrophages cells 
(Zemecke et al., 2008; Liu and Jiang, 2011). In particular, CX3CR1/CX3CL1 
synergizes with CCR2/CCL2 to maximize foam cell formation and the inflammatory 
response during atherogenesis (Tacke et al., 2007). Blockade of CCR2 and/or CX3CR1 
may therefore be beneficial in atherosclerotic cardiovascular disease (Barlic and 
Murphy, 2007). These chemokine receptors are G protein-coupled receptors containing 
7 transmembrane domains that are found predominantly on the surface of leukocytes 
(Colvin et al, 2006). Many factors can modulate the expression of these receptors 
including chemokine and proatherogenic and inflammatory cytokines. Pro- 
inflammatory cytokines, IFN-y and TNF-a are critical mediators of atherosclerosis in 
murine models (Boehm et al, 1997) being crucial in the establishment of the 
inflammatory microenvironment that promotes accumulation and activation of 
monocytes/macrophages in the arterial wall (Apostolakis et al., 2007). TNF-a and IFNy 
induce expression of the CX3CL1/CX3CR1 system in macrophages cells through 
activating NF-kB, AP-1, STAT and MAPK (Liu and Jiang, 2011). These inflammatory 
cytokines can also affect the expression of CCL2/CCR2 and thus modulate the 
recruitment of monocytes and accumulation of macrophges in sites of acute and chronic 
inflammation, including the developing atherosclerotic lesions (Tangirala et al., 1997 
Weber etal., 1999).
4.1.1.1 Monocyte/macrophage cells and testosterone treatment
There was improvement in the health of patients who suffered from CHD following 
testosterone treatment in short-term studies (Jones and Saad, 2009). Furthermore, 
according to animal studies, there was a significant reduction in deposition of lipid in 
the arterial walls of an atherosclerotic mouse model, following testosterone treatment 
(Nettleship et al., 2007b, 2009; Kelly et al., 2012b). In addition, testosterone had the 
ability to reduced inflammatory factors including TNF-a, IL-6 and IL-1 P and increased 
anti-inflammatory cytokines in murine macrophages (D’Agostino et al., 1999). These 
factors have a role in atherosclerosis events. Therefore, replacement therapy for this
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testosterone deficiency may lead to reduced atherosclerosis. Moreover, stimulation of 
the AR influences the expression of chemokine receptors CCR2 (Lai et al, 2009) and 
CCR1 (Akashi et al, 2006), and consequent chemokine responses, in mice 
macrophages and in prostate cancer cells, respectively.
It is thought that the effect of testosterone could be through modulating the expression 
or action of both chemokine receptors, CX3CR1 and CCR2, expressed on macrophages 
therefore reducing atherosclerosis events. However the effect of testosterone on these 
receptors has not yet been investigated in macrophages. The action of testosterone could 
be via stimulation of the AR on macrophages. Furthermore, testosterone can act through 
an ER mechanism. A previous study found that macrophages had the ability to express 
aromatase and estrogen receptors (Mor et al, 1998). The same group in 2001 confirmed 
that monocytic (undifferentiated) THP-1 cells had no aromatase activity, upon 
differentiation with PMA into tissue macrophages, they express aromatase and have 
aromatase activity, (Mor et al, 2001). Therefore, testosterone could be converted to 
estradiol and via ER on macrophages. Additionally, others have observed that 
testosterone can exhibit its action on immune cells (Wehling et al, 1997, Benten et al, 
1999; Heinlein and Chang, 2002) or macrophages (Cutolo et al, 2005) via non-genomic 
receptors. This effect is on intracellular signaling pathways where testosterone has the 
ability to rapidly induce an increase in intracellular Ca2+ which is linked to a G protein- 
coupled receptor in immune cells (Gradisnik et al, 2008) and macrophage cells (Benten 
eta l, 1999).
4.1.2 Adipocyte-derived proteins in T2DM and atherosclerosis
The development of adipose tissue is regulated by a complex interaction of transcription 
factors and adipocytokines. As mentioned in chapter 1, adipose tissue acts as an 
endocrine organ secreting adipocyte-derived proteins. Adiponectin, PP ARp/5, leptin, 
PAI-1, CCL2 and CX3CL1 are involved in the development of adipose tissue in normal 
and obesity cases. Adiponectin and PP ARp/8 are reduced with obesity and correlated to 
insulin-sensitizing and anti-inflammatory properties (reviewed from Cefalu et al, 2011; 
Szanto et al, 2008). In contrast, leptin, PAI-1, CCL2 (Taube et al, 2012; Morton and 
Schwartz, 2011; Alessi et a l , 2007; Guilherme et al, 2008) and CX3CL1 (reviewed by 
Cefalu et al, 2011; Shah et al, 2011) have been found to be increased in obesity and 
associated with T2DM and CVD. Moreover, the production of chemokines (CX3CL1
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and CCL2) by adipose tissue infiltrated with macrophages is a further cause of 
endothelial dysfunction in adipose tissue and in the artery wall leading to the 
development of inflammation (Cefalu et al., 2011; Gustafson et al., 2007; Taube et al., 
2012). Recently, it has been reported that CX3CR1 and CCR2, with their ligands, have 
important roles in monocyte-adipocyte interactions by recruitment of leukocytes to 
adipose tissue in obesity (Cefalu, 2011). Especially, detection of CX3CR1 (Polyak et al., 
2014, Shah et al., 2011; Lumeng et al., 2007) and CCR2 (Kanda et al., 2006) on 
macrophages as well as their ligand CX3CL1 (Shah et al., 2011) and CCL2 (Kanda et 
al., 2006) in adipose tissue led to support this concept.
4.1.2.1 Adipocyte cells and testosterone treatment
Adipose tissue expands in obesity cases and this is accompanied by low testosterone 
levels as clearly documented in an 11-year follow-up patient study (Laaksonen et al., 
2005). A further study suggested a strong inverse correlation between body fat and 
testosterone levels (Kapoor et al., 2005), with hypogonadal men exhibiting a reduced 
lean body mass and an increased fat mass. Several studies have shown that TRT in 
obese men reduces BMI and visceral fat mass as well as IR (Rebuffe'-Scrive et al., 
1991; Marin et al., 1992a, b, 1995; Saad et al., 2007, 2008; Agledahlet al., 2008; Kelly 
and Jones, 2013).
Nevertheless, the mechanism by which testosterone affects fat storage and obesity is 
unclear. There are specific receptors for androgens in adipose tissue, which indicate an 
important role for these hormones in the regulation and function of this organ. These 
sex steroid hormones perform their action in adipose tissues via stimulation of both 
genomic and non-genomic pathways. It is now recognized that there are ER and AR in 
adipose tissues, so their actions could be direct by AR or by ER after conversion of 
testosterone to estradiol by aromatase in adipose tissue (Saad, 2009). For instance, in 
stem cell culture studies, testosterone treatment showed a direct effect on adipogenesis. 
Singh et al., (2003) stated that treatment of isolated mouse pluripotent stem cells with 
testosterone stimulated the growth of cells of myocyte lineage rather than adipocytes, 
whereas testosterone deficiency induced the development of adipocytes over myocytes. 
Singh et al. (2006) reported that testosterone and dihydrotestosterone inhibit adipocyte 
differentiation in vitro through an AR-mediated nuclear translocation of beta-catenin 
and activation of downstream Wnt signalling. In addition, sex steroid hormones could
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stimulate hormone-sensitive lipase leading to lipolysis in adipose tissue by activation of 
the cAMP cascade (Mayes and Watson, 2004).
In a clinical study, it was shown that testosterone inhibits triglyceride uptake and 
lipoprotein lipase activity. In this study, testosterone administration returned 
testosterone levels to mid normal values with a treatment duration of 8-9 months, 
leading to a decline in the visceral fat mass (Saad, 2009). Therefore, the action of 
testosterone seems to be implicated in the regulation of both preadipocyte proliferation 
and differentiation by affecting lipoprotein lipase action. The above studies are 
examples on the effect of testosterone in modulating adipose tissue and adiposity; 
however, other studies have been carried out to investigate the correlation between 
testosterone and adipocyte-derived proteins (Kalinchenko et al, 2010). Changes in 
these adipocyte-derived proteins as well as in testosterone levels in obesity resulting in 
MetS were observed (Allan et al, 2007). The role of testosterone is established by 
findings in men with prostate cancer who undergo androgen ablation therapy 
(Kalinchenko et al, 2010) particularly in the longer-term, which affects all components 
of the MetS (Braga-Basaria et al, 2006). The resulting metabolic consequences include 
abdominal obesity, IR, and atherogenic dyslipidemia along with a pro-thrombotic, 
inflammatory profile (Maneschi et al, 2012).
Previous studies in hypogonadal men showed that TRT inhibits adiponectin levels, even 
though both adiponectin and testosterone have an inverse correlation with obesity 
(Lanfranco et al, 2004). There have been contradictory results related to the effect of 
testosterone treatment and adiponectin. While in one study, testosterone treatment led to 
increased levels of adiponectin (Heufelder et al, 2009), in another study a decrease was 
observed in diabetic patients (Kapoor et al, 2007); a decrease was also seen in studies 
using high doses of testosterone (Page et al, 2005a) however a further study saw no 
change (Page et a l , 2005b). In contrast to adiponectin, leptin levels increased in direct 
proportion to the adipose tissue mass (Kapoor et al, 2007). Leptin has a suppressive 
effect on testosterone production (Saad and Jones 2010). An inverse relationship has 
been reported between serum testosterone and leptin concentrations in men (Isidori et 
al, 1999). TRT has been found to decrease serum leptin levels in hypogonadal men (Sih 
et al, 1997). PAI-1 is also secreted highly in obesity and acts as a pro-thrombotic factor 
(Russo et al, 2012). TRT was associated with reduction in its level in endothelial cells 
(Jin et al, 2007), whereas others found no change (Smith et a l , 2005). In contrast, to
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the best of our knowledge, no research has been performed to investigate the effect of 
testosterone treatment on CX3CL1, CCL2 and PPARp/5 in adipose tissue. Sex 
hormones have been reported to influence the differentiation process of adipocytes 
(Monjo et al., 2005). However, it is unclear whether testosterone treatment could 
influence these factors through adipogenesis processes and adipocyte differentiation 
including adiponectin, PP ARp/5, PAI-1, leptin, CX3CL1 and CCL2.
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4.1.5 Aims of this chapter
1. To investigate the effect of testosterone on CX3CR1 and CCR2 mRNA expression in 
PMA-differentiated THP-1 cells, as a model of macrophages involved in atherosclerosis, 
in the presence or absence of cytokines.
2. To investigate the effect of testosterone on the secretion of anti/pro-inflammatory 
mediators by PMA-differentiated THP-1 cells before and after stimulation with pro- 
inflammatory cytokines.
3. To investigate the effect of testosterone on mRNA expression of adipocyte derived 
associated proteins (adiponectin, PPARp/8, PAI-1, leptin, CX3CL1 and CCL2) during 
the differentiation process in the mouse 3T3L1 cell line, as a model of preadipocyte 
differentiation.
4. To investigate the effect of testosterone on the secretion of adiponectin, CX3CL1 and 
CCL2 from mature 3T3L1 adipocyte cells.
5. To investigate whether testosterone is acting via an androgen-receptor (AR) or non­
androgen receptor mechanism, by blocking the AR with flutamide in each of the above 
studies.
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4.2 Materials and methods
4.2.1 Cell culture models
Both cell lines (Human acute monocytic leukaemia cell line (THP-1) and Mouse 
Preadipocyte 3T3L1 cell line) were maintained for indefinite periods in a defined 
culture medium. Sterile cell culture techniques were used throughout to avoid microbial 
contamination. All experiments were repeated three times with two replicates for all 
experimental conditions.
4.2.1.1 THP-1 cell line
THP-1 is a human acute monocytic leukaemia cell line isolated from the peripheral 
blood of a 1 year old human male with acute monocytic leukaemia (AML) at relapse in 
1978 and was originally obtained from the European collection of cell cultures (EC ACC, 
UK). The THP-1 cell line is a valuable model for studying the mechanisms involved in 
macrophage differentiation, physiological functions and the expression of plasma 
membrane receptors, and cytokines (Apostolakis et al, 2007). Phorbol myristate acetate 
(PMA) induces differentiation of THP-1 to macrophage-like cells.
4.2.1.2 3T3-L1 preadipocytes cell line
Mouse 3T3-L1 preadipocyte cell line was developed by clonal expansion from murine 
Swiss 3T3 cells and was originally obtained from American Type Culture Collection 
(ATCC, UK). The mouse embryonic fibroblast cell line 3T3-L1 is a favoured model for 
metabolism and obesity research, because the cells can be chemically induced to 
differentiate into adipocytes, where they are sensitive to lipogenic and lipolytic 
hormones and drugs. The mixture of dexamethasone (DEX), 1-methyl-3- 
isobutylxanthine (MIX), and insulin is used for stimulating cell differentiation of the 
Mouse 3T3-L1 preadipocyte to mature adipocytes.
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4.2.2 Growing and maintaining of cell lines
4.2.2.1 Human monocytic THP-1 cells
THP1 cells were seeded in suspension and maintained in 75 cm2 tissue culture flasks 
(Fisher Scientific, UK) containing RPMI 1640 (GIBCO®, UK) media supplemented 
with 2mM glutamine, 10% foetal bovine serum (FBS), (GIBCO®, UK), 1% (2mM) 
penicillin/streptomycin (GIBCO®, UK) and 1% (lOOmM) sodium pyruvate (GIBCO®, 
UK) at 37°C with relative humidity in a 5%COil 95% air incubator (Heraeus Instrument, 
Germany). At 70-90% confluence, medium was changed from the culture flasks and 
cells were placed into universal 30 ml tubes (Fisher Scientific, UK) and centrifuged for 
5 minutes at 200g (Kendro Laboratory, USA). Media was changed approximately every 
72 hours. The passage number of this cell line was unknown.
4.2.2.2 Mouse 3T3L1 cells
Cells were maintained in growth medium (preadipocyte medium, PM) containing 
Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO®, UK) supplemented with 
10% FBS and 1% (2mM) penicillin/streptomycin into 175 cm2 tissue culture flasks. 
They were kept at 37°C with 5% C02/95% air in a humidified incubator until use and 
subcultured every 5-7 days. The passage number of this cell line was 7-10 in all 
experiments.
-At 70-90% confluence, medium was removed from the culture flasks and cells were 
washed twice with phosphate buffered saline (PBS) (Invitrogen, UK) and then aspirated. 
One ml of trypsin/EDTA solution (0.5% trypsin and 0.53nM EDTA (GIBCO®, UK)) 
was added to the cells in al75 cm2 flask and incubated at 37°C for 3 minutes. The flask 
was tapped gently to remove cells from the bottom surface and an equal amount of 
complete medium was added to the flask to neutralise the actions of trypsin/EDTA. The 
cell suspension was transferred to a sterile 50 ml-Falcon tube and centrifuged for 5 
minutes at 200g as above. After removing the supernatant, the cells were suspended in 
lml of fresh medium. Viable cell numbers were determined by adding lOpI of this cell 
suspension to lOpl of trypan blue solution (Sigma-Aldrich, UK) and incubated for 5 
minutes. Viable cells do not stain whereas dead cells stain blue. Cells were counted 
using an automatic cell counter designed to measure cell count and viability
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(Countess™, Invitrogen, UK). Cells were then further diluted to working densities and 
used in the experimental procedures, sub-cultured or cryopreserved.
4.2.3 Differentiation of THP-1 cells into macrophage cells
Induction of terminal differentiation from monocyte-like state to macrophage-like cells 
was performed by using PMA. PMA (Sigma-Aldrich, UK) was dissolved in DMSO at 
1 mg/ml and stored at -20°C as a stock solution. Additional dilutions of PMA were made 
in medium at 1:1000. Working concentration of PMA lOOng/ml was added to THP-1 
cells, which is an effective dose for differentiating these cells. The cells were plated in 
six-well plates (Fisher Scientific, UK) in duplicate at a density of 3x105 cells/ml (2.5ml 
per well) for 24,48, 72 and 96 hours.
4.2.4 Differentiation of 3T3L1 preadipocyte cells
To differentiate mouse preadipocyte cells to mature adipocyte cells, they were seeded 
into six-well plates in duplicate a density of 4xl05 cells/ml (2.5ml per well). Once the 
cells were confluent, they were incubated for an additional 48 hours before initiating 
differentiation by incubating in differentiation medium (DM), DMEM supplemented 
with 0.5 pM isobutylmethylxanthine (Sigma-Aldrich, UK), lpM dexamethasone 
(Sigma-Aldrich, UK) and 10 pg/ml insulin (Sigma-Aldrich, UK) for 3 days. DM was 
replaced with adipocyte maintenance medium (AM) containing 10 pg/ml insulin only. 
The medium was changed every 2-3 days and replaced by AM until ready for use. 3T3- 
L1 adipocytes were suitable for most assays 7-14 days post differentiation, where more 
than 80% of the cells had differentiated by 7 days.
4.2.5 Freezing cells protocol
Both cell lines were frozen with freezing medium (70% medium, 20% FBS, 10% 
Dimethyl sulphoxide, (DMSO), (Sigma-Aldrich, UK)) at lxlO6 cells/ml. In brief, cells 
were collected from tissue culture flasks into Falcon universal tubes and centrifuged at 
200g at 20 °C for 5 min. The supernatant was discarded and cells were re-suspended and 
counted, as described above. 3 ml of freezing media was added to the cells following re­
suspension of cells and 1ml was aliquoted into labelled cryovials (Nalgene, Fisher, UK)
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and packed with plenty of tissue in a polystyrene container (Nalgene, Fisher, UK) and 
stored at -80 °C freezer overnight. Following this cryovials were transferred into a 
dewar containing liquid nitrogen (Forma Scientific, USA).
4.2.6 Thawing cells protocol
Cell vials were removed from liquid nitrogen and quickly thawed in a water bath at 
37°C until thawed. In a laminar flow hood, 1 ml of warm complete medium was added 
to cells in the cryovial, and then transferred to 10 ml of medium in a sterile universal 
tube, gently mixed and then centrifuged at 200g for 5 min. After discarding the 
supernatant cells were re-suspended and viable cells counted as above.
4.2.7 Collection of supernatants and adherent cells for analysis
Cells were treated as in section 4.2.2.2 and supernatants were collected in 5ml tube 
(Fisher Scientific, UK) to analyse cytokines production from these cells in media and 
cell pellets were stored at -80 freezers for extraction of RNA.
4.2.8 Oil Red O staining and 3T3L1 cells
The Oil Red O method is a common staining technique used for demonstrating the 
presence of fat or lipids in fresh and frozen tissue sections. The basis for staining lipids 
with an oil-soluble dye lies in its high solubility in fatty substances. For staining 3T3L1 
cells, the stain must be freshly prepared from the stock solution and the cells fixed. A 
stock solution of stain was prepared by dissolving 0.3 g of Oil Red O (Sigma-Aldrich, 
UK) in 100 ml of isopropanol. A working solution was prepared by dilution of 30 ml of 
the stock stain with 20 ml of distilled water and left to stand for 10 minutes and then 
filtered using filter paper (Fisher Scientific, UK) into a Coplin jar, and covered 
immediately. Fixation of cells was performed by incubation of cells in wells of a 6-well 
plate in 4% paraformaldehyde (Sigma-Aldrich, UK) for 30-40 minutes at RT. Then, the 
fixative was aspirated and cells were rinsed three times for 5-10 minutes with PBS. 
Following aspiration of PBS, cells were washed twice with H2O and then stained with 1 
ml of freshly prepared Oil Red O working solution. The Oil Red O solution was 
removed and cells were washed three times with H2O. Once the cells were dried the red
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colour of lipid particles was monitored and photographed using a microscope with Xli 
camera (Leica Microsystems, UK Ltd).
4.2.9 Experimental treatment of THP-1 cell
4.2.9.1 Experimental conditions for testing the effects of testosterone with or 
without flutamide on CX3CR1 and CCR2 expression in THP-1 cells
Testosterone (Sigma-Aldrich, UK) was dissolved in absolute ethanol (Fisher Scientific, 
UK) at an initial concentration of 10‘3M and stored as a stock solution at 4°C until used. 
Additional dilution was performed at 1:1000 in medium and then further dilutions were 
made to prepare working concentrations. Furthermore, flutamide (Sigma-Aldrich, UK) 
was dissolved in absolute ethanol (Fisher Scientific, UK). Flutamide was stored at 4°C 
as a stock solution at 10'3 M. Dilution was performed in medium at 1:1000 and then 
further dilutions were made to prepare working concentrations before use.
Cells were cultured at a density of 3 x 105 cells/ml in six well plates (2.5 ml) for 24 h 
and then differentiated with PMA (100 ng/ml) for 48h. Testosterone was added to cells 
at 10 and 100 nM per well in duplicate and incubated with testosterone from 24 to 96h 
alone and in combination with flutamide at concentration of 100 and 1000 nM, 
respectively. Untreated cells were used as the negative control. Ethanol, at a volume 
equal to that of the diluted working solution of testosterone or flutamide was not added 
to control cells as vehicle because previous studies have shown no effect of ethanol at 
this concentration on these cells (Kilby et al, 2012). Following collection of cells as 
detailed in section (4.2.7), cells and supernatants were stored at -80°C prior to RNA 
extraction and flow cytometric bead assay analysis.
4.2.9.2 Experimental conditions for testing the effects of 24h cytokine and 
testosterone with or without flutamide on CX3CR1 and CCR2 expression in THP- 
cells
THP-1 cells were seeded in 6 well plates at a density of 3 xio5 cells/ml (2.5 ml per 
well) and then differentiated with PMA as described in section (4.2.3. In the presence of 
cytokines TNFa plus IFNy combined, at concentrations of 10 and 100 ng/ml, cells were 
treated with testosterone at 10 and lOOnM alone and in combination with flutamide at 
100 and 1000 nM, respictivley. Untreated cells without cytokines and cells with
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cytokines but without testosterone were used as negative controls. Collection and 
storage of cells and supernatants were performed as described above.
4.2.10 Measurement of pro- and anti- inflammatory concentrations in 
supernatants of THP-1 macrophages by Human Enhanced Sensitivity 
Cytometric Bead Array
The principle of this method was described in chapter 2 and was used for investigating 
levels of pro- and anti-inflammatory biomarkers in serum. Here, this method was used 
for measuring levels of IL-ip, IL-6, IL-8 and IL-10 TNF-a, and IFN-y in the 
supernatants from THP-1 macrophages, following treatment with the previous 
experimental conditions. The assay followed the same protocol as described in chapter 2 
section (2.2.4).
4.2.11 Experimental treatment of mouse 3T3L1 cells
4.2.11.1 Experimental conditions for testing the effects of testosterone with or 
without flutamide on adipocyte derived associated proteins in mouse 3T3L1 cells
Cells were seeded at a density of 4 x 105 cells/ml (2.5ml per well) in six well plates (for 
3, 5 and 9 days following differentiation. Testosterone was added at 10, 100 nM with 
DM for 3 days followed by AM for 5 and 9 days alone and in combination with 
flutamide at 100 and 1000 nM to cells per well in duplicate, respectively. Untreated pre­
adipocyte and mature adipocyte 3T3L1 cells were used as negative controls and 
untreated cells were used as the negative control. Ethanol, at a volume equal to that of 
the diluted working solution of testosterone or flutamide was not added to control cells 
as vehicle because previous studies have shown no effect of ethanol at this 
concentration on these cells (Tang et al, 2012). All treatments were applied in duplicate, 
with experiments that were repeated at least three times for each condition. Collection 
of cells and supernatants were performed as previously above.
4.2.12 Measurement of the secretion of adiponectin, CX3CL1 and 
CCL2 in supernatants of mouse 3T3L1 cells by ELISA
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Adiponectin, CX3CL1 and CCL2 were measured in supernatants of adipocyte cells 
following the above treatments using ELISA kits from R&D Systems. The method for 
each ELISA was the same apart from the volumes of reagents used and the 
concentrations of standards, as detailed below.
4.2.12.1 Investigation of adiponectin in supernatants of mouse 3T3L1 adipocyte by 
ELISA
Method
All reagents and 96 well microplate in kits the Mouse adiponectin/Acrp30 Quantikine 
ELISA kit (R&D Systems, USA) were brought from 4°C to RT. 50pl of assay diluents 
was added to each well and then 50pl of adiponectin standards (0, 0.16, 0.31, 0.62, 1.25,
2.5, 5 and 10 ng/ml) and test supernatants were pipetted into the wells in duplicate and 
left at RT for 3 hours. Following aspiration and washing each well five times with 400 
pi wash buffer, the plate was inverted and blotted against clean paper towels. lOOpl of 
adiponectin antibody-enzyme conjugate was added to each well and left for 1 hour at 
RT. After that washing was repeated and then 100 pi of substrate solution (TMB) was 
added to each well and left protected from light for 30 minutes at RT. Following 
addition 100 pi of stop solution (hydrochloric acid) per well to end the reaction, the 
plate was read on a microplate reader within 30 minutes at 450 nm.
4.2.12.2 Investigation of CX3CL1 in supernatants of mouse 3T3L1 cells by ELISA 
Method
CX3CL1 was investigated by using the Mouse CX3CLl/fractalkine Quantikine ELISA 
kit (R&D Systems, USA). Reagents were brought from 4°C to RT. 50 pi of assay 
diluent was added to each well and then 50pl of fractalkine standards (0, 0.62, 1.25, 2.5, 
5, 10, 20 and 40 ng/ml) and test supernatants were pipetted into the wells in duplicate 
and left for 2 hours. Subsequently, the plate was processed as above for the adiponectin 
assay.
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4.2.12.3 Investigation of CCL2 in supernatants of mouse 3T3L1 adipocyte by 
ELISA
Method
CCL2 was investigated by using the CCL2/JE/MCP-1 Quantikine ELISA kit (R&D 
Systems, USA). 50j_il of assay diluent was added to each well and 50pl of CCL2 
standards (0, 15.6, 31.2, 62.5, 125, 250, 500 and lOOOng/ml) and test supernatants were 
pipetted into the wells in duplicate and left for 2 hours at RT. The assay then followed 
the same protocol as described above for adiponectin
4.2.13 Investigation of gene expression in THP-1 macrophages and 
mouse 3T3L1 cells using qRT-PCR
The qRT-PCR principle was previously described in chapter 3 section (3.2.1) using 
SYBR Green Dye I.
4.2.13.1 Isolation of RNA
RNA was extracted using RNeasy Lipid Tissue Mini Kit (Qiagen, UK). This method is 
designed to inhibit RNases with the ability to remove contamination by using 
QIAzollysis reagent (Qiagen UK), which is a monophasic solution of phenol and 
guanidine thiocyanate. Adding chloroform (Sigma-Aldrich, UK) leads to protein, DNA 
and RNA separating into phases of aqueous and organic layers in a RNeasy spin column.
Method
According to the manufacturer’s protocol, RNA was extracted by adding 1ml of 
QIAzollysis reagent (Qiagen UK) to cell pellets in Eppendorf tubes and incubated for 
5min at RT. 200pl of chloroform was added and the tubes were vigorously vortexed for 
15 s, then samples were centrifuged (Heraeus Fresco 17 Refrigerated Micro Centrifuge, 
USA) at 12,000 g for 15min at 4°C to separate protein, DNA and RNA into three layers. 
The upper aqueous layer containing RNA was separated and collected (about 600pl) 
into a clean 1.5ml Eppendorf tube and mixed with 600pi of 70 % ethanol. Samples were
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removed to the RNeasy spin column in two steps, in each one about 600pl were 
transferred, and centrifuged for 15s at > 8000g. The supernatant was discarded and the 
precipitated RNA pellet was washed with 700 pi of buffer RW1 in the spin column and 
centrifuged at 8000g for 15s. The supernatant was discarded and the precipitated RNA 
pellet was washed with 500 pi of buffer RPE in the spin column and centrifuged at 
8000g for 15s. Again, the supernatant was discarded and the precipitated RNA pellet 
was washed with 500pl of buffer RW1 in the spin column and centrifuged at 8000g for 
2min. The RNeasy column was transferred to a clean 1.5ml Eppendorf tube and 
centrifuged for lmin at 8000g. Finally, the RNeasy column was transferred to a clean 
1.5ml tube and mixed with 30-40pl of RNA free water and then centrifuged for lmin at 
8000g. The precipitated RNA pellet was stored at -20°C initially and then at -80°C prior 
to use in cDNA synthesis and q-RT-PCR.
4.2.13.2 Quantification of RNA concentration
Quantity and high quality of RNA extraction from samples are essentially required for 
reduing the variation among these samples when reverse transcription of RNA applied 
for cDNA synthesis. For this the determination of exact of RNA concentration without 
contamination is advantageous and was performed by using The NanoDrop® ND1000 
(Labtech International Ltd, UK).
The purity of RNA can be determined via the ratio of 260/280nm. The ratio of 260/280 
in close proximity to 2.0 reflects purity of nucleic acids with respect to protein or 
solvent contaminants but this is not only enough for determination of purity nucleic 
acids, therefore, estimate the absorbance of nucleic acids at 260nm relation to 230nm 
can be also used as a further indication of purity ranging between 1.8-2.0 (Gallagher, 
2007)
Method
RNA free water was used to blank The NanoDrop® ND1000, 2pl of sample was placed 
on the measurement pedestal, the measurement column was then drawn between the 
ends of two optical fibres to establish the measurement path. The measurement is 
normally finished at 5-10 seconds, and the spectrum and its analysis is shown on the 
screen of the attached PC. Once the measurement was made, the sample was wiped
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from the measurement pedestals. Between each sample measurement, 2 pi of RNA free 
water was used as a blank and to avoid any contamination between samples.
4.2.13.3 Investigation of RNA quality
An additional method used alongside the Nanodrop to examine the integrity of total 
RNA was to run an aliquot of the RNA sample on a denaturing agarose gel stained with 
ethidium bromide. RNA with high integrity is visualized as sharp, clear 28S and 18S 
rRNA bands. The 28S rRNA band should appear approximately twice as intense as the 
18S rRNA band. This 2:1 ratio (28S:18S) is considered an excellent signal 
demonstrating that the RNA has high integrity (Huggett et al, 2005; Sambrook and 
Russel, 2001).
Method
In an Eppendorf tube, 3pi of the extracted RNA sample was mixed with 5pi loading 
buffer, (Invitrogen, USA) and run on a 1.5 % agarose gel pre-stained with ethidium 
bromide (Sigma-Aldrich, UK). Using TAE as the buffer, the gel was run for 30 minutes 
at 110 v and the resulting gel was visualised on a UVP Bioimaging system using Lab 
Works 4 software (Bio-Rad, UK).
4.2.13.4 Synthesis of cDNA
Process of complementary DNA (cDNA) synthesis is called Reverse Transcription 
where high quality mRNA template is reverse transcribed into (cDNA) in vitro. 
Preparing cDNA requires mRNA, primers and the Reverse Transcriptase (RT) enzyme. 
It is advantageous to generate these cDNA samples by using random primers which can 
efficiently prime any RNA present in the sample. In addition, this type of primer can 
extend the RNA template at non-specific points and also give higher cDNA yields from 
limited mRNA. Therefore, random primers were used as a suitable method for cDNA 
synthesis. It is important that the initial RNA sample is free of genomic DNA. 
Consequently, RNA samples were mixed with gDNA wipeout buffer to remove 
contaminating genomic DNA from RNA samples. Then, the RNA template is reverse 
transcribed into cDNA by the enzyme reverse transcriptase (RT). The RT primer mix
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contains a specially optimized mixture of oligo-dT and random primers, RT elongates 
the sequence using dNTPs to produce highly accurate cDNA.
Method
cDNA synthesis was performed by using a QuantiTect ©Reverse Transcription kit, 
(Qiagen, Germany). In brief, 2pl of the gDNA wipeout buffer was mixed with template 
RNA sample and specific RNA free water to give 14pl of total volume in the first 
microcentrifuge-tube (Sigma-Aldrich, UK). Following 2min incubation at 42°C in a 
thermocycler, tubes were immediately placed on ice. In the second tube, 1 pi of reverse- 
transcription master mix, 4pl of Quantiscript RT buffer and lpl of RT Primer Mix with 
14pl of RNA template from the first tube and then incubated at 42°C for 15min in a 
thermocycler followed by 3min at 95°C to inactivate Quantiscript RT. Synthesized 
cDNA samples were stored at -20°C for RT-PCR analysis.
4.2.13.5 Selection of endogenous control reference genes
For perfect and reliable gene expression analysis, normalization of gene expression data 
against housekeeping genes (reference or internal control genes) is needed. The steps 
involved are described in chapter 3 section (3.2.1.2). However, the list of house keeping 
gene in this part were 12 human housekeeping genes (ACTB, SDHA, RPL13, ATPSB, 
EIF4A, 18S, YWHAZ, CYC1, B2M, CANX, UBC, and GADH) for THP-1 cell line 
and similarly 12 mouse housekeeping genes (B actin, P2M, GADPH, TOPI, RPL13A, 
SDHA, UBC, YWHAZ, 18S, UCB, EFI4A2 and ATP5B) for 3T3L1 cell line on 8 
samples from each cell line, at different conditions of experiments that were used in this 
study. Each reference gene was tested with each sample in duplicate.
4.2.13.6 qRT-PCR using SYBR® Green dye methodology
The same protocol was performed as previously described in chapter 3. Products 
amplified by the SYBR® Green qRT-PCR analysis for each target were validated by 
visualisation on an agarose gel with a lOObp ladder (Invitrogen, UK) for THP-1 
macrophages and 200bp ladder (Promega, UK) for 3T3L1 adipocyte cells.
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Media RPMI 1640 containg 
FBS
sodium pyruvate 
glutamine (2mM) 
penicillin/streptomycin(2mM)
DMEM containing I 
FBS
penicillin/streptomycin
(2mM)
Media differentiation RPMI 1640 + PMA DMEM + INS/IBMX/Dex
after differentiation Macrophage cells Mature adipocyte cells
Investigated
parameters
CX3CR1, CCR2, IL-1 p, IL-6, 
IL-8, TNF-a and IFNy
Adiponectin, PPARp/5, 
PAI-1, CX3CL1,CCL2 
and Leptin
Assay technique qRT-PCR and Cytometric Bead 
Array
qRT-PCR and ELISA
Table 4.1: Summary table of in vitro study. The details of cell lines, media 
composition, target genes, analysis method used in this study.
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4.2.14 Statistical Analysis
Data is presented as mean ± SEM. The statistical analysis was made by using GraphPad 
Prism 5 and StatsDirect. To determine statistical differences of relative fold 
increase/decrease in expression of target gene between untreated (control) and treated 
samples and between groups were analysed by one way, two way ANOVA or Kruskal- 
Wallis and Friedman test for parametric and nonparametric data, respectively. When 
these tests revealed significance differences between the groups, then multiple 
comparison of groups were performed. All comparisons were two tailed and p  values 
less than 0.05 were considered statistically significant.
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4.3 Results
4.3.1 Differentiation of Human THP-1 cells and Mouse 3T3L1 cells line
4.3.1.1 Human THP-1 cells
In the present study, differentiation of human monocytic cell line THP-1 in response to 
PMA stimulation at time different periods showed that PMA treatment resulted in 
remarkable phenotypic changes; according to cell adherence to the bottom of the culture 
flasks, which increased with incubation time with PMA. In addition, change to the 
irregular shape of these cells was seen from 24h incubation and this was clearer at 96h 
treatment with PMA (figure 4.1).
4.3.1.2 Mouse 3T3L1 cells
Figure 4.2 illustrates the morphological changes observed when monitoring the 
accumulation of lipid droplets in the cytoplasm where the preadipocyte 3T3-L1 cells 
start to take on adipocyte morphology. Lipid droplets, which are triglycerides, appeared 
within 4-7 days following induction of differentiation. The size of lipid droplets 
increased during the experiment period. The droplets extremely small initially and then 
fuse to form several large ones indicating that the 3T3-LI cells were efficiently 
differentiated into mature adipocytes based on the Oil Red O staining (figure 4.3).
4.3.2 qRT-PCR in THP-1 and 3T3L1
4.3.2.1 RNA extraction and cDNA synthesis
RNA was extracted for all samples and separated by agarose gel electrophoresis assay. 
The presence of two sharp bands corresponding to the two ribosomal bands 28S and 
18S rRNA subunits that reflect adequate RNA integrity was obtained for the majorty of 
samples (figure 4.4).
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Figure 4.1: Morphological changes of THP-1 cells in response to PMA. Human 
monocyte THP-1 cell line before differentiation (A) compared to post treatment with 
PMA (lOOng/ml) for 24, 48, 72, 96h (B-E respectively). Cells changes from regular, 
round cell morphology to irregular shapes over time. PMA (Phorbol 12-myristatel3- 
acetate).
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Figure 4.3: 3T3-L1 cells have differentiated into adipocytes and stained with Oil
Red O. Visualization of cells after staining for the presence of neutral lipids with Oil 
Red O.
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Figure 4.4: Agarose gel electrophoresis of RNA extracted from THP-1 
macrophages. The 18S and 28S ribosomal RNA bands are clearly visible in the intact 
RNA sample where each lane represents a separate extracted RNA sample, with perfect 
quality RNA indicated. The same results were obtained for 3T3-L1 cells (not shown).
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43.2.2 Selection of endogenous control reference gene
To select the best housekeeping gene for use as an internal control to determine the 
relative expression change in target genes, in THP-1 macrophages, 12 housekeeping 
genes (ACTB, SDHA, RPL13, ATPSB, EIF4A, 18S, YWHAZ, CYC1, B2M, CANX, 
UBC, and GAPDH) were tested on 8 samples at different treatment conditions in 
experiments using qRT-PCR. The results were calculated by utilising geNorm software 
analysis. Housekeeping genes with an M-value above 1.5 were removed. Results 
showed that ACTB was the most stable gene because it had M-value less than 1.5, 
indicating its constant stability in relative mRNA expression under different 
experimental conditions. Similarly in the mouse 3T3L1 cell line, 12 mouse 
housekeeping genes (B actin, 02M, CANX, GADPH, TOPI, RPL13A, SDHA, 
YWHAZ, 18S, UCB, EFI4A2 and ATP5B) were tested on 8 samples of 3T3L1 cells 
using qRT-PCR. Following calculation of M values for each housekeeping gene 
demonstrated that CANX was the most stable housekeeping gene which had a M value 
less than 1.5.
4.3.2.3 Primer efficiencies and validation of primer targets
Determination of primer efficiency for target genes and reference gene in these cells 
was undertaken to validate the constant amplification of each PCR product at two 
cycles each time. In THP-1 macrophages the target and reference genes have similar 
and nearly 100% efficiencies in the range (93%-110%) as shown in table 4.2A and 
figure 4.5. Therefore, the 2'AAct (Livak) method was used to determine the relative 
difference in expression level of target gene in different samples compared to the 
internal control, reference gene. In contrast, the Pfaffl method was used in the 3T3L1 
cell line to determine the relative expression of the target gene in different samples 
because amplification efficiencies of target and reference genes were not in an 
acceptable range of ideal amplification efficiencies as shown in table 4.2B and figure
4.6. Data from the two cell lines was compared to control data, which was normalized 
to a value of 1. Primer products from qRT-PCR revealed a single product and expected 
sizes when analysed by agarose gel electrophoresis. Figures 4.7 and 4.8 show the 
expression of target genes AR, CD14, CX3CR1, CCR2 and ACTB, in human THP-1 
macrophages, whereas figures 4.9 and 4.10 show target genes AR and adiponectin, 
PPARp/8, leptin, PAI-1, CX3CL1 and CCL2 respectively in mouse 3T3L1 cells.
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AACTB 1.968 96.84
CX3CR1 1.941 94.08
CCR2 1.931 93.04
CD14 2.102 110.18
B
CANX 2.4 142.00
Adiponectin 2.1 115.00
PAI-1 2.346 134.00
PPARp/5 2.2 121.00
Leptin 2.276 127.59
CX3CL1 2.29 128.976
CCL2 2.054 105.35
Table 4.2: Primer efficiencies of PCR amplification in THP-1 macrophages and 
3T3L1 cells. Determination of primer efficiency percentage for target genes and 
reference gene in THP-1 macrophages (A) and 3T3L1 cells (B) using the formula, E =
jQ (-l/slope) _ |
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ACTB
Cj  2 0
0 1 2 3 4
CX3CR1
e  20
o 41 2 3
Log Dilution Factor Log Dilution Factor
CD 14
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C 20
0 1 2 3 4
y = -3.3x + 31.8 
—R*j^0M 66CCR2
C 20
0 2 4
Log Dilution Factor Log Dilution Factor
Figure 4.5: Standard-curve plot for calculation of primer efficiency genes in THP- 
1 macrophages. The efficiency of amplification of target genes and internal control 
(ACTB) was determined using real-time PCR and SYBR Green detection. The Ct 
values for each dilution were used to calculate the slope of the line representing the log 
of their amplification efficiencies. An ideal slope should be -3.32 for 100% PCR 
efficiency.
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CANX
y = -2.6x + 27.9 
R2 = 0.9941 Adiponectin
= -3.0x + 34.0 
R2 = 0.973
2
Log Dilution Factor
0 2
Log Dilution Factor
PAI-1 y = -2.7x + 29.3 R2 = 0.9918
Log Dilution Factor
PPARp/5 y = -2.9x + 29.5 R2 = 0.9842
Log Dilution Factor
Leptin -2.8x + 27.2 R2 -  0.98
Log Dilution Factor
CX3CL140 
30 
u  20 
10 
0
y = -2.77x + 27.0 
R2 -  0.997
Log Dilution Factor
CCL2 y = -3.2x + 30.7 R2 = 0.9731
Log Dilution Factor
Figure 4.6: Standard-curve plot for calculation of primer efficiency genes in 3T3L1 
cells. The efficiency of amplification of target genes and internal control (CANX) was 
determined using real-time PCR and SYBR Green detection. The Ct values for each 
dilution were used to calculate the slope of the line representing the log of their 
amplification efficiencies. An ideal slope should be -3.32 for 100% PCR efficiency.
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Figure 4.7: Agarose gel electrophoresis for PCR product amplification in human 
THP-1 macrophages. Androgen receptor (AR) mRNA was expressed from 24h to 96h 
while CD 14 mRNA was observed following 48h treatment with PMA (lOOng/ml).
Figure 4.8: Agarose gel electrophoresis showing RT-PCR amplification for primer 
product in human THP-1 macrophages. Single shaip bands indicate a single 
detectable product for all target genes. L- Ladder, lane - 1 CX3CR1, lane - 2 CCR2, 
and lanes 3-5 ACTB.
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Figure 4.9: Agarose gel electrophoresis showing RT-PCR amplification for primer 
for androgen receptors in 3T3L1 cell line. Single and sharp bands indicate single 
detectable product for AR gene. L-ladder, lanes-1 and 2 AR in preadipocytes, lanes-3 
and 4 AR in mature adipocyte cells.
500bp—
200bp—
Figure 4.10: Agarose gel electrophoresis showing RT-PCR amplification for 
primer product in 3T3L1 cell line. Single sharp bands indicate single detectable 
product for all target genes. L-ladder, lane-1 CCL2, lane-2 CX3CL1, lane-3 
adiponectin, lane-4 PPARp/5, lane-5 leptin and lane-6 PAI-1.
4.3.3 Analysis of CX3CR1 and CCR2 mRNA expression in human 
THP-1 macrophages by qRT-PCR
4.3.3.1 Analysis of CX3CR1 and CCR2 mRNA expression in THP-1 macrophages 
following testosterone treatment, with or without flutamide
At low testosterone concentrations, no significant change was observed in mRNA 
expression of CX3CR1 following testosterone treatment at lOnM concentration, even 
though there was a trend to a decrease in expression after 24 and 72h compared to 
untreated control samples. This effect was reversed, but not significantly by flutamide at 
lOOnM particularly following 24 to 72h (figure 4.1 la). Conversely, there was a trend to 
increase mRNA expression of CCR2 following the same concentration of testosterone 
treatment. This effect was reversed, but not significantly with flutamide from 24 to 96h 
at a concentration of lOOnM as shown in figure 4.12a.
At high testosterone concentration and compared to untreated control samples, no 
significant alteration was seen in mRNA expression of both receptors CX3CR1 (figure 
4.11b) and CCR2 (figure 4.12b) from 24 to 96h following 100 of testosterone treatment 
with or without flutamide at concentrations of lOOOnM, respectively.
4.3.3.2 Analysis of CX3CR1 mRNA expression in THP-1 macrophages following 
24h cytokines and testosterone treatment, with or without flutamide
As shown in figure (4.13 a, b), incubation of THP-1 macrophages with TNFa plus IFNy 
treatment at lOng/ml resulted in a decrease, although not significant, in mRNA 
expression of CX3CR1 after 24h compared to untreated control cells. However, the 
addition of testosterone treatment at 10 or lOOnM had no effect on mRNA CX3CR1 
expression in THP-1 macrophages treated with lOng/ml TNFa plus IFNy stimulation for 
24h (4.13a, b). A significant difference was seen in mRNA expression of CX3CR1 
(p<0.05) after co-treatment with lOOOnM flutamide (figure 4.13b).
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CX3CR1
Con 24
T10
T10+F100
Hours
CX3CR1
Hours
■ T100
■  T100+F1000
Figure 4.11: CX3CR1 mRNA expression in THP-1 macrophages following testosterone 
treatment, with or without flutamide from 24 to 96h by qRT-PCR. Results shown as 
mean±SEM from three separate experiments. Con=control, (A) T10=Testosterone lOnM, 
F100=Flutamide lOOnM, (B) T100=TestosteronelOOnM, F1000=Flutamide lOOOnM. Two way 
ANOVA.
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72 96
■ T10
■ T10+F100
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■ T100
■ T100+F1000
Con 24 48 72 96
Hours
Figure 4.12: CCR2 mRNA expression in THP-1 macrophages following testosterone 
treatment, with or without flutamide from 24 to 96h by qRT-PCR. Results shown as 
mean±SEM from three separate experiments. Con= control, (A) T10=Testosterone lOnM, 
F100=Flutamide lOOnM, (B) T100=Testosterone lOOnM, F1000=Flutamide lOOOnM. Two way 
ANOVA.
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A CX3CR1
2.5
-  1-5Ua
0.5
Con CIO C10+T10 C10+T10+F100
CX3CR1
I
Con CIO C10+T100 C10+T100+F1000
Figure 4.13: CX3CR1 mRNA expression in THP-1 macrophages following 24h cytokine 
and testosterone treatment, with or without flutamide by qRT-PCR. Results are shown as 
mean±SEM from three separate experiments. Con=control, C10=cytokine (TNF-a+IFN-y) 
lOng/ml, (A) T10=testosterone lOnM, F100=flutamide lOOnM, (B) T100=testosterone lOOnM, 
F1000=flutamide lOOOnM.##P<0.01 vs CIO, QP<0.05 vs C10+T100. Kruskal-Wallis.
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In addition, as shown in figure (4.14 a, b), stimulation of THP-1 macrophages for 24h 
with TNFa plus IFNy treatment at lOOng/ml led to reduced, but not significantly, 
expression of CX3CR1 mRNA compared to untreated control cells. Although not 
statistically significant, lOnM testosterone decreased expression of CX3CR1 mRNA 
following stimulation with lOOng/ml TNFa plus IFNy compared to cells treated with 
cytokines alone. This reduction was significantly abolished by flutamide at lOOnM 
(P<0.05) (4.14a). In contrast, lOOnM testosterone increased, but not significantly, 
expression of CX3CR1 mRNA, an effect that was not altered by blocking the AR with 
lOOOnM flutamide (figure 4.14b).
4.3.3.3 Analysis of CCR2 mRNA expression in THP-1 macrophages following 24h 
cytokine and testosterone treatment, with or without flutamide
There was a trend towards a decrease in expression of CCR2 mRNA following 
incubation of THP-1 macrophages for 24h with cytokines treatment at lOng/ml 
compared to untreated control cells (P=0.06). Conversely, the combination of 24h 
cytokine treatment at lOng/ml and testosterone treatment at lOnM or lOOnM with cells 
tended to increase expression of mRNA for CCR2 (P=0.08 and P=0.06 respectively) 
compared to cells stimulated with cytokines at lOng/ml (figure 4.15 a, b). No significant 
effect was seen after flutamide treatment at 100 or lOOOnM.
In addition, 24h cytokine treatment at lOOng/ml significantly down regulated expression 
of CCR2 mRNA compared to untreated control cells (p<0.01) (4.16 a, b). However, 
lOnM testosterone treatment significantly increased expression of CCR2 mRNA 
following stimulation with lOOng/ml cytokines compared to cells treated with cytokine 
treatment alone (p<0.001). This increase was significantly and partly reduced by co­
treatment with lOOnM flutamide (4.16a). Moreover, combination of testosterone 
treatment at lOOnM with lOOng/ml TNF-a plus IFNy for 24h significant increased 
(p<0.01) CCR2 mRNA expression compared to cells treated with cytokine treatment 
alone. This increase in expression of CCR2 mRNA was not altered by lOOOnM 
flutamide (figure 4. 16b).
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Con C100 C100+T10 CIOO+TIO+FIOO
B CX3CR1
2.5
2
Con ClOO CIOO+TIOO CIOO+TIOO+FIOOO
Figure 4.14: CX3CR1 mRNA expression in THP-1 macrophages following 24h cytokine 
and testosterone treatment, with or without flutamide by qRT-PCR. Results shown as 
mean±SEM from three separate experiments. Con=control, C100=cytokine (TNF-a+IFN-y) 
lOOng/ml, (A) T10=testosterone lOnM, F100=flutamide lOOnM, (B) T100=testosterone lOOnM, 
F1000=flutamide lOOOnM. °P<0.05 vs C100+T10, Kruskal-Wallis.
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Con CIO C10+T100 CIO+TIOO+FIOOO
Figure 4.15: CCR2 mRNA expression in THP-1 macrophages following 24h cytokine and 
testosterone treatment, with or without flutamide by qRT-PCR. Results shown as 
mean±SEM from three separate experiments. Con=control, C10=cytokine (TNF-a+IFN-y) 
lOng/ml, (A) T10=testosterone lOnM, F100=flutamide lOOnM, (B) T100=testosterone lOOnM, 
F1000=flutamide lOOOnM. IUi?<0.0\ vs CIO. Kruskal-Wallis.
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Figure 4.16: CCR2 mRNA expression in THP-1 macrophages following 24h cytokine and 
testosterone treatment, with or without flutamide by qRT-PCR. Results shown as 
mean±SEM from three separate experiments. (Con=control, C100=cytokine (TNF-a+IFN-y) 
lOOng/ml, T10=testosterone lOnM, F100=flutamide lOOnM, T100=testosterone lOOnM, 
F1000=flutamide lOOOnM. **P<0.01 vs Con, ><0.01, #><0.001 vs C100, QDP<0.01vs 
C100+T10, Kruskal-Wallis.
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4.3.4 Investigation of pro and anti- inflammatory secretion by human 
THP-1 macrophages measured by CBA
There was high variability in the results of the CBA analysis. For IL-lp, IL-6, IL-10, 
TNF-a and IFN-y the results were not reliable due to high coefficients of variation in the 
supernatant of THP-1 macrophages. IL-8 was the only analyte determined by this 
method in the supernatant of the unstimulated cells. This is probably due to very low 
levels of the other cytokines, with higher levels of IL-8 detected. In addition, TNF-a 
and IL-8 were detected reliably following incubation with 24hr cytokines and 
testosterone treatment, with or without AR blocked, again this is due to the higher levels 
of these analytes on stimulating the cells with cytokines, compared to the other analytes.
4.3.4.1 Analysis of IL-8 levels in supernatants of THP-1 macrophages following 
testosterone treatment, with or without flutamide
At the low concentration of testosterone (lOnM), there was generally a trend to decrease 
IL-8 levels from 24 to 48h but this was not significant. Furthermore, there was a large 
increase but not significant in IL-8 after incubation with testosterone for 96h compared 
to untreated control cells. This may be due to high levels of variability or small number 
of samples. An effect that was reversed by flutamide at lOOnM but this effect was not 
significant as shown in (figure 4.17a).
Testosterone treatment (lOOnM) with or without flutamide (lOOOnM) had no significant 
effect on levels of IL-8 from 24 to 96h, compared with untreated control cells (figure 
4.17b).
4.3.4.2 Analysis of IL-8 levels in supernatants of THP-1 macrophages following 
24h cytokine and testosterone treatment, with or without flutamide
As shown in figures 4.18 a, b cytokine treatment at lOng/ml led to a significant increase 
in the production of IL-8 (P<0.01) compared to untreated cells. In contrast, testosterone 
treatment at lOnM or lOOnM reduced significantly levels of IL-8 (P<0.05) in cells 
stimulated with cytokines for 24h. However, this reduction did not approach the levels 
secreted from untreated control cells. The effect was significantly abrogated by 
flutamide at lOOnM (PO.05) and at lOOOnM (P<0.05) compared to cells treated with
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Figure 4.17: CBA analysis of IL-8 level in supernatant of THP-1 macrophages following 
testosterone treatment, with or without flutamide from 24 to 96h. Results shown as 
mean±SEM from three separate experiments Con=control, (A) T10=Testosterone10nM, 
F100=Flutamide lOOnM, (B) T100=Testosterone lOOnM, F1000=Flutamide lOOOnM. Kruskal 
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Figure 4.18: CBA analysis of IL-8 levels in supernatant of THP-1 macrophages following 
24h cytokine and testosterone treatment, with or without flutamide. Results from three 
separate experiments shown as mean±SEM. Con=control, C10=cytokinel0ng/ml (TNFa+IFN- 
y), (A) T10=Testosterone lOnM, F100=Flutamide lOOnM, (B) T100=Testosterone lOOnM, 
F1000=Flutamide lOOOnM. **P<0.01 vs Con, # P<0.05 vs CIO, D P<0.05 vs C10+T10, Kruskal 
Wallis.
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combination of lOng/ml cytokine and testosterone treatment at 10 and 100 nM, 
respectively. Furthermore, cytokine treatment at lOOng/ml significantly increased IL-8 
levels (P<0.001) (figure 4.19 a, b) compared to the untreated control. However, 24h 
cytokine and testosterone treatment at lOnM significantly reduced (P<0.001) IL-8 levels 
compared to cells treated with cytokine alone (figure 4.19a). Blocked AR with 
flutamide at 100 nM prevented the decrease in IL-8 levels as a result of lOnM 
testosterone treatment (p<0.01). This increase in IL-8 level due to flutamide was 
significantly (P<0.05) lower than its level in media of cells treated with lOOng/ml 
cytokine alone (figure 4.19a). In addition, testosterone treatment at lOOng/ml plus 
lOOng/ml cytokines for 24h down-regulated production of IL-8 compared to cells 
treated with lOOng/ml cytokines alone (P<0.01) (figure 4.19b). Blocked AR with 
flutamide at lOOOnM prevented significantly (P<0.01) the reduction in IL-8 levels as a 
result of testosterone treatment (lOOnM).
4.3.4.3 Analysis of TNF-a level in supernatants of THP-1 macrophages following 
24h cytokines and testosterone treatment, with and without flutamide
TNF-a was not detectable in supernatants of unstimulated THP-1 macrophages controls 
in all experimental conditions. However, 24h cytokine treatment at lOng/ml increased 
markedly levels of TNF-a (P<0.01) compared to untreated cells. lOng/ml cytokines plus 
10 or lOOnM testosterone treatment was associated with a significant reduction in level 
of TNF-a (P<0.01) compared to cells treated with cytokine alone. However, 
testosterone treatment reversed the stimulatory effect of cytokine treatment and reduced 
TNF-a to levels which were not significantly different from untreated controls (figure 
4.20 a, b). No effect on levels of TNFa were seen after flutamide treatment at 100 
compared to cells treated with lOnM of testosterone (figure 4.20a). Conversely, 
blocking the AR by flutamide at lOOOnM significantly (P<0.05) reversed the reduction 
in TNFa level due to 100 nM testosterone treatment (figure 4.20b).
100 ng/ml cytokine treatment for 24h significantly increased concentrations of TNF-a in 
the media of THP-1 macrophages (P<0.01) compared to untreated cells (figure 4.21a, b). 
This increase was significantly abrogated with testosterone treatment at 10 or lOOnM 
(P<0.05) compared to cells treated with cytokine alone. Flutamide at lOOnM did not 
prevent the decline in TNF due to lOnM testosterone treatment (figure 4.21a) while this 
decrease was almost significant (P=0.06) and partly reversed by flutamide at 1000 nM 
(figure 4.21b).
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Figure 4.19: CBA analysis of IL-8 levels in supernatants of THP-1 macrophages following 
24h cytokine and testosterone treatment, with or without flutamide. Results shown as 
mean±SEM from three separate experiments. Con=control, C100=cytokine 100 ng/ml 
(TNFa+IFN-y), (A) T10=Testosterone 10 nM, F100=Flutamide 100 nM, (B) T100=Testosterone 
100 nM, F1000=Flutamide 1000 nM. **P<0.01, ***P<0.001vs Con, #P<0.05, ##P<0.01 vs C100, 
anP<0.01 vs C100+T10 or C100+T100, Kruskal-Wallis.
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Figure 4.20: CBA analysis of TNF-a levels in supernatants of THP-1 macrophages 
following 24h cytokine and testosterone treatment, with or without flutamide. Results 
shown as mean±SEM from three separate experiments. Con=control, C10=Cytokine 
(TNFa+IFN-y) lOng/ml (A) T10=Testosterone lOnM, F100=Flutamide lOOnM, (B) 
T100=Testosterone 1 OOnM, F1000=Flutamide lOOOnM, **P>0.01vs Con, ##P>0.01 vs CIO, a 
P<0.05 vs C10+T100, Kruskal-Wallis.
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Figure 4.21: CBA analysis of TNF-a levels in supernatants of THP-1 macrophages 
following 24h cytokine and testosterone treatment, with or without flutamide. Results 
shown as mean±SEM from three separate experiments. Con=control, C100=Cytokine 
(TNFa+IFN-y) 100 ng/ml, (A) T10=Testosteronel0 nM, F100=FlutamidelOOnM, (B) 
TlOO^TestosteronelOO nM, F1000=Flutamide lOOOnM. **P>0.01vs Con, #P>0.05 vs C100, 
Kruskal-Wallis.
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mRNA expression CX3CR1 NC NC
CCR2 NC NC
protein level IL-8 NC NC
Table 4.3: Summary of results of effect of testosterone on chemokines receptors 
expression and level of IL-8 in human THP1 macrophages cells. NC=no change.
mRNA expression CX3CR1 NC NC NC NC
CCR2 NC +*** NC
protein level IL-8 I*  ^*** I**
TNF-a I** I** 1* i*
Table 4.4: Summary of results of effect of testosterone on chemokines receptors 
expression, level of IL-8 and TNF-a following cytokines stimulation in human 
THP1 macrophages cells. T: testosterone, C: cytokines, NC=no change.AEC. (t): 
increase, (j): decrease, *P<0.05, **P<0.01, ***P<0.001.
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4.3.5 Analysis of expression of adipokines and inflammatory factors in 
mouse 3T3L1 cells by q-RT-PCR
4.3.5.1 Analysis of adiponectin mRNA expression in 3T3L1 cells following 
testosterone treatment, with or without flutamide
No significant change was seen in mRNA expression of adiponectin in adipocyte cells 
treated with low or high testosterone, with or without flutamide over time up to 9 days 
compared to untreated preadipocytes or mature adipocyte control cells as shown in 
figures 4.22a, b.
4.3.5.2 Analysis of PAI-1 mRNA expression in 3T3L1 cells following testosterone 
treatment with or without flutamide
In figure 4.23a after 3 days, there was an non-significant increase in expression of PAI- 
lmRNA in untreated mature adipocyte cells compared to untreated preadipocyte cells. 
PAI-1 mRNA expression following testosterone at 10 nM decreased but not significant 
(p=0.06) compared to untreated preadipocyte cells and non-significant change was seen 
compared to untreated mature adipocyte cells after 3 days. No significant difference 
between the effect of flutamide at lOOnM and testosterone at lOnM on the expression of 
mRNA PAI-1 was seen. Following 5 days, a significant (P=0.01) reduction was seen in 
expression of mRNA PAI-1 in untreated adipocytes compared to untreated preadipocyte 
cells. Testosterone at lOnM significantly increased (p<0.01) PAI-1 mRNA expression 
compared to untreated mature adipocyte cells; an effect which was significantly 
(p<0.01) abrogated by lOOnM flutamide. After 9 days, decrease in PAI-1 mRNA 
expression (p=0.05) was observed in untreated mature adipocyte cells compared to 
untreated preadipocyte cells. No significant change in expression of PAI-1 mRNA was 
seen in cells treated with testosterone (lOnM), with or without flutamide (lOOnM) 
compared to both untreated control cells.
In figure 4.23b, there was no significant change in expression of PAI-1 mRNA in 
untreated mature adipocyte cells compared to undifferentiated cells or in cells treated 
with testosterone (lOOnM), with or without flutamide (lOOOnM) compared to both 
untreated cells after 3 and 9 days. However, there was a significant reduction in 
expression of PAI-1 mRNA after 5 days in untreated mature adipocyte cells (p<0.01) 
and in cells treated with testosterone (p<0.05), with or without flutamide (p<0.05),
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Figure 4.22: Adiponectin mRNA expression in 3T3L1 cell following testosterone 
treatment, with or without flutamide from 3 to 9 days by qRT-PCR. Results shown as 
mean±SEM from three separate experiments. (A) T10=testosterone lOnM, F100=Flutamide 
lOOnM, (B) TIOCMestosterone lOOnM, F1000=Flutamide lOOOnM. Friedman test.
|  Con l=untreated preadipocyte 
[ Con2=untreated mature adipocyte 
|  Mature adipocytes treated with testosterone
Mature adipocytes treated with testosterone and flutamide
3 5 9
Days
196
A
3
2.5
2
t;
9  1.5rsi
1
0.5
0
PAI-1
1 HH
** **## **_
l C onl 
Con2 
IT10
T10+F100
5
Days
B PAI-1
3
2.5
2
■ C on l
■  T100+F1000
Days
Figure 4.23: PAI-1 mRNA expression in 3T3L1 cell following testosterone treatment, with 
or without flutamide from 3 to 9 days by qRT-PCR. Results shown as mean±SEM from 
three separate experiments. (A) T10=testosterone lOnM, F100=Flutamide lOOnM, (B) 
T100=testosterone lOOnM, F1000=Flutamide lOOOnM. *P<0.05, ** P<0.01, *** p<0.0001vs 
Conl. m PO.Olvs Con2,DDP< 0.01 T10 vs T10+F100 or T100, Friedman test.
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compared to only untreated preadipocyte cells; however the changes in expression level 
were small.
4.3.5.3 Analysis of PPARp/5 mRNA expression in 3T3L1 cells following 
testosterone treatment, with or without flutamide
No significant alteration was observed in expression of PPARp/8 mRNA in untreated 
mature adipocyte cells and cells treated with testosterone, with or without flutamide at 
low and high concentrations compared to untreated preadipocyte cell controls as a result 
of time or treatment (figures 4.24a, b).
4.3.5.4 Analysis of leptin mRNA expression in 3T3L1 cells following testosterone 
treatment, with or without flutamide
After 3 days, a significant decrease was seen in expression of leptin mRNA (p<0.001) 
in untreated mature adipocyte cells compared to untreated preadipocyte cells (figure 
4.25a). Similarly, there was a significant reduction in leptin mRNA expression 
following testosterone treatment at 10 nM (p<0.05) compared to untreated preadipocyte 
cells, but not untreated mature adipocyte cells. Following 5 days, no significant change 
was observed in expression of leptin mRNA in untreated adipocyte cells compared to 
untreated preadipocyte cells. While testosterone treatment at lOnM significantly 
reduced leptin mRNA expression (p<0.01) in mature adipocyte cells compared to 
untreated preadipocyte cells, testosterone tended to reduce mRNA leptin expression 
(p=0.06) in mature adipocyte cells compared to untreated mature adipocyte cells. At 9 
days, there was a significant reduction in expression of leptin mRNA in untreated 
mature adipocyte cells (p<0.01) compared to untreated preadipocyte cells. Testosterone 
significantly decreased leptin mRNA expression (p<0.01) in mature adipocyte cells 
compared to untreated preadipocyte cells but not untreated mature adipocyte cells. 
Finally, there was no significant difference between the effect of flutamide at lOOnM 
and testosterone at lOnM on the expression of mRNA leptin in treated cells over all 
time points.
As shown in figure (4.25b), a significant decrease was seen in expression of leptin 
mRNA in untreated mature adipocyte cells at 3 days (p<0.001) compared to untreated 
preadipocyte cells. Similarly, significant reduction was observed in cells treated with 
lOOnM testosterone at 3 days (p<0.01) compared to untreated preadipocyte cells but not
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Figure 4.24: PPARp/5 mRNA expression in 3T3L1 cells following testosterone treatmen, 
with or without flutamide, from 3 to 9 days by qRT-PCR. Results shown as mean±SEM 
from three separate experiments. (A) T10=testosterone lOnM, F100=Flutamide lOOnM, (B) 
T100=testosterone lOOnM, F1000=Flutamide lOOOnM. *P<0.05 vs Conl. Friedman test.
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Figure 4.25: Leptin mRNA expression in 3T3L1 cell following testosterone treatment, with 
or without flutamide, from 3 to 9 days by qRT-PCR. Results shown as mean±SEM from 
three separate experiments. (A) T10=testosterone lOnM, F100=Flutamide lOOnM, (B) 
T100=testosterone lOOnM, F1000=Flutamide lOOOnM *P<0.05, ** P<0.01, *** PO.OOOlvs 
Conl, Friedman test.
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to untreated adipocyte cells. At 5 days, no significant alteration was seen in expression 
of mRNA leptin in untreated adipocyte cells compared to untreated preadipocyte cells. 
Testosterone at lOOnM tended to reduce (p=0.08) expression of leptin mRNA in mature 
adipocyte cells compared to untreated adipocyte cells. Following 9 days, a significant 
reduction was observed in expression of leptin mRNA in untreated adipocyte cells 
(p<0.01) and in cells treated with testosterone at lOOnM compared to untreated 
preadipocyte cells. There was no significant change between cells treated with 
testosterone and untreated adipocyte cells. Flutamide at 1000 nM did not alter the action 
of testosterone at 100 nM in the expression of leptin mRNA over all time points.
4.3.5.5 Analysis of CX3CL1 mRNA expression in 3T3L1 cells following 
testosterone treatment, with or without flutamide
Testosterone treatment at lOnM, with or without AR blocked at lOOnM, had no effect 
on expression of CX3CL1 mRNA in mature adipocyte cells compared to both untreated 
control cells after three and five days (figure 4.26a). While no difference in expression 
of CX3CL1 mRNA was seen between untreated preadipocyte cells and untreated 
mature adipocyte cells after 3days, there was a trend to slightly decrease (p=0.05) the 
expression of CX3CL1 mRNA in untreated mature adipocyte cells compared to 
untreated preadipocyte cells after 5 days. However, there was a non-significant increase 
in expression of CX3CL1 mRNA in untreated mature adipocyte cells and cells treated 
with testosterone at lOnM compared to untreated preadipocyte cells following 9 days. 
Testosterone increased (but not significantly) CX3CL1 mRNA expression in mature 
adipocyte cells compared to untreated adipocyte cells. This might be as result of high 
variability among data. Flutamide at 10 nM did not prevent this alteration.
In figure (4.26b), there was a slight but significant decrease in mRNA CX3CL1 
expression in untreated adipocyte compared to untreated preadipocyte cells after 
three(p<0.05) and five (p<0.01) days. Conversely, after 9 days, there was increase (but 
not significant) in mRNA leptin expression in untreated adipocyte compared to 
untreated preadipocyte cells. Testosterone at lOOnM, with or without flutamide at 
lOOOnM had no effect on CX3CL1 mRNA expression compared to untreated control 
cells after 3 and 5 days. At 9 days, an increase in expression of CX3CL1 mRNA due to 
testosterone treatment (lOOnM) was seen but this was not significant compared to 
untreated preadipocyte cells. Flutamide at lOOOnM abrogated, (but not significantly) 
this increase.
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Figure 4.26: CX3CL1 mRNA expression in 3T3L1 cell following testosterone treatment,
with or without flutamide from 3 to 9 days by qRT-PCR. Results shown as mean±SEM from
three separate experiments. (A) T10=testosterone lOnM, F100=Flutamide lOOnM, (B)
T10O=testosterone lOOnM, F1000=Flutamide. *P<0.05, ** PO.Ol, vs Conl. # P<0.05 vs
Con2. Friedman test.
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4.3.5.6 Analysis of CCL2 mRNA expression in 3T3L1 cells following testosterone 
treatment with or without flutamide
CCL2 mRNA expression was not changed in untreated mature adipocytes compared to 
untreated preadipocyte cells and in treated cells with testosterone compared to untreated 
mature adipocytes at 3 days (figure 4.27a). However, at 5 days, a significant reduction 
in CCL2 mRNA expression was seen in untreated mature adipocyte cells (p<0.01) 
compared to untreated preadipocyte cells. There was not significant change in CCL2 
mRNA expression in cells treated with testosterone compared to untreated mature 
adipocytes. After 9 days, no significant alteration was seen in mRNA expression of 
CCL2 in untreated mature adipocyte cells compared to untreated preadipocyte cells. 
There was trend to decrease mRNA expression of CCL2 in treated cells with 
testosterone compared to untreated mature adipocyte cells. Flutamide at 100 nM did not 
alter the action of testosterone at 10 nM on the expression of mRNA CCL2 over all time 
points.
In figure (4.27b), no significant alteration in expression of mRNA CCL2 expression in 
untreated mature adipocyte cells compared to untreated preadipocyte cells as well as in 
treated cells with testosterone treatment (lOOnM) compared to untreated mature 
adipocyte cells after 3 days. In contrast, there was considerable reduction in expression 
of CCL2 mRNA in untreated mature adipocyte (p<0.01) and in cells treated with 
testosterone (p<0.05) compared to untreated preadipocyte cells over 5 days. However, 
there was no significant change in mRNA CCL2 expression in treated cells with 
testosterone compared to untreated mature adipocyte. Following 9 days, expression of 
CCL2 mRNA increased but this was not significant in untreated mature adipocyte cells 
compared to untreated preadipocyte cells. There was a non-significant reduction in the 
expression of CCL2 mRNA in cells treated with testosterone (lOOnM) compared to both 
untreated mature adipocyte cells. Flutamide at 1000 nM did not alter the action of 
testosterone at 100 nM on the expression of CCL2 mRNA over all time points.
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Figure 4.27: CCL2 mRNA expression in 3T3L1 cell following testosterone treatment, with 
or without flutamide from 3 to 9 by qRT-PCR. Results shown as mean±SEM from three 
separate experiments. (A) T10=testosterone lOnM, F100=Flutamide lOOnM, (B) 
T100=testosterone lOOnM, F1000=Flutamide lOOOnM. *P<0.05, ** P<0.01, vs Conl. Friedman 
test.
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4.3.6 Analysis of adiponectin, CX3CL1 and CCL2 by ELISA in 
supernatants of adipocyte 3T3L1 cells
4.3.6.1 Analysis of adiponectin levels in supernatants of adipocyte 3T3L1 cells 
following testosterone treatment, with or without flutamide
There was no significant change in the level of adiponectin in media from cells treated 
with testosterone (10 or lOOnM) or after blocking the AR by flutamide (100 or lOOOnM) 
compared to untreated mature adipocyte control following 3, 5 and 9 days (figure 4.28a, 
b). There were significant differences in the adiponectin levels in media from cells 
treated with flutamide compared to those treated with testosterone after 9 days at both 
concentrations, however as there was no difference between the controls and the 
testosterone treated cells in adiponectin secretion, this finding is unlikely to be of 
biological significance.
4.3.6.2 Analysis of CX3CL1 levels in supernatants of adipocyte 3T3L1 cells 
following testosterone treatment, with or without flutamide
There was a significant reduction in the level of CX3CL1 in the media of cells treated 
with testosterone (lOnM) (p<0.05) after 3days compared to untreated mature adipocyte 
cells. Flutamide (lOnM) did not prevent this reduction. After 5 days, no significant 
change in CX3CL1 secretion in cells treated with testosterone, with and without 
flutamide (lOOnM). A significant decrease was seen in CX3CL1 secretion from cells 
treated with testosterone (lOnM) compared to untreated mature adipocyte cells after 9 
days. There was a significant difference in CX3CL1 secretion between cells treated with 
testosterone and flutamide (p=0.01) (figure 4.29a). The reduction due to flutamide was 
significantly higher than the reduction due to testosterone treatment which is unlikely to 
be of biological significance. No alteration was observed in CX3CL1 secretion in cells 
treated with lOOnM testosterone, with or without lOOOnM flutamide after 3 and 5 days 
compared to untreated mature adipocyte cell (figure 4.29b). Nevertheless, the level of 
CX3CL1 in media of cells was reduced by testosterone (but not significantly) and 
flutamide at lOOOnM did not prevent this reduction after 9 days.
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Figure 4.28: ELISA analysis of adiponectin levels in supernatants of 3T3L1 adipocytes 
following testosterone treatment, with or without flutamide from 3 to 9 days. Results 
shown as mean±SEM from three separate experiments. (A) T10=testosterone lOnM, 
F100=Flutamide lOOnM, (B) T100=testosterone lOOnM, F1000=Flutamide lOOOnM. °P <0.05 
T10 vs T10+F100 or T100 vs T100+F1000, Friedman test.
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Figure 4.29: ELISA analysis of CX3CL1 level in supernatant of 3T3L1 adipocyte following 
testosterone treatment, with or without flutamide from 3 to 9 days. Results shown as 
mean±SEM from three separate experiments. (A) T10=testosteronel0nM, 
F100=flutamidelOOnM, (B) T100=testosteronelOOnM, F1000=Flutamide lOOOnM. *P<0.05 vs 
Con, ><0.01 T10 vs T10+F100, Two way ANOVA.
Con ^untreated mature adipocyte 
|  Mature adipocytes treated with testosterone
Mature adipocytes treated with testosterone and flutamide
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4.3.6.3 Analysis of CCL2 levels in supernatants of adipocyte 3T3L1 cells following 
testosterone treatment, with or without flutamide
After 3 days, a slight but significant reduction in the level of CCL2 (p<0.05) was 
observed in cells treated with testosterone treatment at lOnM compared to untreated 
mature adipocyte cells, an effect which was markedly (p<0.001) abrogated by flutamide 
at (lOOnM). In contrast, production of CCL2 was significantly elevated after 
testosterone at lOnM (p<0.01) following 5 days, an effect that was significantly 
reversed by flutamide at lOOnM. Similarly after 9 days, testosterone significantly raised 
levels of CCL2 in the media of adipocyte cells; an effect that was markedly abolished 
by flutamide at lOOnM (p<0.001) (figure 4.30a).
However, no change was seen in levels of CCL2 in media of cells treated with lOOnM 
testosterone, with or without lOOOnM flutamide, compared to untreated mature 
adipocyte cells following 3 and 5 days (figure 4.30b). Conversely, the production of 
CCL2 in media of cells increased, but not significantly following testosterone at lOOnM 
treatment compared to untreated mature adipocyte cells after 9 days. This increase was 
reversed significantly by blocking the AR by flutamide at lOOOnM (p<0.05).
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Figure 4.30: ELISA analysis of CCL2 levels in supernatants of 3T3L1 adipocytes following 
testosterone treatment, with or without flutamide, from 3 to 9 days. Results shown as 
mean±SEM from three separate experiments. (A) T10=testosterone 1 OnM, 
F100=flutamidelOOnM, (B) T100=testosterone lOOnM, F1000=Flutamide lOOOnM. * P<0.05, 
** P<0.01, vs Con, # P<0.05, T100 vs T100+F1000, m P<0.01, *##P<0.001 T10 vs T10+F100, 
Friedman test.
Con =untreated mature adipocyte 
^  Mature adipocytes treated with testosterone
Mature adipocytes treated with testosterone and flutamide
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mRNA
expression
Adiponectin NC NC
PPARp/5 NC NC
PAI-1 Increased at 5 days NC
Leptin NC NC
CX3CL1 NC NC
CCL2 NC NC
protein level 
in
supernatant
Adiponectin NC NC
CX3CL1 Decreased at 3 and 9 days NC
CCL2
Decreased at 3 days and 
Increased at 5 and 9 days NC
Table 4.5: Summary of results of effect of testosterone on expression of gene and 
protein of all parametersin mouse 3T3L1 adipocyte cells. T: testosterone. NC=no 
change.
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4.4 Discussion
4.4.1 Human THP1 macrophages
As monocytes migrate from circulating blood into the endothelial space they become 
activated and differentiate into macrophages. This part of the study aimed to investigate 
the expression of some of the key molecules expressed during this process using PMA- 
stimulated THP-1 cells as a model of macrophages. It was hypothesized that the 
interaction of CX3CR1 and CCR2 with their ligands is a crucial step in the migration of 
monocyte cells from circulating blood into the endothelial space of the artery wall, 
therefore, testosterone as an immune modulator and anti-inflammatory factor may 
influence this process by modulating the expression of these receptors and other 
markers of macrophage activation and inflammation such as IL-8 and TNF-a 
production. In particular, Veillard and colleagues (2006) suggested that the reduction of 
inflammation by inhibiting chemokines and their receptors is a novel therapeutic target 
for CVD. Testosterone can act through a number of mechanisms, including via ARs 
therefore the AR blocking agent, flutamide, was included in the experiments to 
investigate the mechanism of action of any effect seen with testosterone.
4.4.1.1 Expression of CX3CR1 and CCR2 mRNA in human THP-1 macrophages
A first set of experiments was conducted to establish whether the CX3CR1 and CCR2 
receptors for CX3CL1 and CCL2 respectively, were expressed by THP-1 macrophages. 
mRNA expression of both chemokine receptors were observed in THP-1 macrophages 
by using qRT-PCR.
4.4.1.2 The effect of testosterone treatment with or without flutamide on CX3CR1 
and CCR2 mRNA expression in THP-1 macrophages
Testosterone treatment, with or without blocked AR using flutamide, did not induce 
with any significant changes in expression of both receptors over 96h. To our 
knowledge, there is no other research studying the effect of testosterone on these 
receptors in THP-1 macrophages. Previous studies were performed to study the 
expression of chemokine receptors and their ligands in other cell types following 
androgen treatment with flutamide and other receptor blockers. Some of these studies
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found that regulation of these chemokines and their receptors was controlled by 
androgen, and these actions were reversed by anti-androgen receptors (Dole and 
Holdsworth, 1997, Akashi et al, 2006; Jamieson et al, 2008) while others found no 
changes (Kelly et al, 2012b). However, the presence of AR receptors was identified in 
the present study by qRT-PCR to exclude the fact that loss of its influence was the 
result of a lack of AR. Testosterone may not have an effect on unstimulated 
macrophages in absence of inflammation therefore activation of macrophages by 
cytokines was investigated.
4.4.1.3 The effect of cytokine stimulation on CX3CR1 mRNA expression in THP-1 
macrophages for 24h
THP-1 macrophages incubated with cytokines, TNF-a plus IFNy, at 10 ng/ml 
concentration for 24h tended to reduce CX3CR1 mRNA expression, whilst at lOOng/ml 
there was no effect. Previous studies have investigated the effect of TNF-a plus IFNy on 
CX3CR1 in THP-1 cells and found that CX3CR1 protein expression was upregulated, 
however these studies were carried out on undifferentiated cells (Apostolakis, 2007; 
Sung et al., 2010). Therefore the data presented here implies that the effect of cytokines 
on chemokine receptor mRNA expression varies depending on the stage of 
differentiation of the cells.
4.4.1.4 The effect of cytokine stimulation on CCR2 mRNA expression in THP-1 
macrophages for 24h
CCR2 mRNA was also down regulated after stimulation for 24h with TNF-a plus IFNy 
at lOOng/ml. This was seen in previous studies by Tangirala et al. (1997) and Weber et 
al. (1999). In these studies TNF-a induced a down-regulation of CCR2 mRNA and 
surface expression in THP-1 cells, isolated blood monocytes and Mono Mac 6 cells 
suggesting that pro-inflammatory cytokines can decrease as well as increase chemokine 
receptor expression. Several in vitro studies have established that selective changes in 
the expression of specific chemokine receptors occur during the differentiation of blood 
monocytes to macrophages (Opalek et al, 2007). For example, the reduction of CCR2 
expression takes place after 4 hours in monocyte cultures (Kaufinann et al, 2001). This 
decline in CCR2 expression continues for up to seven days, at which time no CCR2 is 
detected (Fantuzzi et al, 1999). While it is supposed that endogenous maturational
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events lead to lack of CCR2 expression in monocytes differentiated in vitro, some 
studies suggest that the lack of CCR2 expression is a direct consequence of binding 
secreted CCL2 (Mack et al, 2001). In a related study, Sica and colleagues (1997) found 
that LPS induced inhibition of CCR2 mRNA expression was associated with a 
reduction of both CCL2 binding and chemotactic responsiveness. Another study 
established that exposure of monocytes to OxLDL reduces CCR2 expression, causesing 
a rapid loss of functional CCR2 protein, and inhibition of the physiological response of 
monocytes to CCL2, suggesting that it acts as a negative regulator of monocyte CCR2 
expression (Han et al, 2000). CCR2 may be important to promote the arrest of newly 
recruited monocytes in the arterial wall, allowing for their cytokine- and growth factor- 
induced maturation to macrophages (Han et al, 1998). The results presented in the 
current study support the hypothesis that CCR2 is down-regulated on the surface of 
monocytes as they undergo in vitro differentiation to macrophages (Fantuzzi et al, 
1999; Kaufmann et al, 2001) and indicate that PMA-differentiated THP-1 cells 
stimulated with cytokines can be considered a model of differentiated macrophages at 
the stage where they have migrated into the arterial wall. The difference in the response 
to cytokines of CCR2 and CX3CR1, where a greater effect was seen on CCR2 mRNA 
expression confirms finding by Umehara et al., (2001) who found a differential 
response of these two chemokine receptors in a THP-1 cell line model of chemotaxis.
4.4.1.5 The effect of testosterone with or without flutamide on CX3CR1 mRNA 
expression in THP-1 macrophages stimulated with 24h cytokines
This present study showed no significant change in expression of CX3CR1 mRNA in 
THP-1 macrophages following 24h incubation with cytokines and testosterone, in the 
presence or absence of flutamide. This finding was observed at all cytokines and 
testosterone concentrations studied. In a parallel study, Kelly and co-workers (2010) 
found that testosterone or dihydrotestosterone (DHT) had no effect on the expression of 
CX3CL1, the ligand of CX3CR1, in vascular cells. This indicates that testosterone 
appears not to influence mechanisms involved in CX3CR1 regulation in macrophages 
with or without inflammation.
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4.4.1.6 The effect of testosterone with or without flutamide on mRNA CCR2 
expression in THP-1 macrophages stimulated with 24h cytokines
In contrast, testosterone induced an increase in CCR2 mRNA expression in TNF-a plus 
EFN-y stimulated THP-1 macrophages. This increase was only significant with 
testosterone treatment at lOnM and lOOnM after stimulating with cytokines at 100 
ng/ml concentration. This action for testosterone was markedly abrogated by lOOnM 
flutamide suggesting testosterone may act via AR.
The effect of testosterone on CCR2 mRNA expression following stimulation by 
cytokine treatment demonstrates that testosterone has the ability to influence the 
regulation of this receptor. In accordance with the hypothesis stated in section (4.4.1.4) 
(that PMA-differentiated THP-1 cells stimulated by cytokines can be used as a model of 
macrophages in the arterial wall), the results presented here imply that testosterone may 
play a beneficial role by inhibiting the conversion of these cells to lipid laden foam cells 
which are consequently involved in atherosclerotic events. This is demonstrated by the 
upregulation of CCR2 by testosterone indicating that the cells are arrested at an earlier 
stage of this process when increased CCR2 is required for chemotaxis of monocytes. 
Taken together the CCR2 results imply that this action of testosterone comes from its 
effect on secondary pro-inflammatory factors rather than its direct effect on CCR2 
receptor. This is indicated by the lack of an effect of testosterone on CCR2 in THP-1 
macrophages that were not previously treated with cytokines.
4.4.1.7 The effect of testosterone on pro and anti-inflammatory cytokines in 
supernatants of THP-1 macrophages before and after stimulation with cytokine 
for 24h
The levels of IL-lp, IL-6, IL-8, IL-10, TNF-a and IFN-y in supernatants of THP-1 
macrophages are measured by Enhanced Sensitivity CBA assay. The obtained data for 
IL-ip, IL-6, IL-10, and IFN-y were not reliable and excluded due to the high variability 
among these data. The values of IL8 secretion by macrophages following testosterone 
treatment before and after cytokines stimulation were reliable. Furthermore, TNF values 
was reliable following treated THP-1 macrophage cells with combination of testosterone 
and cytokine treatment.
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4.4.1.8 The effect of testosterone with or without flutamide on IL-8 levels in 
supernatants of THP-1 macrophages before and after stimulation with cytokine 
for 24h
Testosterone treatment with or without flutamide was not associated with any change in 
levels of IL-8 in the media from cells prior to cytokine treatment. However, testosterone 
treatment and blocking the AR showed an effect on IL-8 following cytokine treatment. 
24hr cytokine treatment significantly increased the IL-8 levels at both cytokines 
concentrations compared to untreated cells. Furthermore, testosterone significantly 
decreased level of IL-8 in the media of the cells after 24h stimulation with cytokine. 
Testosterone showed its inhibitive action on IL-8 only after using cytokines; therefore, 
its action may not be directly on IL-8 but indirectly by inhibiting the action of TNF-a 
and IFNy; this agrees with the effect of testosterone on CCR2 discussed in the previous 
section. This effect of testosterone was via AR as the addition of flutamide reversed the 
effect of testosterone.
Previous studies using testosterone treatment at pharmacological doses have shown that 
testosterone suppresses the production of IL-8 in human granulocytes and monocytes 
stimulated with LPS or zymosan and a similar effect was observed in differentiated HL- 
60 cells (Boje et al, 2012). In the latter study, flutamide was unable to antagonize 
testosterone suppression of IL-8 secretion, which is in contrast to the present study.
4.4.1.9 The effect of testosterone with or without flutamide on TNF-a levels in 
supernatants of THP-1 macrophages before and after stimulation with cytokine 
for 24h
A significant increase was seen in the level of TNF-a following cytokines treatment at 
both concentrations compared to untreated cells. Furthermore, testosterone significantly 
reduced the level of TNF-a in the media after 24h cytokines treatment. Flutamide 
partially blocked this effect, indicating that the action of testosterone was partly via AR, 
but also via the AR-independent pathway. The low levels of TNF-a measured in the 
testosterone treated cells also indicates that most of the added TNF as one of the 
cytokines used for stimulation was no longer present in the media at the time point 
studied as the TNF-a added was at ng/ml concentrations and the levels measured by the
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assay were at pg/ml levels.. Therefore the effect observed was on TNF-a secretion by 
the cells, and not due to the added TNF-a.
In previous cell culture studies, testosterone incubated with human monocytes obtained 
from younger individuals, fibroblasts, and rodent macrophage cell models led to a 
decline in pro-inflammatory cytokine expression of TNF-a, IL-lp, and IL-6 (Chao et al, 
1995, Kanda et al., 1996, Kanda et al, 1997, Parkar et al., 1998, D’Agostino et al., 
1999, Gomstein et al., 1999; Corcoran et al., 2010). Previous clinical studies have 
shown conflicting results about the effect after using physiological and 
supraphysiological concentrations of testosterone on TNF-a level. An increase 
(Metcalfe et al, 2008) no change (Kapoor et al, 2007) or a decrease (Hatakeyama et al., 
2002, Malkin et al, 2004a, Malkin et al, 2004b; Corrales et al., 2006) in the level of 
TNF-a have all been reported. In animal studies, no significant change was seen in 
serum levels of TNF-a following testosterone treatment in Tfm mice on high-fat diet 
compared to litteimates and placebo controls (Kelly et al, 2012b). In contrast, it has 
been stated that castrated mice show heightened TNF-a responsiveness to the injection 
of LPS, while testosterone replacement decreased this (Spinedi et al., 1992).
A similar anti-inflammatory effect has been shown for androgen in human endothelial 
cells, where DHT or testosterone decreased TNFa-induced inflammatory responses 
through the inhibition of NF-kB signalling pathways (Hatakeyama et al., 2002, Norata 
et al, 2006; Jin et al, 2009). In an interesting study using human macrophage cells 
obtained from elderly men and postmenopausal women, testosterone, but not estrogen 
treatment reduced expression of TNF-a in cells from both men and women (Corcoran et 
al, 2010). Therefore, the authors suggested that the effect seen with testosterone 
treatment was not due to aromatization to estrogen but was due to an androgen specific 
action of testosterone via the AR. When considered with the results of the current study 
in which flutamide only partially blocked the action of testosterone on TNF-a secretion, 
it can be suggested that testosterone mediates TNFa secretion in part via AR and also by 
an AR-independent pathway.
Taking the data presented in the current study together, testosterone treatment increased 
expression of CCR2 mRNA after stimulation with cytokines via the AR. Therefore 
testosterone may be exerting its effect by preventing or arresting the process of change 
to lipid laden foam cells at the early stage when CCR2 expression is higher. Indeed, 
this was clear from the decreased levels of IL-8 via AR and TNF-a via AR and AR-
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independent pathway in media of these cells in response to the addition of testosterone 
indicating a downregulation of inflammatory processes. All these outcomes will lead to 
a reduction in atherosclerosis development and reflect the role of testosterone as anti­
inflammatory factor. On the other hand, the lack an effect of testosterone on CX3CR1 
in macrophage cells can be explained by previous study which indicates that these two 
receptors are controlled by separate mechanisms (Umehara et al., 2001).
4.4.1.10 Limitations of the study
The in vitro conditions used in present study may not reflect the in vivo environment in 
artery wall. Furthermore, research on expression of CX3CR1 or CCR2 by macrophages 
alone is limited as it does not take into account the interaction with receptors in vascular 
cells thus it is difficult to address the full role of testosterone in this situation. In 
addition, THP-1 cells are a cancerous cell line derived from a 3-4 year old boy; 
consequently, they do not reflect typically normal human monocytes/ macrophage cells. 
It would be better to use isolated human monocyte-derived macrophage (HMDMS) 
from, particularly older people who have a high prevalence and severity of 
atherosclerosis with increasing age (Lloyd-Jones et al, 2010).
4.4.1.11 Summary of finding in THP-1 macrophages
The key finding of the present study demonstrated that PMA-differentiated THP-1 cells 
stimulated with cytokines are a good model of differentiated macrophages at the stage 
where they have migrated into the arterial wall and for studying chemokine receptors 
CX3CR1 and CCR2 expression by these cells. Testosterone had no significant influence 
on the expression of CX3CR1 and CCR2 and on IL-8 levels secreted by unstimulated 
THP-1 macrophages cells. Cytokines treatment had no effect on CX3CR1 mRNA 
expression whereas they significantly decreased expression of CCR2 mRNA. However, 
while testosterone treatment did not modulate CX3CR1 mRNA expression after 
cytokines stimulation, testosterone was associated with a significant increase in CCR2 
mRNA via AR following cytokines treatment. Testosterone inhibited levels of IL-8 via 
AR and TNF-a via AR-dependent and or AR-independent pathways indicting the role 
of testosterone as a modulator of inflammation.
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4.4.2 Mouse 3T3L1 cells
In this part of the study, 3T3L1 adipocyte cells were treated with testosterone with or 
without flutamide to block AR with the aim to investigate whether testosterone can 
influence expression of adiponectin, PPARp and leptin or on factors involved in 
obesity-induced inflammation including: PAI, CX3CL1 and CCL2 during adipogenesis 
processes and adipocyte differentiation. The presence of AR receptors was identified in 
these cells by qRT-PCR which was previously reported by (Singh et al, 2006). This 
also points to a role for testosterone and its receptors in these cells.
4.4.2.1 The effect of testosterone with or without flutamide on adiponectin mRNA 
expression and secretion of adiponectin in mouse 3T3L1 cells
The current study found that testosterone had no effect on adiponectin mRNA 
expression or its secretion into the media by 3T3L1 cells with or without the addition of 
flutamide. There was a significant difference in the levels of adiponectin in the 
flutamide treated cells, compared to the testosterone treated cells at both testosterone 
concentrations. However, the fold change was very small and as there was no observed 
difference between cells treated with testosterone and the control cells this is unlikely to 
be of biological significance.
In a previous study using the same cells, it was found that testosterone or 5-DHT 
reduced levels of adiponectin in the media of 3T3L1 without any change in adiponectin 
protein or mRNA expression (Nishizawa et al, 2002). In that study testosterone therapy 
reduced plasma adiponectin concentration in both sham-operated and castrated mice 
without changing mRNA and protein in adipose tissue, indicating that the process of 
adiponectin secretion from intracellular stores is controlled independently from 
transcription and it is this secretion mechanism that is influenced by testosterone. 
Similarly, Bai et al. (2011) found that testosterone decreased adiponectin secretion and 
mRNA expression in human adipocytes. This was in agreement with the findings of in 
vivo patient studies reported in chapter 3, indicating that testosterone treatment 
decreased the production of adiponectin in plasma after 3 months. In contrast, Combs et 
al, (2003) found that castration of mice in neonatal life but not adult life resulted in 
increased plasma adiponectin concentrations compared with adult females, proposing 
that additional influences besides gonadal steroids may be responsible for sex
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differences in serum adiponectin concentrations (Gui et al., 2004). Furthermore, in vivo 
in Tfin mice in the current study reported in chapter 3, a significant increase was seen in 
hepatic mRNA adiponectin expression in Tfin mice treated with testosterone compared 
to Tfin treated with placebo. However, it is unknown whether these testosterone effects 
on adiponectin expression occur in other tissues. Therefore, this increase may be related 
to the liver tissue and the Tfin condition.
4.4.2.2 The effect of testosterone with or without flutamide on PAI-1 mRNA 
expression in mouse 3T3L1 cells
A significant increase was seen in PAI-1 mRNA expression following lOnM 
testosterone treatment after five days; compared to the untreated mature adipocyte 
control. This slight increase was reversed by the addition of flutamide (lOOnM). At 
lOOnM testosterone the only significant effect was a reduction seen at five days 
compared to the undifferentiated control. These results are consistent with the data 
presented in chapter 3 in the in vivo Tfin mouse study, where testosterone treatment 
increased hepatic PAI-1 mRNA expression. However, other studies established that 
testosterone had an inhibitive effect on PAI-1 synthesis (Jin et al., 2007). PAI-1 is 
known to increase with obesity while testosterone will decrease (Plaisancea et al., 2009). 
Furthermore, adiponectin is reduced with obesity and has an inverse relationship with 
PAI-1 and leptin (Furukaw et al., 2004; Swarbrick and Havel, 2008). Interestingly, a 
deterioration of cardiovascular biochemical risk markers is observed after initiation of 
androgen deprivation therapy, as evidenced by increased fibrinogen, PAI-1 and t-PA 
(Haidar et al., 2007). In addition, physiological doses of testosterone or DHT, are 
associated with decreased PAI-1 expression by endothelial cells, where both hormones 
act on endothelial cells through the AR or via conversion to estradiol. However, these 
actions are largely lost when higher doses of testosterone were used, (Goglia et al., 
2010). The changes in PAI-1 shown in the data presented here, although significant, are 
small and therefore may not be of biological relevance.
4.4.2.3 The effect of testosterone with or without flutamide on PPARp/8 mRNA 
expression in mouse 3T3L1 cell,
In this study, mRNA expression of PPARp/5 was not affected by testosterone treatment 
over a 9 day period. On the contrary, as reported in chapter (3) testosterone therapy
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significantly increased hepatic expression of PP ARp/8 in the in vivo Tfin mouse study. 
Limited information is available regarding the effect of testosterone therapy on 
PPARp/5 especially in adipocytes or generally in adipose tissue. Therefore the lack of 
the effect of testosterone on mRNA PPARp/5 expression in this in vitro 3T3L1 cell 
study cannot be fully explained at the present time. Further experiments are needed to 
see testosterone has an effect after stimulating these cells with pro-inflammatory 
cytokines.
4.4.2.4 The effect of testosterone with or without flutamide on leptin mRNA 
expression in mouse 3T3L1 cells
Leptin mRNA expression was decreased in most treatments of mature adipocytes 
compared to untreated preadipocyte cells. The expression of leptin mRNA was 
previously reported in 3T3L1 preadipocytes (Chen et al, 1998). There was no difference 
in expression of leptin mRNA between testosterone treated cells and control mature 
adipocytes at either concentration of testosterone. This is an agreement with a previous 
study that reported testosterone treatment for 24h was ineffective in modulating leptin 
gene expression in differentiated 3T3L1 adipocytes (Monjo et al, 2005). In contrast, 
another study showed that testosterone reduced leptin secretion and mRNA expression 
in human adipocytes (Bai et al., 2011). A negative relationship between serum leptin 
and testosterone was observed in previous studies (Luukkaa et al., 1998, Behre et al., 
1997; Isidori et al., 1990). Furthermore, it was found that men had lower levels of leptin 
than women (Saad et al., 1997, Nishizawa et al., 2002). In line with this, human studies 
reported that testosterone treatment decreased leptin levels in hypogonadal men with 
T2DM (Kapoor et al., 2007) and in healthy men with testosterone deficiency (Simon et 
al, 2001) also in young and old hypogonadal men (Jockenhovel et al, 1997; Sih et al., 
1997). Conversely, in a study in mice, castration was not associated with any change in 
levels of leptin (Nishizawa et al., 2002). Furthermore, other clinical studies found no 
correlation between leptin and testosterone in older hypogonadal men (Sih et al., 1999) 
in non-diabetic men (Haffner, 1997) or in diabetic patients (Kapoor et al., 2007). 
Importantly, the use of an aromatase inhibitor which can inhibit conversion of 
testosterone to estradiol is associated with a decrease in leptin concentrations as well as 
a rise in testosterone (Blouin et al., 2005). Furthermore, it is known that high levels of 
leptin are not only associated with increased adipose tissue but also has an undesirable 
influence on testosterone production via the negative effect of leptin on Leydig cell
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function or by reducing the hypothalamic-pituitary-testicular axis (Caprio et al, 1999; 
Kelly and Jones, 2013).
4.4.2.5 The effect of testosterone with or without flutamide on mRNA expression 
and secretion of CX3CL1 in mouse 3T3L1 cells
Testosterone had no effect on CX3CL1 mRNA expression, however it significantly 
reduced its secretion level into the supernatant of adipocyte cells at 10 nM after 3 and 9 
days compared to control mature cells. Flutamide at lOOnM did not reverse this effect 
(in fact it significantly increased the effect). There are limited details in the literature 
about the action of testosterone on chemokines expression in adipocyte cells. However, 
previous studies have been conducted to investigate the effect of testosterone treatment 
on these chemokines in other cells. For example, Kelly and colleagues (2010) found no 
effect of testosterone or DTH on TNFa and IFNy-induced CX3CL1 mRNA expression 
in vascular cells. The latter study suggested that this could be due to testosterone's 
inability to affect the greatly elevated expression of these molecules caused by the 
combined cytokine stimulation used.
4.4.2.6 The effect of testosterone with or without flutamide on mRNA expression 
and secretion of CCL2 in mouse 3T3L1 cell
CCL2 mRNA expression decreased significantly in mature adipocytes on day 5 
compared to control undifferentiated cells. Testosterone, with or without flutamide, 
tended to decrease of CCL2 mRNA expression after 5 and 9 days, compared to the 
control undifferentiated cells. This reduction reached significance with lOOnM 
testosterone after 5 days. However, no significant difference was seen in the 
testosterone treated cells compared to the mature adipocyte control cells. In contrast, 
testosterone (10 nM) reduced secretion of CCL2 into the culture media after 3 days and 
then increased this secretion after 5 and 9 days. The action of testosterone was reversed 
by flutamide at 100 and lOOOnM at the same time, suggesting that testosterone may act 
through an AR-dependent mechanism. Similarly, a previous study found that elevated 
secretion of CCL2 by 3T3L1 cells treated with testosterone for 24h, which was 
dependent on NF-kB signalling (Su et al., 2009). On the contrary, Kelly et al. (2010) 
reported that no change in expression of CCL2 following testosterone or DTH treatment 
in human aortic vascular cells and in the level of CCL2 in serum of Tfin mice with
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testosterone (2012b). Norata et al., (2006) reported that DTH reduced CCL2 by 
mediating the AR and this was partly reversed by AR antagonism. The same group in 
2010 found that, 17p estradiol did not associated with any changing in CCL2 expression. 
It is worth mentioning that in latter studies androgen treatment was used after 
stimulating vascular cells with pro-inflammatory markers such as (TNF-y and IFN-y or 
IL-1) which was not done in the present study.
4.4.2.7 Limitations of the study
3T3L1 preadipocytes are a cell line derived from mice therefore, they do not represent 
human adipocyte cells. It would be better to investigate the effect of testosterone 
treatment on adipocyte-derived protein in human adipocyte cells as well as in the 
absence and presence of inflammatory condition. This could give a clearer picture for 
the effect of testosterone treatment. Furthermore, using receptor blockers for AR and 
ER or aromatase inhibitor can demonstrate the mechanism by which testosterone acts.
4.4.2.8 Summary
Considered together, testosterone had no effect at the level of gene expression for 
adiponectin, PPARp, leptin, CX3CL1 and CCL2. However, PAI-1 mRNA was 
increased by testosterone and this varied depending on the dose and time of treatment. 
Testosterone decreased secretion of CX3CL1 and increased CCL2 in the media of cells 
and this also varied depending on dose and time of treatment. Furthermore, the effect of 
testosterone and its action was mediating by both AR-dependent and AR-independent 
mechanisms. In addition, it is recognized that most of the changes in expression of the 
target genes were at five days. This may be because these cells contain the enzymes 
involved in lipolysis and lipogenesis at this time point (Ntambi et al., 2000). It is 
possible that testosterone can show more clearly its beneficial action after stimulating 
these cells with pro-inflammatory factors to create inflammatory conditions particularly, 
leptin and PAI-1 that increase with obesity-induced inflammation. Similarly, pro- 
inflammatory chemokines CX3CL1 and CCL2 increase with obesity and are involved in 
the migration of macrophage cells to adipose tissue by binding to their receptors on 
these cells. Lastly, it would be worth investigating the effect of testosterone on key
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transcription factors at various points in the adipogenic and lipogenic processes, to 
determine the transcription pathways involved.
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5.1 General discussion
This study was designed to assess a role for the effect of testosterone on factors 
associated with the diabetes and atherosclerosis and the obesity, which are associated 
with low testosterone levels in men. The role of testosterone in these conditions was 
examined to assess whether it has anti-inflammatory and anti-atherogenic actions 
through investigating parameters related to these conditions including markers of 
obesity ( BMI, WC and W/HR), adipocyte-derived associated proteins (adiponectin, 
PPAR8, PAI-1 and leptin), pro-inflammatory cytokines and chemokines and their 
receptors (TNF-a, CRP, IL-8, CX3CL1, CCL2, CX3CR1 and CCR2) and 
apolipoprotein and HDL with its fractions (Apo Al, Apo B, Apo E, LP (a), HDL2, 
HDL3 and HDL2/HDL3). For these investigations different techniques were used 
including: CBA, ELISA and qRT-PCR in samples from human patients, animal and cell 
culture models. In vitro, testosterone treatment was used at two different concentrations, 
with and without blocked AR (using flutamide), which helped to define the mechanism 
by which testosterone acts and whether any actions of testosterone were a direct result 
of its action on the AR or was through other mechanisms. In patient groups, 
testosterone was administered either by intramuscular injection or gel application.
5.1.1 Background to the investigations
An association between obesity and low testosterone in men has been reported. Low 
testosterone is associated with components of MetS including IR, increased central 
obesity, dyslipidaemia, and CVD (Wang et al., 2011). This relationship between low 
testosterone and these conditions is not yet fully defined with obesity-induced androgen 
deficiency and hypogonadism- induced obesity both likely contributing to a 
bidirectional effect on disease pathology (Kelly and Jones 2013). Cohen (1999) 
suggested that obesity impairs testosterone levels while low testosterone levels promote 
increased fat deposition based on the hypogonadal-obesity cycle hypothesis. In this line, 
many prospective studies on ADT-treated men with prostate cancer have shown 
increased fat mass and metabolic and cardiovascular perturbations (Choong et al., 2010). 
A longitudinal study demonstrated association between a low testosterone concentration 
in men independently predicting the future development of IR and T2DM (Haring et al.
2009).
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An increase in pro-inflammatory modulators such as cytokines and chemokines, 
reduction in anti-inflammatory factors such as adiponectin and IL-10 are a link between 
obesity and CVD, T2DM and testosterone deficiency (Mazur et al., 2014; Malkin et al.,
2010). Moreover, there is evidence based on studies involving castration of mice as 
well as female mice treated with testosterone, that males have a lower incidence of 
autoimmune diseases compared to females (Liva et al, 2001). In particular, an 
inhibitive effect of testosterone on pro-inflammatory factors was seen in previous 
studies (Malkin et al, 2004a; Kalinchenko et al, 2010). Additionally, improvements in 
central obesity, lipid profile and insulin sensitivity were observed when men were 
treated with testosterone (Kapoor et al, 2007; Saad et al, 2008). Thus it is important to 
study the role of testosterone and its use as a treatment to compensate for its deficiency, 
and its positive role in preventing disease. This role for testosterone may be through an 
effect on body composition, inflammation factors, and atherogenic markers. It is also 
necessary to elucidate the mechanism by which testosterone beneficially acts on these 
factors i.e. whether it is by AR- dependent or AR- independent pathways.
5.1.2 Testosterone as an anti-adipogenic factor and its effect on fat 
distribution/body composition
It is known that testosterone deficiency is associated with abdominal obesity and vice 
versa. Abdominal obesity is associated with IR. IR is the key central biochemical 
defect in development of the MetS, T2DM and atherosclerosis (Jones 2010). The 
present 6 months study found that testosterone had no effect on body composition (BMI, 
WC and W/HR) in the double-blind placebo study on diabetic patients. This is 
supported by data from diabetic patients in the longitudinal study where no change was 
seen in body composition in patients treated with testosterone and in IHD patients 
compared to the untreated control group. Similarly, previous studies did not find 
changes in W/HR (Tripathy et al., 1998) and in BMI and W/HR (Lee et al., 2005) after 
androgen treatment. In contrast to the present studies data, some clinical studies 
reported that a significant reduction was seen due to testosterone treatment in WC 
(kapoor et al., 2006; Gooren and Beher, 2008; Saad; Gooren, 2009 and Heufelder et al.,
2009) in diabetic patients even though there was no change in BMI in those studies. 
However, the difference is likely explained by the amount and length of time 
testosterone was administered or study design. In spite of the fact that BMI has an
inverse relationship with total testosterone (reviewed by Dandona et al, 2011).
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Furthermore, in cases of treatment of IR by rosiglitazone which works as an insulin 
sensitizer, by binding to the PPAR receptors in fat cells, this led to restored testosterone 
levels to mid-normal values in men with T2DM (Kapoor et al, 2008). Similarly, TRT 
decreases fat mass and increases lean body mass in men in middle-age over 52 weeks 
(Allan et al, 2008) and in older hypogonadal men over 36months (Page et al, 2005). 
Testosterone therapy also decreased visceral fat accumulation in proportion to the 
increase in testosterone levels (Allan et al, 2008). However, the lack of change in BMI, 
WC and W/HR in diabetic patient from the double-blind placebo study undertaken here 
may be due to the shorter duration and smaller study group size. Testosterone treatment 
for 6 months may not be sufficient for testosterone to exert its action. Additionally, the 
small population studied may not show the effect of testosterone treatment in as a larger 
population. Finally, the diverse and small population especially in the IHD subgroup 
and small numbers of patients in longitudinal study on diabetic patients could also 
explain the absence of an observed effect of testosterone on body composition. 
Therefore, a long-term controlled study with limited variability in patient population 
would be required to elucidate effect of testosterone on obesity.
The mechanism by which testosterone acts in reduction of adipose tissue mass is 
thought to be by inhibition of LPL enzyme, a key regulating enzyme for energy 
metabolism, catabolizing plasma triglycerides into free fatty acids and glycerol. It is 
known that testosterone acts by binding with AR by genomic and non-genomic 
mechanisms in adipose tissue. Stimulation of the cAMP cascade by sex steroid 
hormones, would activate hormone-sensitive lipase leading to lipolysis in adipose 
tissues (Saad, 2009). A possible beneficial mechanism of testosterone treatment in 
addition to reduction in fat mass, is, the influence of adipocyte derived associated 
proteins during the differentiation processes of preadipocyte cells to mature adipocytes 
(Blouin et al, 2005 and 2008). These proteins include adiponectin, PPARp/8, leptin and 
PAI-1.
Adiponectin has a role as an anti-diabetic, anti-atherogenic and anti-inflammatory factor. 
In human cross-sectional studies, plasma adiponectin levels are negatively correlated 
with obesity, W/HR, IR, dyslipidemia, diabetes and cardiovascular disease (reviewed by 
Matsuzawa 2005). In the current study, testosterone showed contradictory results with 
regards to adiponectin at the level of genes and protein. In the current clinical study, 
reduction in levels of adiponectin was observed in diabetic patients in the double-blind
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controlled study after 3 months of testosterone treatment, however it increased in the 
Tfin study and did not change in the other studies. Previous research has shown that 
testosterone treatment reduced adiponectin level in clinical (Kapoor et al, 2007) and 
experimental studies (Nishizawa et al, 2002). A decrease in total adiponectin levels was 
seen in healthy boys during puberty, simultaneously with increasing endogenous 
androgen production (Bottner et al, 2004). Furthermore, adiponectin levels in 
hypogonadal men are higher than in eugonadal males, and decreased after testosterone 
treatment (Lanfranco et al, 2004). Additionally, testosterone deficiency leads to 
increased adiponectin in hypogonadal men with diabetes (Kapoor et al, 2007) and 
without diabetes (Page et al, 2005b), despite of the fact that adiponectin and 
testosterone have anti-inflammatory actions and are both associated with improvement 
in T2DM and atherosclerosis development (Rasul et al, 2011; Saad et al, 2012). 
However, other studies have shown that testosterone treatment over one year increased 
levels of adiponectin (Heufelder et al, 2009). Moreover, a positive correlation between 
adiponectin and serum levels of total testosterone in the diabetic male (Rasul et al,
2011), in non-diabetic men (Yasui et al, 2007) and in men and postmenopausal women 
(Laughlin et al, 2007) has been established. This is consistent with the data from the in 
vivo Tfin mice in the current study. Testosterone treatment increased hepatic 
adiponectin mRNA expression compared to mice treated with placebo. However, in the 
present study there was a lack of testosterone modulation on expression and secretion of 
adiponectin in the media of 3T3L1 adipocytes in the in vitro study. This confirmed a 
previous report at the level of the gene in this model (Nishizawa et al, 2002). This 
agreed with data from the longitudinal study on diabetic patients in this thesis where 
testosterone treatment had no effect on the levels of adiponectin in patients treated with 
testosterone and in IHD subgroups.
The contrasting effects of testosterone on adiponectin in previous studies have been 
clearly represented in the current study. However, the reduction in adiponectin in 
patients after 3 months in the double-blind placebo study may be a temporary effect of 
testosterone as this was not sustained at 6 months. As Gooren and Bunck (2004) 
reported, the reduction in circulating adiponectin concentrations might be due to the 
different routes of testosterone administration used, or after intramuscular testosterone 
injections, circulating testosterone levels are known to peak above the physiologic range, 
whereas transdermal testosterone gel produces testosterone levels within the reference 
range for young adults. This may explain the reduction in adiponectin in diabetic patient
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in the double-blind placebo study, who were treated with intramuscular injections while 
in the second study no effect was seen on adiponectin level in those treated with 
testosterone gel. Furthermore, other studies indicated that there are further factors 
associated with the changes in adiponectin levels for instance, smoking (Miyazaki et al, 
2003), age (Adamczakt et al., 2005) and dietary factors such as a carbohydrate-rich diet 
and alcohol consumption (Thamer et al, 2004). Thus, these factors which affect 
testosterone treatment especially in human in vivo studies need to be controlled for.
In the mouse study, the lack of effect of testosterone on adiponectin at the mRNA and 
protein levels in 3T3L1 adipocytes might be related to this specific mouse strain. Thus, 
it may be better to study the effect of testosterone on adiponectin by analysing other 
mouse models or cells from whole adipose tissue. Other possible explanations are that 
changes in adiponectin can be due to the type of testosterone treatment, the level of dose 
or its metabolites (Page et al., 2005b). This might explain the increase in hepatic 
adiponectin mRNA expression in Tfin mice after testosterone treatment. This increase 
was mediated either by ER after aromatising testosterone to estradiol or via a non- 
genomic pathway since these mice have non-functional ARs, especially since a recent 
study found that 17-p estradiol increased adiponectin mRNA expression in adipocyte 
cells (Capllonch-Amer, 2014). However, this action of testosterone could be specific for 
the liver of Tfin mice. Alternatively, testosterone may act on adiponectin receptors such 
as adipo-Rl and adipo-R2, which are involved in production and secretion of 
adiponectin; it was found that testosterone and E2 increase adiponectin receptor-1 and - 
2 mRNA and protein in adipose tissue in women with polycystic ovary syndrome (Tan 
et al., 2006). Thus, it would be worthwhile to carry out further work to investigate 
whether testosterone influences adiponectin receptors in human adipocyte cells.
PAI-1 is a further factor produced by adipose tissue and has positively correlation with 
obesity, T2D, CVD and low testosterone (Pergola et al.L 2000; Alessi et al, 2007). PAI- 
1 was investigated in 3T3L1 cells and Tfin mice. Testosterone treatment increased it at 
a concentration of 10 nM after 5 days and this was mediated by AR, this is supported by 
the in vivo Tfin mice data where hepatic PAI-1 mRNA expression was elevated after 
testosterone treatment; however this was mediated by AR-independent mechanism. 
Although, contradicting the data from the mouse model, where the AR is non-functional 
and therefore not involved in the observed effects, In previous study using human
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endothelial cells, it was found that higher doses of DHT or testosterone increased 
expression of PAI-1 mRNA where DHT exerted these actions through AR, testosterone 
acted in part through aromatase-dependent conversion to 17p-estradiol (Goglia et al.,
2010). In that study, testosterone and DHT also had similar action on expression of 
PAI-1 mRNA in the aorta of Wistar rats. Therefore, this may explained the action of 
testosterone on mRNA expression of PAI-1 by mediating ER in the current study of 
Tfin mice. However, these observations are in opposite of the previous studies in which 
reduction in PAI-1 was seen after androgen treatment (Bavenholm et al., 1998; Pugh et 
al., 2002). The changes in PAI-1 seen in in mouse 3T3L1 adipocyte, although 
significant, are small and therefore may not be of biological relevance. The effect of 
testosterone on PAI-1 in the Tfin mice may related to the condition of these mice and to 
other factors such as body weight or HFD as explained in section (3.4.3). The reason 
behind this increase in both study unclear and thus certain conclusions cannot be made. 
Since the limited of details related to the effect of testosterone on PAI-1 gene in the 
liver of Tfin mice, therefore, further research need to be performed with involving 
receptor blockers for AR and ER or involving aromatase inhibitor. This can demonstrate 
the mechanism by which testosterone acts.
PPARp is another factor expressed in adipose tissue and has valuable effect on lipid 
metabolism, glycaemic control and is a potential target of anti-obesity agents. The 
current study showed that testosterone had not an effect on PPARpin 3T3L1 adipocyte. 
These findings are inconsistent with data of in vivo Tfin mice in which testosterone 
increased significantly mRNA PPARp gene expression of liver. This may due action of 
testosterone via AR-independent pathway. The lack of influence of testosterone on 
PPARp in 3T3L1 cell cannot be elucidated as well as a little is known about the 
association between PPARp/5 and testosterone in different tissues such as liver and 
adipose tissue.
Leptin is an additional factor produced by adipose tissue and increases with obesity. It 
has an inverse relationship with adiponectin and testosterone. It is associated with 
reduction of testosterone level in obese men and CVD, T2DM. There was no significant 
effect for testosterone on mRNA leptin expression compared to untreated mature 
adipocyte cells. This is in an agreement with previous study where testosterone 
treatment for 24h was ineffective in modulating leptin gene expression in differentiated 
3T3-L1 adipocytes (Monjo et al., 2005). Similarly, in animal study, plasma levels of 
leptin were similar in male mice with or without castration (Nishizawa et al., 2002).
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This is in contrast to previous study that found decrease in leptin following testosterone 
treatment (Jockenhovel et al, 1997; Sih et al, 1997; Simon et al, 2001 and Kapoor et 
a l , 2007). Furthermore, a considerable decline in serum leptin levels after short-term 
aromatase inhibition in healthy young and elderly men has been observed (Lapauw et 
al, 2009). However, the differences in the observations could be due to the different 
type of studies and multiple factors involved in mRNA expression of leptin.
The conflicting results related to adiponectin, PAI-1, PP ARp/5 and leptin during 
differentiated processes in in vitro 3T3L1 adipocyte and in vivo Tfin mice studies make 
it difficult to draw convinced conclusion that gives the correct interpretation of the 
action of treatment. However, the effect of testosterone on these parameters could be 
clear after stimulated 3T3L1 adipocyte with pro-inflammatory mediator as the condition 
in obesity. Furthermore, measuring the level of secretion of PA-I-1 and leptin in the 
media of 3T3L1 adipocyte would be valued to elucidate effect of testosterone on obesity. 
Additionally, using human adipocyte cells would be more useful advantageous for 
future investigations. Involving of receptor blockers for AR and ER or aromatase 
inhibitor in vivo Tfin mice study, would answer how testosterone acts.
5.1.3 Testosterone as an anti-inflammatory factor
5.1.3.1 Pro-inflammatory cytokines
Testosterone act as an anti-inflammatory factor through its beneficial effect on 
decreasing levels of inflammatory factors such as 3L-1 p IL-6, TNF-a, IFNy and IL-8, 
where these factors are raised as a consequence of obesity and are involved in the 
development of T2DM, atherosclerosis and testosterone deficiency (Ferroni et al, 2004; 
Shoelson et al, 2007; Heufelder et al, 2009; Jones, 2010). CRP which is synthesized in 
the liver under stimulation of IL-6 and TNFa, is also known as general indicator of 
inflammation (Fahed et al, 2012).
In the present study, cytokines were measured in serum samples from diabetic patients 
in the double-blinded placebo-controlled and longitudinal studies, and also were studied 
in THP-1 macrophages. However, some of these factors (IL-lp, IL-6, IL-10, IFNy) were 
not reliably detected. No significant change was seen in TNF-a and CRP levels in serum 
samples from diabetic patients over six month's testosterone treatment. In addition, there
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was no difference in serum levels of IL-8 between patient subgroups in the longitudinal 
study. Similarly, in human THP-1 macrophages, there was no significant change in 
levels of IL-8 in media of cells after testosterone treatment in unstimulated cells. 
However, in cells stimulated with cytokines, testosterone significantly decreased TNF-a, 
and IL-8 levels in the media. Effects on TNF-a were via both AR and AR-independent 
pathways whereas IL-8 production was only influenced via AR-dependent pathways. 
Testosterone therapy had no effect on CRP levels in diabetic patients in either clinical 
study. A previous study showed that CRP increased in male rats after testosterone 
treatment (Wataru, 1990). An inverse correlation between CRP and testosterone levels 
was seen in some clinical studies (Bhatia et al, 2006; Kapoor et al, 2007). Similar to 
the present clinical study other studies (Ng et al, 2002, Lanffanco et al., 2004; Kapoor 
et al., 2007) did not report changes in TNF-a and CRP levels. In the present cell culture 
study, testosterone decreased TNF-a and IL-8, which is in agreement with a previous 
cell culture study (Hatakeyama, 2002; Boje et al, 2012) and a clinical study (Malkin et 
al, 2004a).
To summarise, although the clinical study did not show positive effects of testosterone 
on pro-inflammatory factors, in cell culture however, beneficial effects of testosterone 
were observed, it may be because the clinical study was more complex due to variability 
of the patients group.
5.1.3.2 Pro-inflammatory chemokines and their receptor expression
Chemokines, CX3CL1 and CCL2, and their receptors, CX3CR1 and CCR2, are 
associated with chronic inflammation related to obesity such as IR, T2DM and CVD 
(Ota et al, 2013). This association is by mediating recruitment and accumulation of 
leukocytes and trigging low-grade chronic inflammation in adipose tissue, liver and the 
arterial wall (Panee et a l , 2012, Shah et a l , 2011; Yao et al, 2014).
This study demonstrated that CX3CR1 mRNA was expressed in the liver of Tfin mice, 
although testosterone treatment was not associated with any change in its expression. 
This is in agreement with the data from the in vitro study using human THP-1 
macrophages. These cells were shown to express CX3CR1 mRNA, however, 
testosterone had no effect on CX3CR1 mRNA expression, with or without flutamide 
over 96 hours. Similarly, when cells were treated with TNF-a plus IFNy and 
testosterone with or without flutamide there was no effect of testosterone on effect
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CX3CR1 mRNA expression. A previous co-culture study reported that CX3CL1 and 
CX3CR1 are involved in monocyte/macrophage accumulation in the atherosclerotic 
plaque, where pro-atherogenic factors such as oxLDL induce a chemokine receptor 
switch: CCR2 off, CX3CR1 on (Barlic and Murphy, 2007). In the presence of ox-LDL, 
the CCR2hieh CX3CRl'°w monocytes will be differentiated into CCR2low CX3CRlhi6h 
subtype and this CX3CRlon-CCR2ofr regulation is helpful to inhibit CCR-dependent 
monocyte migration and to enhance the CX3CR1 -dependent monocyte recruitment and 
adhesion (Barlic et al, 2006). This pro-adhesive chemokine receptor switch may 
prevent CCR2-dependent migration and may induce CX3CR1-dependent retention 
(Barlic and Murphy, 2007). Therefore macrophages and foam cells are prone to 
accumulate in vascular wall (Liu and Jiang, 2011). As a result the absence of oxLDL in 
the media of THP-1 macrophages in the present study, may explain the lack of effect of 
cytokine stimulation on this receptor. Thus, addition of oxLDL into media in 
combination with TNF-a plus IFNy could actually reflect the conditions of the site of 
inflammation in the artery wall and consequently this system could then be used to test 
the effect of testosterone on CX3CR1 expression.
Expression of CCR2 mRNA was seen in the liver of Tfm mice and in THP1 
macrophages. Testosterone did not show any effect on CCR2 mRNA expression in the 
liver of Tfin mice. Similarly, testosterone had no effect on CCR2 mRNA expression in 
the in vitro study of unstimulated THP-1 macrophages. However, incubation of these 
cells with lOOng/ml of TNF-a plus IFNy for 24h significantly decreased the expression 
of CCR2 mRNA. The data from the present THP-1 macrophage study extended the 
previous findings on the reduction of surface expression of CCR2 and mRNA 
expression in monocyte/ macrophages (Han et al., 2000, Fantuzzi et al, 1999 Opalek et 
al, 2007). These studies suggested that the down regulation of CCR2 mRNA 
expression may be vital to promote the arrest of newly recruited 
monocytes/macrophages in the arterial wall, allowing for their cytokine- and growth 
factor-induced maturation to macrophages. Therefore, this study provided evidence in 
agreement with previous findings and indicated that that PMA-differentiated THP-1 
cells stimulated with cytokines can be considered a model of differentiated 
macrophages at the stage where they have migrated into the arterial wall.
High and low concentrations of testosterone treatment significantly increased 
expression of CCR2 mRNA following stimulation with lOOng/ml of TNF-a plus IFN-y
in THP-1 macrophages. This increase was abrogated by 100 nM flutamide, suggesting 
testosterone may function through AR-dependent mechanisms. This is consistent with 
the data from the Tfm mice which have non-functional AR and no effect for 
testosterone on CCR2 expression was observed in these mice. The CCR2 results 
indicated that this action of testosterone comes from its effect on pro-inflammatory 
factors rather than a direct effect on the CCR2 receptor. This is evidenced by the 
absence of an effect of testosterone on CCR2 expression in unstimulated THP-1 
macrophages. The action of testosterone may be through suppression of the NF-kB 
signalling pathway which is a master transcription factor in inflammation (Norata et al., 
2006; Jin et al., 2009). Testosterone exerted its effects by arresting the 
monocytets/macrophages in the artery wall preventing the conversion of these cells to 
lipid laden foam cells which are consequently involved in atherosclerotic events. 
However, the beneficial effect of testosterone on these receptors or on regulatory of 
macrophage function remains under debate, especially since recent study has shown that 
testosterone treatment increase genes related to atherosclerosis in macrophage cells 
including atherogenic and pro-inflammatory factors (Ng et al, 2003).
The present study is the first study to investigate the effect of testosterone as an anti­
inflammatory modulator of CCR2 and CX3CR1 mRNA in THP1 macrophages, 
therefore, little is known about the effect of testosterone on these receptors an further 
research is needed. In addition, the expression of CX3CR1 and CCR2 mRNA was only 
investigated after 24h with cytokines treatment, therefore, it may be advantageous to 
investigate this expression at earlier time points, particularly, as previous studies 
showed that the maximal surface expression of CX3CR1 was observed after 15 min 
after stimulation with pro-inflammatory modulators (Green et al, 2006). Furthermore, 
as earlier mentioned, oxLDL differentiated macrophages into CCR2low CX3CRlh,gh 
subtype, thus, investigation of the effects of testosterone treatment on CX3CR1 and 
CCR2 mRNA expression in the presence of oxLDL plus cytokines in THP-1 
macrophages, may actually give a clear picture on this effect.
This study demonstrated that CX3CL1 and CCL2 mRNA were expressed in the liver of 
Tfin mice and in preadipocyte and mature adipocytes of the mouse 3T3L1 cell line. 
Testosterone treatment was not associated with any change in CX3CL1 mRNA 
expression in the liver of Tfin mice. In addition, testosterone treatment had no effect on 
expression of mRNA CX3CL1 in mouse 3T3L1 cells supporting the data from the
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animal model. However, testosterone reduced significantly the level of secreted 
CX3CL1 at low testosterone concentrations after three and nine days. This reduction 
was not reversed by AR blockade. This reduction in CX3CL1 in the media may indicate 
a beneficial effect of testosterone as an anti-inflammatory factor. There is little previous 
work on CX3CL1 in other cell types e.g. vascular or hepatocyte cells, and this effect 
may be cell specific. In support of this, previous work in our laboratory found that an 
apparent reduction of CX3CL1 expression in aortic lipid streaks of Tfin mice receiving 
testosterone treatment proposing the protective effect of testosterone in atherogenesis is 
via local anti-inflammatory actions and at least partially via AR-independent 
mechanisms (Kelly et al, 2010). In that study, testosterone treatment reduced cytokine- 
induced expression of CX3CL1 at the molecular level in HASMC, an effect not 
prevented by blockade of the AR. Therefore further work should include cell culture 
studies on the effect of testosterone on other cell types present in liver and co-culture 
systems. In addition, the process of CX3CL1 secretion from intracellular stores may be 
controlled independently from transcription and it is this secretion mechanism that is 
influenced by testosterone, in a similar way to that of adiponectin as discussed 
previously.
Testosterone had no effect on expression of CCL2 mRNA in the liver of Tfin mice. 
Similarly, there was no significant effect of testosterone on CCL2 mRNA expression 
compared to the untreated mature adipocyte cells in 3T3L1. However, testosterone 
treatment significantly reduced the level of secreted CCL2 by these cells following 3 
days at a low concentration, whereas testosterone increased CCL2 protein level after 5 
and 9 days in culture. This effect was prevented by blockade of the AR by increasing 
CCL2 mRNA expression after 3 days while decreasing it after 5 and 9 days suggesting 
an AR-dependent mechanism. Although, there are limited studies regarding to 
testosterone effects on CCL2, the inconsistency of data of testosterone effects on CCL2 
at the level of gene or protein in the present study was similarly observed in previous 
studies in vivo in animals (Kelly et al, 2012b) and in vitro cell culture studies (Su et al, 
2009; Norata et al, 2006,2010) as shown in chapter 3 and 4.
The lack of the effect of testosterone on hepatic CCL2 mRNA expression in Tfm mice 
might be due to the lack of AR function suggesting that if testosterone does influence 
CCL2 expression it is via AR-dependent pathways. This was supported through the 
effect of testosterone on secretion of CCL2 via the AR pathway in mouse 3T3L1 
adipocytes. In addition, the modulation of secretion of CCL2 by testosterone was
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dependent on the time and treatment dose. Moreover, the contradicting data on the 
impact of testosterone on mRNA expression and secretion of CCL2 from these cells 
may be due to the lack of correlation between the mRNA expression of CCL2 and 
protein level in media. However, it is not always the case that mRNA expression 
reflects the level of protein expression, the differences between mRNA and protein 
quantification may be due to some factors including the half-lives of specific mRNAs or 
proteins, and the intracellular location that can affect the of post-transcriptional 
processes and the translation rate of the proteins (Gygi et al., 1999). Therefore, the 
difference in the response of mRNA and protein expression of CCL2 to testosterone 
may depend on the ability of testosterone action on the level of gene expression or 
protein secretion.
Since, there is limited published information related to the effect of testosterone on 
chemokine receptors and ligands in THP-1 macrophages or 3T3L1 adipocytes and Tfin 
mice respectively, contradictions in the results of the present study cannot be fully 
explained. However, the presence or the absence of appropriate atherogenic stimulator 
in ideal media in THP-1 macrophages or pro-inflammatory cytokines in 3T3L1 
adipocyte could reveal clearly the influence of testosterone treatment. Furthermore, 
using further receptor blockers for AR and ER or enzyme inhibitors for aromatase or 
reductase would be valuable to understand the mechanism by which testosterone works.
5.1.4 Testosterone as anti-atherogenic factor:
Apolipoproteins are considered more sensitive indicators of cardiovascular risk than 
lipid and lipoprotein levels (Sotiropoulos et al, 2008). These proteins act as enzyme co­
factors during lipid metabolism, helping to stabilize lipoproteins during transportation 
from cell or tissue to their destination (Han, 2004). In the current study, apolipoproteins 
were investigated after testosterone treatment in human and mice in vivo.
Testosterone had no effect on apolipoprotein (Apo Al, Apo B and Apo E) and LP (a) 
levels in sera of diabetic patient in both studies. This is also supported by the result from 
the Tfin mice study where testosterone treatment was not associated with any change in 
apo Al and apo E at the level of the gene. The absence of action of testosterone on 
apolipoprotein levels was also observed in another study using physiological 
testosterone concentrations (Snyder et al., 2001; Herbst et al., 2003) while alternative
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studies showed opposing data with a decrease or increase in some of these parameters 
(Singh et al, 2002, Von Eckardstein et al, 1997, Jones et al, 2011; Dickerman et al, 
1996). It was suggested that the mechanism of action of testosterone in modulation of 
apolipoproteins would be through inhibition of fat mass and this may explain the lack of 
apolipoprotein changes because there was no change in WC, W/HR and BMI of patients 
in the clinical study.
In the present study, testosterone similarly did not modulate the level of HDL and its 
fractions including (HDL2, HDL3 and HDL2/HDL3 ratio) in sera of diabetic patients of 
the double -blind placebo- controlled study. However, there was an increase, but not 
significant, in levels of HDL, and a significant increase in HDL2 and HDL2/HDL3 ratio 
while there was significantly decreased levels of HDL3 in serum of diabetic patients 
who were treated with testosterone in the longitudinal study. No change was seen in 
HDL and its fraction in the IHD subgroup in the latter study. HDL has atheroprotective 
functions and is negatively associated with atherosclerosis (Traish et al, 2009). It is 
widely accepted that spherical HDL possesses atheroprotective functions such as 
antioxidant and anti-inflammatory properties, while it also promotes reverse cholesterol 
transport from peripheral tissues to the liver, where it delivers cholesterol to hepatocytes 
through binding to the HDL-receptor (Maeda et al, 2011; Traish et al, 2009). HDL 
subftractions includes HDL2 and HDL3, which play an important role in the function of 
the HDL molecule. Case control studies have shown that the higher HDL2 levels rather 
than HDL3 are responsible for the inverse relationship between HDL levels and CAD 
(Sotiropoulos et al, 2008). Lagos et al. (2009) recently reported that the HDL 
phenotype includes a greater percentage of small HDL3 and fewer large HDL2, 
resulting in a lower HDL2/HDL3 ratio which is associated with an increase in MetS 
components. In this regard, it was previously found that the HDL2/HDL3 ratio 
correlated positively with the HDL levels, suggesting that when the HDL cholesterol 
level decreases, a decrease in the large HDL2 subclass also occurs (Moriyama et al, 
2014). Thus, Moriyama et al. (2014) suggested that the maintenance of a high 
HDL2/HDL3 ratio might be important for subjects with MetS. This may explain the 
finding in the current study where numerical increase in HDL and significant elevated 
in HDL2 and HDL2/HDL3ratio were seen in patient treated with testosterone.
There were data related to the adverse effect of testosterone on HDL and its fractions 
which some of them were partly similar to the current data. 250 mg testosterone esters 
for 3 months reduced significantly the HDL3 subfractions, while it had no effect on
HDL and HDL2 levels in young patients with hypogonadotropic hypogonadism 
(Taslipinar et al, 2010). An additional study found that androgen increased 
significantly the level of HDL2 with no change in HDL and HDL3 (Ozata et al., 1996). 
Moreover, Tan (1998) found that there was a reduction in HDL3 sub-fractions after 
treatment by testosterone as a parenteral testosterone ester for 4-weeks. In contrast to 
the present study, previous studies found that reduction in HDL, HDL2 and HDL3 
(Thompson et al., 1989, Tan 1998; Bagatell et al., 1992) or in HDL and Apo Al (Singh, 
2001 ) or in HDL alone (Emmelot-Vonk et al, 2008, Lapauw et al, 2009; Frederiksen et 
al., 2012a) was seen following androgen treatment. High dose, formulation and type of 
androgen and route of administration may explain these discrepancies. Furthermore, 
Heufelder et al. (2009) reported a synergistic effect between testosterone treatment and 
lifestyle in increasing HDL levels and decreasing TG levels, in recently diagnosed 
T2DM subjects. However, the lack of effect of testosterone on HDL and its fractions 
may be due to the small duration of intramuscular testosterone injection and small group 
size of patients in of the double -blind placebo- controlled study. In the longitudinal 
study, testosterone showed beneficial effects by increasing HDL and HDL2 and HDL2/ 
HDL3 ratio and reducing HDL3 and this may be related to the gel testosterone treatment 
and length of treatment.
5.1.5 Limitation
Diverse results found in the present study may be a result of the small number of 
samples, or also be due to using different samples from animal and human in in vivo and 
in vitro conditions. In addition, in the part of in vitro studies, it was involved cancerous 
cells or mouse cells which may not reflect the actual status of the normal and human 
cells in vivo. Further factors could contribute to contradictory data among these studies 
including differences in study design, doses, formulations and delivery modes of 
testosterone. In clinical studies, factors such as age, smoking, diet, physical exercise, 
body fat distribution and hypogonadal state could affect the action of testosterone 
treatment. Moreover, the lack of normal distribution requiring the use of non-parametric 
statistics for assessing the differences may lead to the absence of statistical significance 
of the data that seemed to include significant changes. On other hand, the usage of 
testosterone as treatment is still subject to controversy. There are many causes for 
controversy in the practice of medicine. These reasons are related to the risk of
238
testosterone therapy which previously was observed. Cancer, liver toxicity and 
reduction of HDL and adiponectin have been the main risks associated with testosterone 
and causes for concern. Furthermore, the precise mechanistic explanations for the action 
of testosterone as beneficial or risk treatment remain undetermined. This was a clear in 
the recent studies where Muraleedharan and co-workers reported that testosterone 
treatment improved the survival of men with T2DM (2013) while other did not find any 
beneficial effect (Vigen et al, 2013). However, some contributors factor such as super- 
physiological dose of testosterone, formulation of testosterone and mode of delivery is 
thought to be associated with these risks, while physiological doses and balancing 
testosterone with the relative abundance of estradiol could aid to achieve the beneficial 
effects while reducing these risks, Indeed, it cannot be ruled out the benefit testosterone 
in improvement of lean body mass and muscle strength, erythropoiesis and bone 
mineral density, sexual function, mood and reduction of fat mass insulin sensitivity, 
vascular tone, blood which have been improved in previous study.
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5.1.6 Future work
5.1.6.1 In vivo study (human)
A longer study and larger population samples in well-controlled clinical trials may give 
a clearer explanation of the mechanism of testosterone, taking into account of BMI, age, 
and treatment with drugs; it was difficult to adjust for these variables with the sample 
size of the current study. It may be valuable to investigate other ways of analysing 
testosterone such as the measurement of SHBG, FT and BT which may better reflect 
biologically relevant concentrations of testosterone and its action. Furthermore, it would 
be valued to investigate additional parameters including subfractions of adiponectin, 
leptin and PAI-1.
5.1.6.2 In vivo study (mice)
It would be useful to study adipose tissue from Tfin mice to see the effect of 
testosterone action on markers and key transcription factors in adipogenic procedures. 
Furthermore, the effect of testosterone treatment on factors involved in fat accumulation 
such as LPL could be investigated. These experiments could be extended by 
investigating the effect of DHT or further blockers of the ER or inhibitors of aromatase 
or reductase enzymes; this will elucidate the mechanism by which testosterone acts. 
The effect of testosterone in other mouse models could also be investigated, for example 
the Apo E knock-out mouse model which is a model of atherosclerosis.
5.1.6.3 In vitro study
Testosterone's effect on CX3CR1 and CCR2 expression in macrophage cells may be 
seen more clearly if these cells are studied in conditions closer to those seen in 
atherosclerosis, inflammation and atherogenesis. Indeed, there is evidence from 
different studies showing the role of testosterone in the reduction of fatty streak 
formation. Therefore, macrophage cells could be stimulated with LDL or native LDL 
such as oxLDL which will offer a closer model of atherogenesis conditions including 
the secretion of pro-inflammatory cytokine and chemokine factors. Therefore, this 
experiment would be worthwhile to investigate the effect of testosterone in a more 
complete atherosclerosis model. Furthermore, it would be favourable to use isolated
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adult human monocyte/macrophage cells from patients with atherosclerosis as an 
atherosclerosis model to investigate what happens in reality in the artery wall instead of 
using cancerous cells (monocyte/macrophage THP-1 cell line). These cells could be 
cultured in conditions which mimic more closely the formation of foam cells. As with 
the studies in mice the addition of receptor blockers or aromatase enzyme inhibitors 
would provide further evidence of the mechanisms of testosterone action.
There is no currently available human adipocyte cell line which is why the data 
presented here was generated using mouse cells. However, the use of isolated human 
preadipocyte cells could be beneficial to get answers for the unknown questions related 
to the role of adipocyte derived associated proteins, in the development of T2DM, 
atherosclerosis and low testosterone in obesity before and after testosterone treatment. 
Furthermore, similar to the experiments suggested above, the use of different 
testosterone receptor and enzyme blockers could be used to investigate how testosterone 
mediates its action. It would be valuable to stimulate these cells by using pro- 
inflammatoiy factors including TNF-a, IFN-y and IL-1 p and so on. This would lead to a 
more adequate model of inflammatory adipocyte cells secreting pro-inflammatory 
factors such as CX3CL1, CCL2, PAI-1 and leptin. Therefore, the effect of testosterone 
on the improvement of the development of an inflammatory response with IR could be 
studied in this model. Moreover, by stimulating these cells, a co-culture model can be 
used by involving human THP-1 macrophages with human preadipocyte type cells. In 
addition, it would be advantageous to investigate the effect of testosterone therapy on 
LPL enzymes as well as key markers of differentiation and transcription factors.
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5.1.7 Conclusion
The aim of this study was investigate of the actions of testosterone in diabetes, 
atherosclerosis and obesity. This was carried out using two patient cohort studies, an 
animal model and cell culture methods. According to the results presented here, both 
positive and negative effects of testosterone were found. Positive effects of testosterone 
included improvement in HDL fraction and HDL2/HDL3 ratio and decreased TNFa, 
IL-8, CCL2, CX3CL1, However, negative effects included a lack of change in BMI, 
WC and W/HR in patients and adverse changes in mediators e.g decreased adiponectin, 
and increased PAI-1. In addition testosterone treatment also had different effects on 
adiponectin in the three investigations undertaken i.e human, mouse and cell culture. 
Conflicts in the data indicate the complexity of the relationships and underlying 
interactions. Therefore the work presented here has yielded positive results indicating 
that testosterone has a beneficial effect on some parameters, other results are more 
difficult to explain; it is clear that further detailed and extensive work is needed to 
clarify the benefits and mechanisms of testosterone treatment for hypogonadism in 
define patients with diabetes, atherosclerosis or obesity.
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